



(86) **Date de dépôt PCT/PCT Filing Date:** 1999/11/24
(87) **Date publication PCT/PCT Publication Date:** 2000/06/08
(45) **Date de délivrance/Issue Date:** 2014/10/14
(85) **Entrée phase nationale/National Entry:** 2001/05/23
(86) **N° demande PCT/PCT Application No.:** US 1999/027990
(87) **N° publication PCT/PCT Publication No.:** 2000/032773
(30) **Priorité/Priority:** 1998/11/27 (US60/110,283)


(51) **Cl.Int./Int.Cl. C12N 15/12** (2006.01),
A01K 67/027 (2006.01), **A61K 38/18** (2006.01),
A61P 19/10 (2006.01), **C07K 14/495** (2006.01),
C07K 14/51 (2006.01), **C07K 16/22** (2006.01),
C12N 15/62 (2006.01), **C12N 15/63** (2006.01),
C12N 5/10 (2006.01), **C12Q 1/68** (2006.01),
G01N 33/53 (2006.01), **G01N 33/68** (2006.01),
A61K 48/00 (2006.01)

(72) **Inventeurs/Inventors:**
BRUNKOW, MARY E., US;
GALAS, DAVID J., US;
KOVACEVICH, BRIAN, US;
MULLIGAN, JOHN T., US; ...

(54) **Titre : COMPOSITIONS ET METHODES D'AUGMENTATION DE LA MINERALISATION DE LA SUBSTANCE OSSEUSE**
(54) **Title: COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION**

(57) **Abrégé/Abstract:**

A novel class or family of TGF- β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.



(72) **Inventeurs(suite)/Inventors(continued):** PAEPER, BRYAN W., US; VAN NESS, JEFFREY, US; WINKLER, DAVID G., US

(73) **Propriétaires(suite)/Owners(continued):**DARWIN DISCOVERY LTD., GB

(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ :C12N 15/12, C07K 14/51, 14/495, C12N
15/63, 5/10, C07K 16/22, C12Q 1/68,
C12N 15/62, A61K 38/18, A61P 19/10,
G01N 33/53, A01K 67/027

A1

(11) International Publication Number:

WO 00/32773

(43) International Publication Date:

8 June 2000 (08.06.00)

(21) International Application Number: PCT/US99/27990

(22) International Filing Date: 24 November 1999 (24.11.99)

(30) Priority Data:

60/110,283

27 November 1998 (27.11.98) US

(71) Applicant (for all designated States except US): DARWIN
DISCOVERY LTD. [GB/GB]; Cambridge Science Park,
Milton Road, Cambridge, Cambridgeshire CB4 4WE (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRUNKOW, Mary, E.
[US/US]; 9829 Triton Drive NW, Seattle, WA 98117 (US).
GALAS, David, J. [US/US]; 854 Guanajuato Drive, Clare-
mont, CA 91711 (US). KOVACEVICH, Brian [US/US];
4308 N.E. 6th Place, Renton, WA 98059 (US). MULLI-
GAN, John, T. [US/US]; 5823 17th Avenue Northeast, Seat-
tle, WA 98105 (US). PAEPER, Bryan, W. [US/US]; 1617
Summit Avenue #43, Seattle, WA 98122 (US). VAN NESS,
Jeffrey [US/US]; 10020 49th Avenue Northeast, Seattle, WA
98125 (US). WINKLER, David, G. [US/US]; 7037 20th Av-
enue NE, Seattle, WA 98115 (US).(74) Agent: MCMASTERS, David, D.; Seed and Berry LLP, Suite
6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG,
BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE,
LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.

(54) Title: COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION

(57) Abstract

A novel class or family of TGF- β bind-
ing proteins is disclosed. Also disclosed are
assays for selecting molecules for increasing
bone mineralization and methods for utilizing
such molecules.

Common Cysteine Backbone

1	human_gremlin.pro	-----	50	-----
	human_cerberus.pro	MHLLLFQLLV	LLPLGKTTTR	QOGRNQSSIL SPVLLPRNQR ELPTGNHEEA
	human_dan.pro	-----	-----	-----
	human_beer.pro	-----	-----	-----
51	human_gremlin.pro	-----	-----	100
	human_cerberus.pro	EEKPDLPVAV	PHLVAT.SPA GEGQRQREKM	LSRPGRFWKK PEREMHPSRD
	human_dan.pro	-----	-----	-----
	human_beer.pro	-----	-----	-----
101	human_gremlin.pro	AI.PPPDKAQ	HNDSEQTQSP	QOPGSRNRGR GQGRGTAMPQ
	human_cerberus.pro	SDSEFPFPPT	QSLIQPID.G	MKMEKSPLE EAKKFWHFM
	human_dan.pro	-----	-----	-----
	human_beer.pro	AFRVVEGQGW	QAFKNDATET	IPELGEYPEP PPELENNKTM
151	human_gremlin.pro	LHVTERKYLK	RDWCKTQPLK	QTIHEGCGNS RTIINRF.CY
	human_cerberus.pro	ILPIKSHVHV	WETCRTVPFS	QTIHEGCEK VVVQNNL.CF
	human_dan.pro	INKLALFPDK	SAWCEAKNIT	QIVGHSGCEA KSIQNR.CL
	human_beer.pro	HHPPETKQVS	EYSCRELHFT	RYVTDGPCRS AKPVTBLVCS
201	human_gremlin.pro	HIRKEEGSFQ	SCSF...CKP	KKFTTMMVTL NCPELQPTK
	human_cerberus.pro	..GAAQHSHT	SCSH...CLP	AKFTTMHLPL NCTELSSVIK
	human_dan.pro	TFPQSTESLV	HCDS...CMP	AQSMWEIVTL ECPGHEEVPR
	human_beer.pro	NAIGRGKWNR	PSGPDFRCIP	DRYRAQRVQL LCPGGEAPRA
250	human_gremlin.pro	-----	-----	-----
	human_cerberus.pro	-----	-----	-----
	human_dan.pro	-----	-----	-----
	human_beer.pro	-----	-----	-----
301	human_gremlin.pro	CRC.ISIDLQ	-----	-----
	human_cerberus.pro	COCKVKTEHE	DGHILHAGSQ	DSFIPGVSA-
	human_dan.pro	CSCQACGKEP	SHEGLSVYVQ	GEDGPGSQPG
	human_beer.pro	CKCKRLTRFH	NQSELKDFGT	EAARPQKGRK
314	human_gremlin.pro	-----	-----	-----
	human_cerberus.pro	-----	-----	-----
	human_dan.pro	PPGAPHTTEE	GAED	-----
	human_beer.pro	-----	-----	-----

WO 00/32773

PCT/US99/27990

COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION

TECHNICAL FIELD

The present invention relates generally to pharmaceutical products and methods and, more specifically, to methods and compositions suitable for increasing the mineral content of bone. Such compositions and methods may be utilized to treat a wide variety of conditions, including for example, osteopenia, osteoporosis, fractures and other disorders in which low bone mineral density are a hallmark of the disease.

BACKGROUND OF THE INVENTION

Two or three distinct phases of changes to bone mass occur over the life of an individual (see Riggs, *West J. Med.* 154:63-77, 1991). The first phase occurs in both men and women, and proceeds to attainment of a peak bone mass. This first phase is achieved through linear growth of the endochondral growth plates, and radial growth due to a rate of periosteal apposition. The second phase begins around age 30 for trabecular bone (flat bones such as the vertebrae and pelvis) and about age 40 for cortical bone (e.g., long bones found in the limbs) and continues to old age. This phase is characterized by slow bone loss, and occurs in both men and women. In women, a third phase of bone loss also occurs, most likely due to postmenopausal estrogen deficiencies. During this phase alone, women may lose an additional 10% of bone mass from the cortical bone and 25% from the trabecular compartment (see Riggs, *supra*).

Loss of bone mineral content can be caused by a wide variety of conditions, and may result in significant medical problems. For example, osteoporosis is a debilitating disease in humans characterized by marked decreases in skeletal bone mass and mineral density, structural deterioration of bone including degradation of bone microarchitecture and corresponding increases in bone fragility and susceptibility to fracture in afflicted individuals. Osteoporosis in humans is preceded by clinical osteopenia (bone mineral density that is greater than one standard deviation but less than 2.5 standard deviations below the mean value for young adult bone), a condition found in approximately 25 million people in the United States. Another 7-8 million patients in the United States have been diagnosed with clinical osteoporosis (defined as bone mineral content greater than 2.5 standard deviations below that of mature young adult bone). Osteoporosis is one of the most expensive diseases for the health care

system, costing tens of billions of dollars annually in the United States. In addition to health care-related costs, long-term residential care and lost working days add to the financial and social costs of this disease. Worldwide approximately 75 million people are at risk for osteoporosis.

5 The frequency of osteoporosis in the human population increases with age, and among Caucasians is predominant in women (who comprise 80% of the osteoporosis patient pool in the United States). The increased fragility and susceptibility to fracture of skeletal bone in the aged is aggravated by the greater risk of accidental falls in this population. More than 1.5 million osteoporosis-related bone
10 fractures are reported in the United States each year. Fractured hips, wrists, and vertebrae are among the most common injuries associated with osteoporosis. Hip fractures in particular are extremely uncomfortable and expensive for the patient, and for women correlate with high rates of mortality and morbidity.

 Although osteoporosis has been defined as an increase in the risk of
15 fracture due to decreased bone mass, none of the presently available treatments for skeletal disorders can substantially increase the bone density of adults. There is a strong perception among all physicians that drugs are needed which could increase bone density in adults, particularly in the bones of the wrist, spinal column and hip that are at risk in osteopenia and osteoporosis.

20 Current strategies for the prevention of osteoporosis may offer some benefit to individuals but cannot ensure resolution of the disease. These strategies include moderating physical activity (particularly in weight-bearing activities) with the onset of advanced age, including adequate calcium in the diet, and avoiding consumption of products containing alcohol or tobacco. For patients presenting with
25 clinical osteopenia or osteoporosis, all current therapeutic drugs and strategies are directed to reducing further loss of bone mass by inhibiting the process of bone absorption, a natural component of the bone remodeling process that occurs constitutively.

 For example, estrogen is now being prescribed to retard bone loss.
30 There is, however, some controversy over whether there is any long term benefit to patients and whether there is any effect at all on patients over 75 years old. Moreover, use of estrogen is believed to increase the risk of breast and endometrial cancer.

 High doses of dietary calcium, with or without vitamin D has also been suggested for postmenopausal women. However, high doses of calcium can often have
35 unpleasant gastrointestinal side effects, and serum and urinary calcium levels must be continuously monitored (see Khosla and Riggs, *Mayo Clin. Proc.* 70:978-982, 1995).

Other therapeutics which have been suggested include calcitonin, bisphosphonates, anabolic steroids and sodium fluoride. Such therapeutics however, have undesirable side effects (*e.g.*, calcitonin and steroids may cause nausea and provoke an immune reaction, bisphosphonates and sodium fluoride may inhibit repair of fractures, even though bone density increases modestly) that may prevent their usage (see Khosla and Riggs, *supra*).

No currently practiced therapeutic strategy involves a drug that stimulates or enhances the growth of new bone mass. The present invention provides compositions and methods which can be utilized to increase bone mineralization, and thus may be utilized to treat a wide variety of conditions where it is desired to increase bone mass. Further, the present invention provides other, related advantages.

SUMMARY OF THE INVENTION

As noted above, the present invention provides a novel class or family of TGF-beta binding-proteins, as well as assays for selecting compounds which increase bone mineral content and bone mineral density, compounds which increase bone mineral content and bone mineral density and methods for utilizing such compounds in the treatment or prevention of a wide variety of conditions.

Within one aspect of the present invention, isolated nucleic acid molecules are provided, wherein said nucleic acid molecules are selected from the group consisting of: (a) an isolated nucleic acid molecule comprising sequence ID Nos. 1, 5, 7, 9, 11, 13, or, 15, or complementary sequence thereof; (b) an isolated nucleic acid molecule that specifically hybridizes to the nucleic acid molecule of (a) under conditions of high stringency; and (c) an isolated nucleic acid that encodes a TGF-beta binding-protein according to (a) or (b). Within related aspects of the present invention, isolated nucleic acid molecules are provided based upon hybridization to only a portion of one of the above-identified sequences (*e.g.*, for (a) hybridization may be to a probe of at least 20, 25, 50, or 100 nucleotides selected from nucleotides 156 to 539 or 555 to 687 of Sequence ID No. 1). As should be readily evident, the necessary stringency to be utilized for hybridization may vary based upon the size of the probe. For example, for a 25-mer probe high stringency conditions could include: 60 mM Tris pH 8.0, 2 mM EDTA, 5x Denhardt's, 6x SSC, 0.1% (w/v) N-laurylsarcosine, 0.5% (w/v) NP-40 (nonidet P-40) overnight at 45 degrees C, followed by two washes with 0.2x SSC / 0.1% SDS at 45-50 degrees. For a 100-mer probe under low stringency conditions, suitable conditions might include the following: 5x SSPE, 5x Denhardt's, and 0.5% SDS overnight at 42-50 degrees, followed by two washes with 2x SSPE (or 2x SSC)

/0.1% SDS at 42-50 degrees.

Within related aspects of the present invention, isolated nucleic acid molecules are provided which have homology to Sequence ID Nos. 1, 5, 7, 9, 11, 13, or 15, at a 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Wilbur-Lipman algorithm. Representative examples of such isolated molecules include, for example, nucleic acid molecules which encode a protein comprising Sequence ID NOs. 2, 6, 10, 12, 14, or 16, or have homology to these sequences at a level of 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Lipman-Pearson algorithm.

Isolated nucleic acid molecules are typically less than 100kb in size, and, within certain embodiments, less than 50kb, 25kb, 10kb, or even 5kb in size. Further, isolated nucleic acid molecules, within other embodiments, do not exist in a "library" of other unrelated nucleic acid molecules (*e.g.*, a subclone BAC such as described in GenBank Accession No. AC003098 and EMB No. AQ171546). However, isolated nucleic acid molecules can be found in libraries of related molecules (*e.g.*, for shuffling, such as is described in U.S. Patent Nos. 5,837,458; 5,830,721; and 5,811,238). Finally, isolated nucleic acid molecules as described herein do not include nucleic acid molecules which encode Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

Also provided by the present invention are cloning vectors which contain the above-noted nucleic acid molecules, and expression vectors which comprise a promoter (*e.g.*, a regulatory sequence) operably linked to one of the above-noted nucleic acid molecules. Representative examples of suitable promoters include tissue-specific promoters, and viral - based promoters (*e.g.*, CMV-based promoters such as CMV I-E, SV40 early promoter, and MuLV LTR). Expression vectors may also be based upon, or derived from viruses (*e.g.*, a "viral vector"). Representative examples of viral vectors include herpes simplex viral vectors, adenoviral vectors, adenovirus-associated viral vectors and retroviral vectors. Also provided are host cells containing or comprising any of above-noted vectors (including for example, host cells of human, monkey, dog, rat, or mouse origin).

Within other aspects of the present invention, methods of producing TGF-beta binding-proteins are provided, comprising the step of culturing the aforementioned host cell containing vector under conditions and for a time sufficient to produce the TGF-beta binding protein. Within further embodiments, the protein produced by this method may be further purified (*e.g.*, by column chromatography, affinity purification, and the like). Hence, isolated proteins which are encoded by the

above-noted nucleic acid molecules (*e.g.*, Sequence ID NOs. 2, 4, 6, 8, 10, 12, 14, or 16) may be readily produced given the disclosure of the subject application.

It should also be noted that the aforementioned proteins, or fragments thereof, may be produced as fusion proteins. For example, within one aspect fusion proteins are provided comprising a first polypeptide segment comprising a TGF-beta binding-protein encoded by a nucleic acid molecule as described above, or a portion thereof of at least 10, 20, 30, 50, or 100 amino acids in length, and a second polypeptide segment comprising a non-TGF-beta binding-protein. Within certain embodiments, the second polypeptide may be a tag suitable for purification or recognition (*e.g.*, a polypeptide comprising multiple anionic amino acid residues – see U.S. Patent No. 4,851,341), a marker (*e.g.*, green fluorescent protein, or alkaline phosphatase), or a toxic molecule (*e.g.*, ricin).

Within another aspect of the present invention, antibodies are provided which are capable of specifically binding the above-described class of TGF-beta binding proteins (*e.g.*, human BEER). Within various embodiments, the antibody may be a polyclonal antibody, or a monoclonal antibody (*e.g.*, of human or murine origin). Within further embodiments, the antibody is a fragment of an antibody which retains the binding characteristics of a whole antibody (*e.g.*, an F(ab')₂, F(ab)₂, Fab', Fab, or Fv fragment, or even a CDR). Also provided are hybridomas and other cells which are capable of producing or expressing the aforementioned antibodies.

Within related aspects of the invention, methods are provided detecting a TGF-beta binding protein, comprising the steps of incubating an antibody as described above under conditions and for a time sufficient to permit said antibody to bind to a TGF-beta binding protein, and detecting the binding. Within various embodiments the antibody may be bound to a solid support to facilitate washing or separation, and/or labeled. (*e.g.*, with a marker selected from the group consisting of enzymes, fluorescent proteins, and radioisotopes).

Within other aspects of the present invention, isolated oligonucleotides are provided which hybridize to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, or 18 or the complement thereto, under conditions of high stringency. Within further embodiments, the oligonucleotide may be found in the sequence which encodes Sequence ID Nos. 2, 4, 6, 8, 10, 12, 14, or 16. Within certain embodiments, the oligonucleotide is at least 15, 20, 30, 50, or 100 nucleotides in length. Within further embodiments, the oligonucleotide is labeled with another molecule (*e.g.*, an enzyme, fluorescent molecule, or radioisotope). Also provided are primers which are capable of specifically amplifying all or a portion of the above-

mentioned nucleic acid molecules which encode TGF-beta binding-proteins. As utilized herein, the term "specifically amplifying" should be understood to refer to primers which amplify the aforementioned TGF-beta binding-proteins, and not other TGF-beta binding proteins such as Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

Within related aspects of the present invention, methods are provided for detecting a nucleic acid molecule which encodes a TGF-beta binding protein, comprising the steps of incubating an oligonucleotide as described above under conditions of high stringency, and detecting hybridization of said oligonucleotide. Within certain embodiments, the oligonucleotide may be labeled and/or bound to a solid support.

Within other aspects of the present invention, ribozymes are provided which are capable of cleaving RNA which encodes one of the above-mentioned TGF-beta binding-proteins (e.g., Sequence ID NOs. 2, 6, 8, 10, 12, 14, or 16). Such ribozymes may be composed of DNA, RNA (including 2'-O-methyl ribonucleic acids), nucleic acid analogs (e.g., nucleic acids having phosphorothioate linkages) or mixtures thereof. Also provided are nucleic acid molecules (e.g., DNA or cDNA) which encode these ribozymes, and vectors which are capable of expressing or producing the ribozymes. Representative examples of vectors include plasmids, retrotransposons, cosmids, and viral-based vectors (e.g., viral vectors generated at least in part from a retrovirus, adenovirus, or, adeno-associated virus). Also provided are host cells (e.g., human, dog, rat, or mouse cells) which contain these vectors. In certain embodiments, the host cell may be stably transformed with the vector.

Within further aspects of the invention, methods are provided for producing ribozymes either synthetically, or by *in vitro* or *in vivo* transcription. Within further embodiments, the ribozymes so produced may be further purified and / or formulated into pharmaceutical compositions (e.g., the ribozyme or nucleic acid molecule encoding the ribozyme along with a pharmaceutically acceptable carrier or diluent). Similarly, the antisense oligonucleotides and antibodies or other selected molecules described herein may be formulated into pharmaceutical compositions.

Within other aspects of the present invention, antisense oligonucleotides are provided comprising a nucleic acid molecule which hybridizes to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, or 15, or the complement thereto, and wherein said oligonucleotide inhibits the expression of TGF-beta binding protein as described herein (e.g., human BEER). Within various embodiments, the oligonucleotide is 15, 20, 25, 30, 35, 40, or 50 nucleotides in length. Preferably, the

oligonucleotide is less than 100, 75, or 60 nucleotides in length. As should be readily evident, the oligonucleotide may be comprised of one or more nucleic acid analogs, ribonucleic acids, or deoxyribonucleic acids. Further, the oligonucleotide may be modified by one or more linkages, including for example, covalent linkage such as a
5 phosphorothioate linkage, a phosphotriester linkage, a methyl phosphonate linkage, a methylene(methylimino) linkage, a morpholino linkage, an amide linkage, a polyamide linkage, a short chain alkyl intersugar linkage, a cycloalkyl intersugar linkage, a short chain heteroatomic intersugar linkage and a heterocyclic intersugar linkage. One representative example of a chimeric oligonucleotide is provided in U.S. Patent No.
10 5,989,912.

Within yet another aspect of the present invention, methods are provided for increasing bone mineralization, comprising introducing into a warm-blooded animal an effective amount of the ribozyme as described above. Within related aspects, such methods comprise the step of introducing into a patient an effective amount of the
15 nucleic acid molecule or vector as described herein which is capable of producing the desired ribozyme, under conditions favoring transcription of the nucleic acid molecule to produce the ribozyme.

Within other aspects of the invention transgenic, non-human animals are provided. Within one embodiment a transgenic animal is provided whose germ cells
20 and somatic cells contain a nucleic acid molecule encoding a TGF-beta binding-protein as described above which is operably linked to a promoter effective for the expression of the gene, the gene being introduced into the animal, or an ancestor of the animal, at an embryonic stage, with the proviso that said animal is not a human. Within other embodiments, transgenic knockout animals are provided, comprising an animal whose
25 germ cells and somatic cells comprise a disruption of at least one allele of an endogenous nucleic acid molecule which hybridizes to a nucleic acid molecule which encodes a TGF-binding protein as described herein, wherein the disruption prevents transcription of messenger RNA from said allele as compared to an animal without the disruption, with the proviso that the animal is not a human. Within various
30 embodiments, the disruption is a nucleic acid deletion, substitution, or, insertion. Within other embodiments the transgenic animal is a mouse, rat, sheep, pig, or dog.

Within further aspects of the invention, kits are provided for the detection of TGF-beta binding-protein gene expression, comprising a container that comprises a nucleic acid molecule, wherein the nucleic acid molecule is selected from
35 the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; (b) a nucleic acid molecule comprising the

complement of the nucleotide sequence of (a); (c) a nucleic acid molecule that is a fragment of (a) or (b) of at least 15, 20 30, 50, 75, or, 100 nucleotides in length. Also provided are kits for the detection of a TGF-beta binding-protein which comprise a container that comprise one of the TGF-beta binding protein antibodies described
5 herein.

For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing one or more candidate molecules with TGF-beta-binding-protein encoded by the nucleic acid molecule according to
10 claim 1 and a selected member of the TGF-beta family of proteins (*e.g.*, BMP 5 or 6), (b) determining whether the candidate molecule alters the signaling of the TGF-beta family member, or alters the binding of the TGF-beta binding-protein to the TGF-beta family member. Within certain embodiments, the molecule alters the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation. Within
15 this aspect of the present invention, the candidate molecule(s) may alter signaling or binding by, for example, either decreasing (*e.g.*, inhibiting), or increasing (*e.g.*, enhancing) signaling or binding.

Within yet another aspect, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising
20 the step of determining whether a selected molecule inhibits the binding of TGF-beta binding-protein to bone, or an analogue thereof. Representative examples of bone or analogues thereof include hydroxyapatite and primary human bone samples obtained via biopsy.

Within certain embodiments of the above-recited methods, the selected
25 molecule is contained within a mixture of molecules and the methods may further comprise the step of isolating one or more molecules which are functional within the assay. Within yet other embodiments, TGF-beta family of proteins is bound to a solid support and the binding of TGF-beta binding-protein is measured or TGF-beta binding-protein are bound to a solid support and the binding of TGF-beta proteins are measured.

30 Utilizing methods such as those described above, a wide variety of molecules may be assayed for their ability to increase bone mineral content by inhibiting the binding of the TGF-beta binding-protein to the TGF-beta family of proteins. Representative examples of such molecules include proteins or peptides, organic molecules, and nucleic acid molecules.

35 Within other related aspects of the invention, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the step of

administering to a warm-blooded animal a therapeutically effective amount of a molecule identified from the assays recited herein. Within another aspect, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the step of administering to a warm-blooded animal a therapeutically effective amount
5 of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins, including bone morphogenic proteins (BMPs). Representative examples of suitable molecules include antisense molecules, ribozymes, ribozyme genes, and antibodies (e.g., a humanized antibody) which specifically recognize and alter the activity of the TGF-beta binding-protein.

10 Within another aspect of the present invention, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the steps of (a) introducing into cells which home to the bone a vector which directs the expression of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs), and (b) administering
15 the vector-containing cells to a warm-blooded animal. As utilized herein, it should be understood that cells "home to bone" if they localize within the bone matrix after peripheral administration. Within one embodiment, such methods further comprise, prior to the step of introducing, isolating cells from the marrow of bone which home to the bone. Within a further embodiment, the cells which home to bone are selected from
20 the group consisting of CD34+ cells and osteoblasts.

Within other aspects of the present invention, molecules are provided (preferably isolated) which inhibit the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins.

Within further embodiments, the molecules may be provided as a
25 composition, and can further comprise an inhibitor of bone resorption. Representative examples of such inhibitors include calcitonin, estrogen, a bisphosphonate, a growth factor having anti-resorptive activity and tamoxifen.

Representative examples of molecules which may be utilized in the afore-mentioned therapeutic contexts include, e.g., ribozymes, ribozyme genes,
30 antisense molecules, and/or antibodies (e.g., humanized antibodies). Such molecules may depending upon their selection, used to alter, antagonize, or agonize the signalling or binding of a TGF-beta binding-protein family member as described herein

Within various embodiments of the invention, the above-described molecules and methods of treatment or prevention may be utilized on conditions such
35 as osteoporosis, osteomalasia, periodontal disease, scurvy, Cushing's Disease, bone fracture and conditions due to limb immobilization and steroid usage.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (e.g., plasmids, etc.).

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration comparing the amino acid sequence of Human Dan; Human Gremlin; Human Cerberus and Human Beer. Arrows indicate the Cysteine backbone.

10 Figure 2 summarizes the results obtained from surveying a variety of human tissues for the expression of a TGF-beta binding-protein gene, specifically, the Human Beer gene. A semi-quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) procedure was used to amplify a portion of the gene from first-strand cDNA synthesized from total RNA (described in more detail in EXAMPLE 2A).

15 Figure 3 summarizes the results obtained from RNA *in situ* hybridization of mouse embryo sections, using a cRNA probe that is complementary to the mouse Beer transcript (described in more detail in EXAMPLE 2B). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos.

20 Figure 4 illustrates, by western blot analysis, the specificity of three different polyclonal antibodies for their respective antigens (described in more detail in EXAMPLE 4). Figure 4A shows specific reactivity of an anti-H. Beer antibody for H. Beer antigen, but not H. Dan or H. Gremlin. Figure 4B shows reactivity of an anti-H. Gremlin antibody for H. Gremlin antigen, but not H. Beer or H. Dan. Figure 4C shows
25 reactivity of an anti-H. Dan antibody for H. Dan, but not H. Beer or H. Gremlin.

Figure 5 illustrates, by western blot analysis, the selectivity of the TGF-beta binding-protein, Beer, for BMP-5 and BMP-6, but not BMP-4 (described in more detail in EXAMPLE 5).

30 Figure 6 demonstrates that the ionic interaction between the TGF-beta binding-protein, Beer, and BMP-5 has a dissociation constant in the 15-30 nM range.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

Prior to setting forth the invention in detail, it may be helpful to an understanding thereof to set forth definitions of certain terms and to list and to define the abbreviations that will be used hereinafter.

“Molecule” should be understood to include proteins or peptides (e.g., antibodies, recombinant binding partners, peptides with a desired binding affinity), nucleic acids (e.g., DNA, RNA, chimeric nucleic acid molecules, and nucleic acid analogues such as PNA); and organic or inorganic compounds.

“TGF-beta” should be understood to include any known or novel member of the TGF-beta super-family, which also includes bone morphogenic proteins (BMPs).

“TGF-beta receptor” should be understood to refer to the receptor specific for a particular member of the TGF-beta super-family (including bone morphogenic proteins (BMPs)).

“TGF-beta binding-protein” should be understood to refer to a protein with specific binding affinity for a particular member or subset of members of the TGF-beta super-family (including bone morphogenic proteins (BMPs)). Specific examples of TGF-beta binding-proteins include proteins encoded by Sequence ID Nos. 1, 5, 7, 9, 11, 13, and 15.

Inhibiting the “binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs)” should be understood to refer to molecules which allow the activation of TGF-beta or bone morphogenic proteins (BMPs), or allow the binding of TGF-beta family members including bone morphogenic proteins (BMPs) to their respective receptors, by removing or preventing TGF-beta from binding to TGF-binding-protein. Such inhibition may be accomplished, for example, by molecules which inhibit the binding of the TGF-beta binding-protein to specific members of the TGF-beta super-family.

“Vector” refers to an assembly which is capable of directing the expression of desired protein. The vector must include transcriptional promoter elements which are operably linked to the gene(s) of interest. The vector may be composed of either deoxyribonucleic acids (“DNA”), ribonucleic acids (“RNA”), or a combination of the two (e.g., a DNA-RNA chimeric). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more selectable markers such as neomycin phosphotransferase or hygromycin phosphotransferase. Additionally, depending on the host cell chosen and the vector

employed, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.

An "isolated nucleic acid molecule" is a nucleic acid molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes a TGF-binding protein that has been separated from the genomic DNA of a eukaryotic cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the genome of an organism. The isolated nucleic acid molecule may be genomic DNA, cDNA, RNA, or composed at least in part of nucleic acid analogs.

An "isolated polypeptide" is a polypeptide that is essentially free from contaminating cellular components, such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. Within certain embodiments, a particular protein preparation contains an isolated polypeptide if it appears nominally as a single band on SDS-PAGE gel with Coomassie Blue staining. "Isolated" when referring to organic molecules means that the compounds are greater than 90 percent pure utilizing methods which are well known in the art (e.g., NMR, melting point).

"Sclerosteosis" Sclerosteosis is a term that was applied by Hansen (1967) (Hansen, H. G., Sklerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin: Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis corticalis generalisata but possibly differing in radiologic appearance of the bone changes and in the presence of asymmetric cutaneous syndactyly of the index and middle fingers in many cases. The jaw has an unusually square appearance in this condition.

"Humanized antibodies" are recombinant proteins in which murine complementary determining regions of monoclonal antibodies have been transferred from heavy and light variable chains of the murine immunoglobulin into a human variable domain.

As used herein, an "antibody fragment" is a portion of an antibody such as $F(ab')_2$, $F(ab)_2$, Fab', Fab, and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. For example, an anti-TGF-beta binding-protein monoclonal antibody fragment binds with an epitope of TGF-beta binding-protein.

The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. For example, antibody fragments include isolated fragments consisting of the

light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("sFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

A "detectable label" is a molecule or atom which can be conjugated to an antibody moiety to produce a molecule useful for diagnosis. Examples of detectable labels include chelators, photoactive agents, radioisotopes, fluorescent agents, paramagnetic ions, enzymes, and other marker moieties.

As used herein, an "immunoconjugate" is a molecule comprising an anti-TGF-beta binding-protein antibody, or an antibody fragment, and a detectable label. An immunoconjugate has roughly the same, or only slightly reduced, ability to bind TGF-beta binding-protein after conjugation as before conjugation.

Abbreviations: TGF-beta - "Transforming Growth Factor-beta"; TGF-bBP - "Transforming Growth Factor-beta binding-protein" (one representative TGF-bBP is designated "H. Beer"); BMP - "bone morphogenic protein"; PCR - "polymerase chain reaction"; RT-PCR - PCR process in which RNA is first transcribed into DNA at the first step using reverse transcriptase (RT); cDNA - any DNA made by copying an RNA sequence into DNA form.

As noted above, the present invention provides a novel class of TGF-beta binding-proteins, as well as methods and compositions for increasing bone mineral content in warm-blooded animals. Briefly, the present inventions are based upon the unexpected discovery that a mutation in the gene which encodes a novel member of the TGF-beta binding-protein family results in a rare condition (sclerosteosis) characterized by bone mineral contents which are one- to four-fold higher than in normal individuals. Thus, as discussed in more detail below this discovery has led to the development of assays which may be utilized to select molecules which inhibit the binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs), and methods of utilizing such molecules for increasing the bone mineral content of warm-blooded animals (including for example, humans).

DISCUSSION OF THE DISEASE KNOWN AS SCLEROSTEOSIS

Sclerosteosis is a term that was applied by Hansen (1967) (Hansen, H. G., Sklerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin: Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis

corticalis generalisata but possibly differing in radiologic appearance of the bone changes and in the presence of asymmetric cutaneous syndactyly of the index and middle fingers in many cases.

Sclerosteosis is now known to be an autosomal semi-dominant disorder which is characterized by widely disseminated sclerotic lesions of the bone in the adult. The condition is progressive. Sclerosteosis also has a developmental aspect which is associated with syndactyly (two or more fingers are fused together). The Sclerosteosis Syndrome is associated with large stature and many affected individuals attain a height of six feet or more. The bone mineral content of homozygotes can be 1 to 6 fold over normal individuals and bone mineral density can be 1 to 4 fold above normal values (e.g., from unaffected siblings).

The Sclerosteosis Syndrome occurs primarily in Afrikaaners of Dutch descent in South Africa. Approximately 1/140 individuals in the Afrikaaner population are carriers of the mutated gene (heterozygotes). The mutation shows 100% penetrance. There are anecdotal reports of increased of bone mineral density in heterozygotes with no associated pathologies (syndactyly or skull overgrowth).

It appears at the present time that there is no abnormality of the pituitary-hypothalamus axis in Sclerosteosis. In particular, there appears to be no over-production of growth hormone and cortisone. In addition, sex hormone levels are normal in affected individuals. However, bone turnover markers (osteoblast specific alkaline phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; (see Comier, C., *Curr. Opin. in Rheu.* 7:243, 1995) indicate that there is hyperosteoblastic activity associated with the disease but that there is normal to slightly decreased osteoclast activity as measured by markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma tartrate-resistant acid phosphatases and galactosyl hydroxylysine (see Comier, *supra*)).

Sclerosteosis is characterized by the continual deposition of bone throughout the skeleton during the lifetime of the affected individuals. In homozygotes the continual deposition of bone mineral leads to an overgrowth of bone in areas of the skeleton where there is an absence of mechanoreceptors (skull, jaw, cranium). In homozygotes with Sclerosteosis, the overgrowth of the bones of the skull leads to cranial compression and eventually to death due to excessive hydrostatic pressure on the brain stem. In all other parts of the skeleton there is a generalized and diffuse sclerosis. Cortical areas of the long bones are greatly thickened resulting in a substantial increase in bone strength. Trabecular connections are increased in thickness

which in turn increases the strength of the trabecular bone. Sclerotic bones appear unusually opaque to x-rays.

As described in more detail in Example 1, the rare genetic mutation that is responsible for the Sclerosteosis syndrome has been localized to the region of human chromosome 17 that encodes a novel member of the TGF-beta binding-protein family (one representative example of which is designated "H. Beer"). As described in more detail below, based upon this discovery, the mechanism of bone mineralization is more fully understood, allowing the development of assays for molecules which increase bone mineralization, and use of such molecules to increase bone mineral content, and in the treatment or prevention of a wide number of diseases.

TGF-BETA SUPER-FAMILY

The Transforming Growth Factor-beta (TGF-beta) super-family contains a variety of growth factors that share common sequence elements and structural motifs (at both the secondary and tertiary levels). This protein family is known to exert a wide spectrum of biological responses on a large variety of cell types. Many of them have important functions during the embryonal development in pattern formation and tissue specification; in adults they are involved, *e.g.*, in wound healing and bone repair and bone remodeling, and in the modulation of the immune system. In addition to the three TGF-beta's, the super-family includes the Bone Morphogenic Proteins (BMPs), Activins, Inhibins, Growth and Differentiation Factors (GDFs), and Glial-Derived Neurotrophic Factors (GDNFs). Primary classification is established through general sequence features that bin a specific protein into a general sub-family. Additional stratification within the sub-family is possible due to stricter sequence conservation between members of the smaller group. In certain instances, such as with BMP-5, BMP-6 and BMP-7, this can be as high as 75 percent amino acid homology between members of the smaller group. This level of identity enables a single representative sequence to illustrate the key biochemical elements of the sub-group that separates it from other members of the larger family.

TGF-beta signals by inducing the formation of hetero-oligomeric complexes of type I and type II receptors. The crystal structure of TGF-beta2 has been determined. The general fold of the TGF-beta2 monomer contains a stable, compact, cysteine knotlike structure formed by three disulphide bridges. Dimerization, stabilized by one disulphide bridge, is antiparallel.

TGF-beta family members initiate their cellular action by binding to receptors with intrinsic serine/threonine kinase activity. This receptor family consists

of two subfamilies, denoted type I and type II receptors. Each member of the TGF-beta family binds to a characteristic combination of type I and type II receptors, both of which are needed for signaling. In the current model for TGF-beta receptor activation, TGF-beta first binds to the type II receptor (TbR-II), which occurs in the cell
5 membrane in an oligomeric form with activated kinase. Thereafter, the type I receptor (TbR-I), which can not bind ligand in the absence of TbR-II, is recruited into the complex. TbR-II then phosphorylates TbR-I predominantly in a domain rich in glycine and serine residues (GS domain) in the juxtamembrane region, and thereby activates TbR-I.

10 Thus far seven type I receptors and five type II receptors have been identified.

BONE MORPHOGENIC PROTEINS (BMPs) ARE KEY REGULATORY PROTEINS IN
DETERMINING BONE MINERAL DENSITY IN HUMANS

A major advance in the understanding of bone formation was the
15 identification of the bone morphogenic proteins (BMPs), also known as osteogenic proteins (OPs), which regulate cartilage and bone differentiation in vivo. BMPs/OPs induce endochondral bone differentiation through a cascade of events which include formation of cartilage, hypertrophy and calcification of the cartilage, vascular invasion, differentiation of osteoblasts, and formation of bone. As described above, the
20 BMPs/OPs (BMP 2-14, and osteogenic protein 1 and -2, OP-1 and OP-2) are members of the TGF-beta super-family. The striking evolutionary conservation between members the BMP/OP sub-family suggests that they are critical in the normal development and function of animals. Moreover, the presence of multiple forms of BMPs/OPs raises an important question about the biological relevance of this apparent
25 redundancy. In addition to postfetal chondrogenesis and osteogenesis, the BMPs/OPs play multiple roles in skeletogenesis (including the development of craniofacial and dental tissues) and in embryonic development and organogenesis of parenchymatous organs, including the kidney. It is now understood that nature relies on common (and few) molecular mechanisms tailored to provide the emergence of specialized tissues
30 and organs. The BMP/OP super-family is an elegant example of nature parsimony in programming multiple specialized functions deploying molecular isoforms with minor variation in amino acid motifs within highly conserved carboxy-terminal regions.

BMP ANTAGONISM

The BMP and Activin sub-families are subject to significant post-

translational regulation. An intricate extracellular control system exists, whereby a high affinity antagonist is synthesized and exported, and subsequently complexes selectively with BMPs or activins to disrupt their biological activity (W.C. Smith (1999) *TIG* 15(1) 3-6). A number of these natural antagonists have been identified, and
 5 based on sequence divergence appear to have evolved independently due to the lack of primary sequence conservation. There has been no structural work to date on this class of proteins. Studies of these antagonists has highlighted a distinct preference for interacting and neutralizing BMP-2 and BMP-4. Furthermore, the mechanism of inhibition seems to differ for the different antagonists (S. Iemura et al. (1998) *Proc*
 10 *Natl Acad Sci USA* 95 9337-9342).

NOVEL TGF-BETA BINDING-PROTEINS

1. Background re: TGF-beta binding-proteins

As noted above, the present invention provides a novel class of TGF-beta binding-proteins that possess a nearly identical cysteine (disulfide) scaffold when
 15 compared to Human DAN, Human Gremlin, and Human Cerberus, and SCGF (U.S. Patent No. 5,780,263) but almost no homology at the nucleotide level (for background information, see generally Hsu, D.R., Economides, A.N., Wang, X., Eimon, P.M., Harland, R.M., "The *Xenopus* Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities," *Molecular Cell* 1:673-683, 1998).

20 One representative example of the novel class of TGF-beta binding-proteins is disclosed in Sequence ID Nos. 1, 5, 9, 11, 13, and 15. Representative members of this class of binding proteins should also be understood to include variants of the TGF-beta binding-protein (e.g., Sequence ID Nos. 5 and 7). As utilized herein, a "TGF-beta binding-protein variant gene" refers to nucleic acid molecules that encode a
 25 polypeptide having an amino acid sequence that is a modification of SEQ ID Nos: 2, 10, 12, 14 or 16. Such variants include naturally-occurring polymorphisms or allelic variants of TGF-beta binding-protein genes, as well as synthetic genes that contain conservative amino acid substitutions of these amino acid sequences. Additional variant forms of a TGF-beta binding-protein gene are nucleic acid molecules that
 30 contain insertions or deletions of the nucleotide sequences described herein. TGF-beta binding-protein variant genes can be identified by determining whether the genes hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 7, 9, 11, 13, or 15 under stringent conditions. In addition, TGF-beta binding-protein variant genes should encode a protein having a cysteine backbone.

As an alternative, TGF-beta binding-protein variant genes can be identified by sequence comparison. As used herein, two amino acid sequences have "100% amino acid sequence identity" if the amino acid residues of the two amino acid sequences are the same when aligned for maximal correspondence. Similarly, two
5 nucleotide sequences have "100% nucleotide sequence identity" if the nucleotide residues of the two nucleotide sequences are the same when aligned for maximal correspondence. Sequence comparisons can be performed using standard software programs such as those included in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Other methods for
10 comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, *The Internet and the New Biology: Tools for Genomic and Molecular Research* (ASM Press, Inc. 1997), Wu et al. (eds.), "Information Superhighway and Computer Databases of Nucleic Acids and Proteins," in *Methods in Gene Biotechnology*, pages
15 123-151 (CRC Press, Inc. 1997), and Bishop (ed.), *Guide to Human Genome Computing*, 2nd Edition (Academic Press, Inc. 1998)).

A variant TGF-beta binding-protein should have at least a 50% amino acid sequence identity to SEQ ID NOs: 2, 6, 10, 12, 14 or 16 and preferably, greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity. Alternatively, TGF-beta
20 binding-protein variants can be identified by having at least a 70% nucleotide sequence identity to SEQ ID NOs: 1, 5, 9, 11, 13 or 15. Moreover, the present invention contemplates TGF-beta binding-protein gene variants having greater than 75%, 80%, 85%, 90%, or 95% identity to SEQ ID NO:1. Regardless of the particular method used to identify a TGF-beta binding-protein variant gene or variant TGF-beta binding-
25 protein, a variant TGF-beta binding-protein or a polypeptide encoded by a variant TGF-beta binding-protein gene can be functionally characterized by, for example, its ability to bind to and/or inhibit the signaling of a selected member of the TGF-beta family of proteins, or by its ability to bind specifically to an anti-TGF-beta binding-protein antibody.

30 The present invention includes functional fragments of TGF-beta binding-protein genes. Within the context of this invention, a "functional fragment" of a TGF-beta binding-protein gene refers to a nucleic acid molecule that encodes a portion of a TGF-beta binding-protein polypeptide which either (1) possesses the above-noted function activity, or (2) specifically binds with an anti-TGF-beta binding-
35 protein antibody. For example, a functional fragment of a TGF-beta binding-protein gene described herein comprises a portion of the nucleotide sequence of SEQ ID Nos:

1, 5, 9, 11, 13, or 15.

2. Isolation of the TGF-beta binding-protein gene

DNA molecules encoding a binding-protein gene can be obtained by screening a human cDNA or genomic library using polynucleotide probes based upon, for example, SEQ ID NO:1.

For example, the first step in the preparation of a cDNA library is to isolate RNA using methods well-known to those of skill in the art. In general, RNA isolation techniques must provide a method for breaking cells, a means of inhibiting RNase-directed degradation of RNA, and a method of separating RNA from DNA, protein, and polysaccharide contaminants. For example, total RNA can be isolated by freezing tissue in liquid nitrogen, grinding the frozen tissue with a mortar and pestle to lyse the cells, extracting the ground tissue with a solution of phenol/chloroform to remove proteins, and separating RNA from the remaining impurities by selective precipitation with lithium chloride (see, for example, Ausubel et al. (eds.), *Short Protocols in Molecular Biology*, 3rd Edition, pages 4-1 to 4-6 (John Wiley & Sons 1995) ["Ausubel (1995)"]; Wu et al., *Methods in Gene Biotechnology*, pages 33-41 (CRC Press, Inc. 1997) ["Wu (1997)"]).

Alternatively, total RNA can be isolated by extracting ground tissue with guanidinium isothiocyanate, extracting with organic solvents, and separating RNA from contaminants using differential centrifugation (see, for example, Ausubel (1995) at pages 4-1 to 4-6; Wu (1997) at pages 33-41).

In order to construct a cDNA library, poly(A)⁺ RNA must be isolated from a total RNA preparation. Poly(A)⁺ RNA can be isolated from total RNA by using the standard technique of oligo(dT)-cellulose chromatography (see, for example, Ausubel (1995) at pages 4-11 to 4-12).

Double-stranded cDNA molecules are synthesized from poly(A)⁺ RNA using techniques well-known to those in the art. (see, for example, Wu (1997) at pages 41-46). Moreover, commercially available kits can be used to synthesize double-stranded cDNA molecules. For example, such kits are available from Life Technologies, Inc. (Gaithersburg, Maryland), CLONTECH Laboratories, Inc. (Palo Alto, California), Promega Corporation (Madison, Wisconsin) and Stratagene Cloning Systems (La Jolla, California).

The basic approach for obtaining TGF-beta binding-protein cDNA clones can be modified by constructing a subtracted cDNA library which is enriched in TGF-binding-protein-specific cDNA molecules. Techniques for constructing subtracted libraries are well-known to those of skill in the art (see, for example, Sargent, "Isolation of

Differentially Expressed Genes," in *Meth. Enzymol.* 152:423, 1987, and Wu et al. (eds.), "Construction and Screening of Subtracted and Complete Expression cDNA Libraries," in *Methods in Gene Biotechnology*, pages 29-65 (CRC Press, Inc. 1997)).

Various cloning vectors are appropriate for the construction of a cDNA library. For example, a cDNA library can be prepared in a vector derived from bacteriophage, such as a λ gt10 vector (see, for example, Huynh et al., "Constructing and Screening cDNA Libraries in λ gt10 and λ gt11," in *DNA Cloning: A Practical Approach Vol. I*, Glover (ed.), page 49 (IRL Press, 1985); Wu (1997) at pages 47-52).

Alternatively, double-stranded cDNA molecules can be inserted into a plasmid vector, such as a pBluescript vector (Stratagene Cloning Systems; La Jolla, California), a LambdaGEM-4 (Promega Corp.; Madison, Wisconsin) or other commercially available vectors. Suitable cloning vectors also can be obtained from the American Type Culture Collection (Rockville, Maryland).

In order to amplify the cloned cDNA molecules, the cDNA library is inserted into a prokaryotic host, using standard techniques. For example, a cDNA library can be introduced into competent *E. coli* DH5 cells, which can be obtained from Life Technologies, Inc. (Gaithersburg, Maryland).

A human genomic DNA library can be prepared by means well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327). Genomic DNA can be isolated by lysing tissue with the detergent Sarkosyl, digesting the lysate with proteinase K, clearing insoluble debris from the lysate by centrifugation, precipitating nucleic acid from the lysate using isopropanol, and purifying resuspended DNA on a cesium chloride density gradient.

DNA fragments that are suitable for the production of a genomic library can be obtained by the random shearing of genomic DNA or by the partial digestion of genomic DNA with restriction endonucleases. Genomic DNA fragments can be inserted into a vector, such as a bacteriophage or cosmid vector, in accordance with conventional techniques, such as the use of restriction enzyme digestion to provide appropriate termini, the use of alkaline phosphatase treatment to avoid undesirable joining of DNA molecules, and ligation with appropriate ligases. Techniques for such manipulation are well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327).

Nucleic acid molecules that encode a TGF-beta binding-protein gene can also be obtained using the polymerase chain reaction (PCR) with oligonucleotide primers having nucleotide sequences that are based upon the nucleotide sequences of the human TGF-beta binding-protein gene, as described herein. General methods for screening libraries with PCR are provided by, for example, Yu et al., "Use of the

Polymerase Chain Reaction to Screen Phage Libraries," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 211-215 (Humana Press, Inc. 1993). Moreover, techniques for using PCR to isolate related genes are described by, for example, Preston, "Use of Degenerate
5 Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 317-337 (Humana Press, Inc. 1993).

Alternatively, human genomic libraries can be obtained from commercial sources such as Research Genetics (Huntsville, AL) and the American Type Culture
10 Collection (Rockville, Maryland).

A library containing cDNA or genomic clones can be screened with one or more polynucleotide probes based upon SEQ ID NO:1, using standard methods (*see, for example*, Ausubel (1995) at pages 6-1 to 6-11).

Anti-TGF-beta binding-protein antibodies, produced as described below,
15 can also be used to isolate DNA sequences that encode TGF-beta binding-protein genes from cDNA libraries. For example, the antibodies can be used to screen λ gt11 expression libraries, or the antibodies can be used for immunoscreening following hybrid selection and translation (*see, for example*, Ausubel (1995) at pages 6-12 to 6-16; Margolis et al., "Screening λ expression libraries with antibody and protein
20 probes," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 1-14 (Oxford University Press 1995)).

The sequence of a TGF-beta binding-protein cDNA or TGF-beta binding-protein genomic fragment can be determined using standard methods. Moreover, the identification of genomic fragments containing a TGF-beta binding-
25 protein promoter or regulatory element can be achieved using well-established techniques, such as deletion analysis (*see, generally*, Ausubel (1995)).

As an alternative, a TGF-beta binding-protein gene can be obtained by synthesizing DNA molecules using mutually priming long oligonucleotides and the nucleotide sequences described herein (*see, for example*, Ausubel (1995) at pages 8-8
30 to 8-9). Established techniques using the polymerase chain reaction provide the ability to synthesize DNA molecules at least two kilobases in length (Adang et al., *Plant Molec. Biol.* 21:1131, 1993; Bambot et al., *PCR Methods and Applications* 2:266, 1993; Dillon et al., "Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 263-268, (Humana Press, Inc.
35 1993); Holowachuk et al., *PCR Methods Appl.* 4:299, 1995).

3. Production of TGF-beta binding-protein genes

Nucleic acid molecules encoding variant TGF-beta binding-protein genes can be obtained by screening various cDNA or genomic libraries with polynucleotide probes having nucleotide sequences based upon SEQ ID NO:1, 5, 9, 11, 13, or 15, using procedures described above. TGF-beta binding-protein gene variants can also be constructed synthetically. For example, a nucleic acid molecule can be devised that encodes a polypeptide having a conservative amino acid change, compared with the amino acid sequence of SEQ ID NOs: 2, 6, 8, 10, 12, 14, or 16. That is, variants can be obtained that contain one or more amino acid substitutions of SEQ ID NOs: 2, 6, 8, 10, 12, 14 or 16, in which an alkyl amino acid is substituted for an alkyl amino acid in a TGF-beta binding-protein amino acid sequence, an aromatic amino acid is substituted for an aromatic amino acid in a TGF-beta binding-protein amino acid sequence, a sulfur-containing amino acid is substituted for a sulfur-containing amino acid in a TGF-beta binding-protein amino acid sequence, a hydroxy-containing amino acid is substituted for a hydroxy-containing amino acid in a TGF-beta binding-protein amino acid sequence, an acidic amino acid is substituted for an acidic amino acid in a TGF-beta binding-protein amino acid sequence, a basic amino acid is substituted for a basic amino acid in a TGF-beta binding-protein amino acid sequence, or a dibasic monocarboxylic amino acid is substituted for a dibasic monocarboxylic amino acid in a TGF-beta binding-protein amino acid sequence.

Among the common amino acids, for example, a "conservative amino acid substitution" is illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine. In making such substitutions, it is important to, where possible, maintain the cysteine backbone outlined in Figure 1.

Conservative amino acid changes in a TGF-beta binding-protein gene can be introduced by substituting nucleotides for the nucleotides recited in SEQ ID NO:1. Such "conservative amino acid" variants can be obtained, for example, by oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like (see Ausubel (1995) at pages 8-10 to 8-22; and McPherson (ed.), *Directed Mutagenesis: A Practical Approach* (IRL Press 1991)). The functional ability of such variants can be determined using a standard method, such as the assay described herein. Alternatively, a variant TGF-beta binding-protein polypeptide can be identified by the ability to specifically bind anti-TGF-beta binding-

protein antibodies.

Routine deletion analyses of nucleic acid molecules can be performed to obtain "functional fragments" of a nucleic acid molecule that encodes a TGF-beta binding-protein polypeptide. As an illustration, DNA molecules having the nucleotide
5 sequence of SEQ ID NO:1 can be digested with *Bal*31 nuclease to obtain a series of nested deletions. The fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for activity, or for the ability to bind anti-TGF-beta binding-protein antibodies. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce
10 deletions or stop codons to specify production of a desired fragment. Alternatively, particular fragments of a TGF-beta binding-protein gene can be synthesized using the polymerase chain reaction.

Standard techniques for functional analysis of proteins are described by, for example, Treuter et al., *Molec. Gen. Genet.* 240:113, 1993; Content et al.,
15 "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in *Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems*, Cantell (ed.), pages 65-72 (Nijhoff 1987); Herschman, "The EGF Receptor," in *Control of Animal Cell Proliferation, Vol. 1*, Boynton et al., (eds.) pages 169-199 (Academic Press 1985); Coumailleau et al., *J. Biol. Chem.*
20 270:29270, 1995; Fukunaga et al., *J. Biol. Chem.* 270:25291, 1995; Yamaguchi et al., *Biochem. Pharmacol.* 50:1295, 1995; and Meisel et al., *Plant Molec. Biol.* 30:1, 1996.

The present invention also contemplates functional fragments of a TGF-beta binding-protein gene that have conservative amino acid changes.

A TGF-beta binding-protein variant gene can be identified on the basis
25 of structure by determining the level of identity with nucleotide and amino acid sequences of SEQ ID NOs: 1, 5, 9, 11, 13, or, 15 and 2, 6, 10, 12, 14, or 16, as discussed above. An alternative approach to identifying a variant gene on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant TGF-beta binding-protein gene can hybridize under stringent conditions to a nucleic
30 acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 9, 11, 13, or, 15, or a portion thereof of at least 15 or 20 nucleotides in length. As an illustration of stringent hybridization conditions, a nucleic acid molecule having a variant TGF-beta binding-protein sequence can bind with a fragment of a nucleic acid molecule having a sequence from SEQ ID NO:1 in a buffer containing, for example, 5xSSPE (1xSSPE =
35 180 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA (pH 7.7), 5xDenhardt's solution (100xDenhardt's = 2% (w/v) bovine serum albumin, 2% (w/v)

Ficoll, 2% (w/v) polyvinylpyrrolidone) and 0.5% SDS incubated overnight at 55-60°C. Post-hybridization washes at high stringency are typically performed in 0.5xSSC (1xSSC = 150 mM sodium chloride, 15 mM trisodium citrate) or in 0.5xSSPE at 55-60°C.

5 Regardless of the particular nucleotide sequence of a variant TGF-beta binding-protein gene, the gene encodes a polypeptide that can be characterized by its functional activity, or by the ability to bind specifically to an anti-TGF-beta binding-protein antibody. More specifically, variant TGF-beta binding-protein genes encode polypeptides which exhibit at least 50%, and preferably, greater than 60, 70, 80 or
10 90%, of the activity of polypeptides encoded by the human TGF-beta binding-protein gene described herein.

4. Production of TGF-beta binding-protein in Cultured Cells

To express a TGF-beta binding-protein gene, a nucleic acid molecule encoding the polypeptide must be operably linked to regulatory sequences that control
15 transcriptional expression in an expression vector and then introduced into a host cell. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene which is suitable for selection of cells that carry the expression vector.

Expression vectors that are suitable for production of a foreign protein in
20 eukaryotic cells typically contain (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance marker to provide for the growth and selection of the expression vector in a bacterial host; (2) eukaryotic DNA elements that control initiation of transcription, such as a promoter; and (3) DNA elements that control the processing of transcripts, such as a transcription termination/polyadenylation sequence.

25 TGF-beta binding-proteins of the present invention are preferably expressed in mammalian cells. Examples of mammalian host cells include African green monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21; ATCC CRL 8544), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61), rat
30 pituitary cells (GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658).

For a mammalian host, the transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus,
35 simian virus, or the like, in which the regulatory signals are associated with a particular gene

which has a high level of expression. Suitable transcriptional and translational regulatory sequences also can be obtained from mammalian genes, such as actin, collagen, myosin, and metallothionein genes.

Transcriptional regulatory sequences include a promoter region sufficient to
 5 direct the initiation of RNA synthesis. Suitable eukaryotic promoters include the promoter of the mouse metallothionein I gene [Hamer et al., *J. Molec. Appl. Genet.* 1:273, 1982], the TK promoter of *Herpes* virus [McKnight, *Cell* 31:355, 1982], the SV40 early promoter [Benoist et al., *Nature* 290:304, 1981], the Rous sarcoma virus promoter [Gorman et al., *Proc. Nat'l Acad. Sci. USA* 79:6777, 1982], the cytomegalovirus promoter [Foecking et al.,
 10 *Gene* 45:101, 1980], and the mouse mammary tumor virus promoter (see, generally, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163-181 (John Wiley & Sons, Inc. 1996)).

Alternatively, a prokaryotic promoter, such as the bacteriophage T3 RNA
 15 polymerase promoter, can be used to control TGF-beta binding-protein gene expression in mammalian cells if the prokaryotic promoter is regulated by a eukaryotic promoter (Zhou et al., *Mol. Cell. Biol.* 10:4529, 1990; Kaufman et al., *Nucl. Acids Res.* 19:4485, 1991).

TGF-beta binding-protein genes may also be expressed in bacterial, yeast, insect, or plant cells. Suitable promoters that can be used to express TGF-beta binding-
 20 protein polypeptides in a prokaryotic host are well-known to those of skill in the art and include promoters capable of recognizing the T4, T3, Sp6 and T7 polymerases, the P_R and P_L promoters of bacteriophage lambda, the *trp*, *recA*, heat shock, *lacUV5*, *tac*, *lpp-lacSpr*, *phoA*, and *lacZ* promoters of *E. coli*, promoters of *B. subtilis*, the promoters of the bacteriophages of *Bacillus*, *Streptomyces* promoters, the *int* promoter of bacterio-
 25 phage lambda, the *bla* promoter of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene. Prokaryotic promoters have been reviewed by Glick, *J. Ind. Microbiol.* 1:277, 1987, Watson et al., *Molecular Biology of the Gene*, 4th Ed. (Benjamin Cummins 1987), and by Ausubel et al. (1995).

Preferred prokaryotic hosts include *E. coli* and *Bacillus subtilis*.
 30 Suitable strains of *E. coli* include BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, DH1, DH4I, DH5, DH5I, DH5IF', DH5IMCR, DH10B, DH10B/p3, DH11S, C600, HB101, JM101, JM105, JM109, JM110, K38, RR1, Y1088, Y1089, CSH18, ER1451, and ER1647 (see, for example, Brown (Ed.), *Molecular Biology Labfax* (Academic Press 1991)). Suitable strains of *Bacillus subtilis* include BR151, YB886, MI119,
 35 MI120, and B170 (see, for example, Hardy, "Bacillus Cloning Methods," in *DNA Cloning: A Practical Approach*, Glover (Ed.) (IRL Press 1985)).

Methods for expressing proteins in prokaryotic hosts are well-known to those of skill in the art (see, for example, Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 15 (Oxford University Press 1995); Ward et al., "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, page 137 (Wiley-Liss, Inc. 1995); and Georgiou, "Expression of Proteins in Bacteria," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), page 101 (John Wiley & Sons, Inc. 1996)).

10 The baculovirus system provides an efficient means to introduce cloned *TGF-beta binding-protein* genes into insect cells. Suitable expression vectors are based upon the *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV), and contain well-known promoters such as *Drosophila* heat shock protein (hsp) 70 promoter, *Autographa californica* nuclear polyhedrosis virus immediate-early gene
15 promoter (*ie-1*) and the delayed early 39K promoter, baculovirus p10 promoter, and the *Drosophila* metallothionein promoter. Suitable insect host cells include cell lines derived from IPLB-Sf-21, a *Spodoptera frugiperda* pupal ovarian cell line, such as Sf9 (ATCC CRL 1711), Sf21AE, and Sf21 (Invitrogen Corporation; San Diego, CA), as well as *Drosophila* Schneider-2 cells. Established techniques for producing
20 recombinant proteins in baculovirus systems are provided by Bailey et al., "Manipulation of Baculovirus Vectors," in *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols*, Murray (ed.), pages 147-168 (The Humana Press, Inc. 1991), by Patel et al., "The baculovirus expression system," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 205-244 (Oxford
25 University Press 1995), by Ausubel (1995) at pages 16-37 to 16-57, by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995), and by Lucknow, "Insect Cell Expression Technology," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 183-218 (John Wiley & Sons, Inc. 1996).

Promoters for expression in yeast include promoters from *GALI* (galactose), *PGK* (phosphoglycerate kinase), *ADH* (alcohol dehydrogenase), *AOXI* (alcohol oxidase), *HIS4* (histidinol dehydrogenase), and the like. Many yeast cloning vectors have been designed and are readily available. These vectors include YIp-based vectors, such as YIp5, YRp vectors, such as YRp17, YEp vectors such as YEp13 and YCp vectors, such as YCp19. One skilled in the art will appreciate that there are a
35 wide variety of suitable vectors for expression in yeast cells.

Expression vectors can also be introduced into plant protoplasts, intact plant

tissues, or isolated plant cells. General methods of culturing plant tissues are provided, for example, by Miki et al., "Procedures for Introducing Foreign DNA into Plants," in *Methods in Plant Molecular Biology and Biotechnology*, Glick et al. (eds.), pages 67-88 (CRC Press, 1993).

5 An expression vector can be introduced into host cells using a variety of standard techniques including calcium phosphate transfection, liposome-mediated transfection, microprojectile-mediated delivery, electroporation, and the like. Preferably, the transfected cells are selected and propagated to provide recombinant host cells that comprise the expression vector stably integrated in the host cell genome. Techniques for
10 introducing vectors into eukaryotic cells and techniques for selecting such stable transformants using a dominant selectable marker are described, for example, by Ausubel (1995) and by Murray (ed.), *Gene Transfer and Expression Protocols* (Humana Press 1991). Methods for introducing expression vectors into bacterial, yeast, insect, and plant cells are also provided by Ausubel (1995).

15 General methods for expressing and recovering foreign protein produced by a mammalian cell system is provided by, for example, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163 (Wiley-Liss, Inc. 1996). Standard techniques for recovering protein produced by a bacterial system is provided by, for example,
20 Grisshammer et al., "Purification of over-produced proteins from *E. coli* cells," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 59-92 (Oxford University Press 1995). Established methods for isolating recombinant proteins from a baculovirus system are described by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc., 1995).

25 More generally, TGF-beta binding-protein can be isolated by standard techniques, such as affinity chromatography, size exclusion chromatography, ion exchange chromatography, HPLC and the like. Additional variations in TGF-beta binding-protein isolation and purification can be devised by those of skill in the art. For example, anti-TGF-beta binding-protein antibodies, obtained as described below,
30 can be used to isolate large quantities of protein by immunoaffinity purification.

5. Production of Antibodies to TGF-beta binding-proteins

Antibodies to TGF-beta binding-protein can be obtained, for example, using the product of an expression vector as an antigen. Particularly useful anti-TGF-beta binding-protein antibodies "bind specifically" with TGF-beta binding-protein of
35 Sequence ID Nos. 2, 6, 10, 12, 14, or 16, but not to other TGF-beta binding-proteins

such as Dan, Cerberus, SCGF, or Gremlin. Antibodies of the present invention (including fragments and derivatives thereof) may be a polyclonal or, especially a monoclonal antibody. The antibody may belong to any immunoglobulin class, and may be for example an IgG, for example IgG₁, IgG₂, IgG₃, IgG₄; IgE; IgM; or IgA antibody. It
5 may be of animal, for example mammalian origin, and may be for example a murine, rat, human or other primate antibody. Where desired the antibody may be an internalising antibody.

Polyclonal antibodies to recombinant TGF-beta binding-protein can be prepared using methods well-known to those of skill in the art (see, for example, Green
10 et al., "Production of Polyclonal Antisera," in *Immunochemical Protocols* (Manson, ed.), pages 1-5 (Humana Press 1992); Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 15 (Oxford University Press 1995)). Although polyclonal antibodies are typically raised in animals
15 such as rats, mice, rabbits, goats, or sheep, an anti-TGF-beta binding-protein antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in Goldenberg et al., international patent publication No. WO 91/11465 (1991), and in Losman et al., *Int. J. Cancer* 46:310,
20 1990.

The antibody should comprise at least a variable region domain. The variable region domain may be of any size or amino acid composition and will generally comprise at least one hypervariable amino acid sequence responsible for antigen binding embedded in a framework sequence. In general terms the variable (V) region domain may
25 be any suitable arrangement of immunoglobulin heavy (V_H) and/or light (V_L) chain variable domains. Thus for example the V region domain may be monomeric and be a V_H or V_L domain where these are capable of independently binding antigen with acceptable affinity. Alternatively the V region domain may be dimeric and contain V_H-V_H, V_H-V_L, or V_L-V_L, dimers in which the V_H and V_L chains are non-covalently associated (abbreviated
30 hereinafter as F_v). Where desired, however, the chains may be covalently coupled either directly, for example via a disulphide bond between the two variable domains, or through a linker, for example a peptide linker, to form a single chain domain (abbreviated hereinafter as scF_v).

The variable region domain may be any naturally occurring variable domain
35 or an engineered version thereof. By engineered version is meant a variable region domain which has been created using recombinant DNA engineering techniques. Such engineered

versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody.

The variable region domain may be covalently attached at a C-terminal amino acid to at least one other antibody domain or a fragment thereof. Thus, for example where a V_H domain is present in the variable region domain this may be linked to an immunoglobulin C_H1 domain or a fragment thereof. Similarly a V_L domain may be linked to a C_K domain or a fragment thereof. In this way for example the antibody may be a Fab fragment wherein the antigen binding domain contains associated V_H and V_L domains covalently linked at their C-termini to a $CH1$ and C_K domain respectively. The $CH1$ domain may be extended with further amino acids, for example to provide a hinge region domain as found in a Fab' fragment, or to provide further domains, such as antibody $CH2$ and $CH3$ domains.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (see, for example, Larrick et al., *Methods: A Companion to Methods in Enzymology* 2:106, 1991; Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in *Monoclonal Antibodies: Production, Engineering and Clinical Application*, Ritter et al. (eds.), page 166 (Cambridge University Press 1995); and Ward et al., "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, Birch et al., (eds.), page 137 (Wiley-Liss, Inc. 1995)).

Antibodies for use in the invention may in general be monoclonal (prepared by conventional immunisation and cell fusion procedures) or in the case of fragments, derived therefrom using any suitable standard chemical e.g. reduction or enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin.

More specifically, monoclonal anti-TGF-beta binding-protein antibodies can be generated utilizing a variety of techniques. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler et al., *Nature* 256:495, 1975; and Coligan et al. (eds.), *Current Protocols in Immunology*, 1:2.5.1-2.6.7 (John Wiley & Sons 1991) ["Coligan"]; Picksley et al., "Production of monoclonal antibodies against proteins expressed in *E.*

coli," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 93 (Oxford University Press 1995)).

Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising a TGF-beta binding-protein gene product, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

In addition, an anti-TGF-beta binding-protein antibody of the present invention may be derived from a human monoclonal antibody. Human monoclonal antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, for example, by Green et al., *Nature Genet.* 7:13, 1994; Lonberg et al., *Nature* 368:856, 1994; and Taylor et al., *Int. Immun.* 6:579, 1994.

Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines et al., "Purification of Immunoglobulin G (IgG)," in *Methods in Molecular Biology, Vol. 10*, pages 79-104 (The Humana Press, Inc. 1992)).

For particular uses, it may be desirable to prepare fragments of anti-TGF-beta binding-protein antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted $F(ab')_2$. This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab

fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patent No. 4,331,647, Nisonoff et al., *Arch Biochem. Biophys.* 89:230, 1960, Porter, *Biochem. J.* 73:119, 1959, Edelman et al., in *Methods in Enzymology* 1:422 (Academic Press 1967), and by Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.

Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Alternatively, the antibody may be a recombinant or engineered antibody obtained by the use of recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions. Such DNA is known and/or is readily available from DNA libraries including for example phage-antibody libraries (see Chiswell, D J and McCafferty, J. *Tibtech.* 10 80-84 (1992)) or where desired can be synthesised. Standard molecular biology and/or chemistry procedures may be used to sequence and manipulate the DNA, for example, to introduce codons to create cysteine residues, to modify, add or delete other amino acids or domains as desired.

From here, one or more replicable expression vectors containing the DNA may be prepared and used to transform an appropriate cell line, e.g. a non-producing myeloma cell line, such as a mouse NSO line or a bacterial, e.g. *E.coli* line, in which production of the antibody will occur. In order to obtain efficient transcription and translation, the DNA sequence in each vector should include appropriate regulatory sequences, particularly a promoter and leader sequence operably linked to the variable domain sequence. Particular methods for producing antibodies in this way are generally well known and routinely used. For example, basic molecular biology procedures are described by Maniatis *et al* (Molecular Cloning, Cold Spring Harbor Laboratory, New York, 1989); DNA sequencing can be performed as described in Sanger *et al* (PNAS 74, 5463, (1977)) and the Amersham International plc sequencing handbook; and site directed mutagenesis can be carried out according to the method of Kramer *et al* (Nucl. Acids Res. 12, 9441, (1984)) and the Anglian Biotechnology Ltd handbook. Additionally, there are numerous publications, detailing techniques suitable for the preparation of antibodies by manipulation of DNA, creation of expression vectors and transformation of appropriate cells, for example as reviewed by Mountain A and Adair, J R in Biotechnology and Genetic Engineering Reviews (ed. Tombs, M P, 10, Chapter 1, 1992, Intercept, Andover, UK) and in International Patent Specification No. WO 91/09967.

Where desired, the antibody according to the invention may have one or

more effector or reporter molecules attached to it and the invention extends to such modified proteins. The effector or reporter molecules may be attached to the antibody through any available amino acid side-chain, terminal amino acid or, where present carbohydrate functional group located in the antibody, always provided of course that this
5 does not adversely affect the binding properties and eventual usefulness of the molecule. Particular functional groups include, for example any free amino, imino, thiol, hydroxyl, carboxyl or aldehyde group. Attachment of the antibody and the effector and/or reporter molecule(s) may be achieved via such groups and an appropriate functional group in the effector or reporter molecules. The linkage may be direct or indirect, through spacing or
10 bridging groups.

Effector molecules include, for example, antineoplastic agents, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, nucleic acids and fragments thereof, e.g. DNA, RNA and fragments thereof, naturally occurring and synthetic
15 polymers e.g. polysaccharides and polyalkylene polymers such as poly(ethylene glycol) and derivatives thereof, radionuclides, particularly radioiodide, and chelated metals. Suitable reporter groups include chelated metals, fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

Particular antineoplastic agents include cytotoxic and cytostatic agents, for
20 example alkylating agents, such as nitrogen mustards (e.g. chlorambucil, melphalan, mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramidate, triethylenethiophosphor-amide, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid or fluorocitric acid, antibiotics, such as bleomycins (e.g.
25 bleomycin sulphate), doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), actinomycins (e.g. dactinomycin) plicamycin, calichaemicin and derivatives thereof, or esperamicin and derivatives thereof; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids, such as ellipticine; polyols such as taxicin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone or testolactone), progestins
30 (e.g. megestrol acetate or medroxyprogesterone acetate), estrogens (e.g. dimethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); anthraquinones, such as mitoxantrone, ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

Particularly useful effector groups are calichaemicin and derivatives thereof
35 (see for example South African Patent Specifications Nos. 85/8794, 88/8127 and 90/2839).

Chelated metals include chelates of di-or tripositive metals having a

coordination number from 2 to 8 inclusive. Particular examples of such metals include technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general the metal is preferably a radionuclide. Particular radionuclides include ^{99m}Tc, ¹⁸⁶Re, ¹⁸⁸Re, ⁵⁸Co, ⁶⁰Co, ⁶⁷Cu, ¹⁹⁵Au, ¹⁹⁹Au, ¹¹⁰Ag, ²⁰³Pb, ²⁰⁶Bi, ²⁰⁷Bi, ¹¹¹In, ⁶⁷Ga, ⁶⁸Ga, ⁸⁸Y, ⁹⁰Y, ¹⁶⁰Tb, ¹⁵³Gd and ⁴⁷Sc.

The chelated metal may be for example one of the above types of metal chelated with any suitable polydentate chelating agent, for example acyclic or cyclic polyamines, polyethers, (e.g. crown ethers and derivatives thereof); polyamides; porphyrins; and carbocyclic derivatives.

In general, the type of chelating agent will depend on the metal in use. One particularly useful group of chelating agents in conjugates according to the invention, however, are acyclic and cyclic polyamines, especially polyaminocarboxylic acids, for example diethylenetriaminepentaacetic acid and derivatives thereof, and macrocyclic amines, e.g. cyclic tri-aza and tetra-aza derivatives (for example as described in International Patent Specification No. WO 92/22583); and polyamides, especially desferrioxamine and derivatives thereof.

Thus for example when it is desired to use a thiol group in the antibody as the point of attachment this may be achieved through reaction with a thiol reactive group present in the effector or reporter molecule. Examples of such groups include an α -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone, or a disulphide. These and other suitable linking procedures are generally and more particularly described in International Patent Specifications Nos. WO 93/06231, WO 92/22583, WO 90/091195 and WO 89/01476.

25 ASSAYS FOR SELECTING MOLECULES WHICH INCREASE BONE DENSITY

As discussed above, the present invention provides methods for selecting and/or isolating compounds which are capable of increasing bone density. For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta binding protein and a selected member of the TGF-beta family of proteins, (b) determining whether the selected molecule stimulates signaling by the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding protein to the TGF-beta family of proteins. Within certain embodiments, the molecule enhances the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation.

Within other aspects of the invention, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta binding-protein and (b) determining whether the expression (or activity) of TGF-beta binding-protein from said exposed cells decreases, and therefrom determining whether the compound is capable of increasing bone mineral content. Within one embodiment, the cells are selected from the group consisting of the spontaneously transformed or untransformed normal human bone from bone biopsies and rat parietal bone osteoblasts. Such methods may be accomplished in a wide variety of assay formats including, for example, Countercurrent Immuno-Electrophoresis (CIEP), Radioimmunoassays, Radioimmunoprecipitations, Enzyme-Linked Immuno-Sorbent Assays (ELISA), Dot Blot assays, Inhibition or Competition assays, and sandwich assays (*see* U.S. Patent Nos. 4,376,110 and 4,486,530; *see also Antibodies: A Laboratory Manual, supra*).

Representative embodiments of such assays are provided below in Examples 5 and 6. Briefly, a family member of the TGF-beta super-family or a TGF-beta binding protein is first bound to a solid phase, followed by addition of a candidate molecule. The labeled family member of the TGF-beta super-family or a TGF-beta binding protein is then added to the assay, the solid phase washed, and the quantity of bound or labeled TGF-beta super-family member or TGF-beta binding protein on the solid support determined. Molecules which are suitable for use in increasing bone mineral content as described herein are those molecules which decrease the binding of TGF-beta binding protein to a member or members of the TGF-beta super-family in a statistically significant manner. Obviously, assays suitable for use within the present invention should not be limited to the embodiments described within Examples 2 and 3. In particular, numerous parameters may be altered, such as by binding TGF-beta to a solid phase, or by elimination of a solid phase entirely.

Within other aspects of the invention, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta and (b) determining whether the activity of TGF-beta from said exposed cells is altered, and therefrom determining whether the compound is capable of increasing bone mineral content. Similar to the above described methods, a wide variety of methods may be utilized to assess the changes of TGF-beta binding-protein expression due to a selected test compound.

For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta-binding-protein and a selected member of the TGF-beta family of proteins, (b) determining whether the selected molecule up-regulates the signaling of the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding-protein to the TGF-beta family of proteins. Within certain embodiments, the molecule enhances the ability of TGF-beta to function as a positive regulator of mechemchymal cell differentiation.

Similar to the above described methods, a wide variety of methods may be utilized to assess stimulation of TGF-beta due to a selected test compound. One such representative method is provided below in Example 6 (see also Durham et al., *Endo.* 136:1374-1380).

Within yet other aspects of the present invention, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the step of determining whether a selected molecule inhibits the binding of TGF-beta binding-protein to bone, or an analogue thereof. As utilized herein, it should be understood that bone or analogues thereof refers to hydroxyapatite, or a surface composed of a powdered form of bone, crushed bone or intact bone. Similar to the above described methods, a wide variety of methods may be utilized to assess the inhibition of TGF-beta binding-protein localization to bone matrix. One such representative method is provided below in Example 7.

It should be noted that while the methods recited herein may refer to the analysis of an individual test molecule, that the present invention should not be so limited. In particular, the selected molecule may be contained within a mixture of compounds. Hence, the recited methods may further comprise the step of isolating a molecule which inhibits the binding of TGF-beta binding-protein to a TGF-beta family member.

CANDIDATE MOLECULES

A wide variety of molecules may be assayed for their ability to inhibit the binding of TGF-beta binding-protein to a TGF-beta family member. Representative examples which are discussed in more detail below include organic molecules, proteins or peptides, and nucleic acid molecules. Although it should be evident from the discussion below that the candidate molecules described herein may be utilized in the

assays described herein, it should also be readily apparent that such molecules can also be utilized in a variety of diagnostic and therapeutic settings.

1. Organic Molecules

Numerous organic molecules may be assayed for their ability to inhibit
5 the binding of TGF-beta binding-protein to a TGF-beta family member.

For example, within one embodiment of the invention suitable organic molecules may be selected from either a chemical library, wherein chemicals are assayed individually, or from combinatorial chemical libraries where multiple compounds are assayed at once, then deconvoluted to determine and isolate the most
10 active compounds.

Representative examples of such combinatorial chemical libraries include those described by Agrafiotis et al., "System and method of automatically generating chemical compounds with desired properties," U.S. Patent No. 5,463,564; Armstrong, R.W., "Synthesis of combinatorial arrays of organic compounds through
15 the use of multiple component combinatorial array syntheses," WO 95/02566; Baldwin, J.J. et al., "Sulfonamide derivatives and their use," WO 95/24186; Baldwin, J.J. et al., "Combinatorial dihydrobenzopyran library," WO 95/30642; Brenner, S., "New kit for preparing combinatorial libraries," WO 95/16918; Chenera, B. et al., "Preparation of library of resin-bound aromatic carbocyclic compounds," WO 95/16712; Ellman, J.A.,
20 "Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support," U.S. Patent No. 5,288,514; Felder, E. et al., "Novel combinatorial compound libraries," WO 95/16209; Lerner, R. et al., "Encoded combinatorial chemical libraries," WO 93/20242; Pavia, M.R. et al., "A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal
25 library," WO 95/04277; Summerton, J.E. and D.D. Weller, "Morpholino-subunit combinatorial library and method," U.S. Patent No. 5,506,337; Holmes, C., "Methods for the Solid Phase Synthesis of Thiazolidinones, Metathiazanones, and Derivatives thereof," WO 96/00148; Phillips, G.B. and G.P. Wei, "Solid-phase Synthesis of Benzimidazoles," *Tet. Letters* 37:4887-90, 1996; Ruhland, B. et al., "Solid-supported
30 Combinatorial Synthesis of Structurally Diverse β -Lactams," *J. Amer. Chem. Soc.* 111:253-4, 1996; Look, G.C. et al., "The Identification of Cyclooxygenase-1 Inhibitors from 4-Thiazolidinone Combinatorial Libraries," *Bioorg and Med. Chem. Letters* 6:707-12, 1996.

2. Proteins and Peptides

A wide range of proteins and peptides may likewise be utilized as candidate molecules for inhibitors of the binding of TGF-beta binding-protein to a TGF-beta family member.

5 a. Combinatorial Peptide Libraries

Peptide molecules which are putative inhibitors of the binding of TGF-beta binding-protein to a TGF-beta family member may be obtained through the screening of combinatorial peptide libraries. Such libraries may either be prepared by one of skill in the art (*see e.g.*, U.S. Patent Nos. 4,528,266 and 4,359,535, and Patent
10 Cooperation Treaty Publication Nos. WO 92/15679, WO 92/15677, WO 90/07862, WO 90/02809, or purchased from commercially available sources (*e.g.*, New England Biolabs Ph.D.TM Phage Display Peptide Library Kit).

b. Antibodies

Antibodies which inhibit the binding of TGF-beta binding-protein to a
15 TGF-beta family member may readily be prepared given the disclosure provided herein. Within the context of the present invention, antibodies are understood to include monoclonal antibodies, polyclonal antibodies, anti-idiotypic antibodies, antibody fragments (*e.g.*, Fab, and F(ab')₂, F_v variable regions, or complementarity determining regions). As discussed above, antibodies are understood to be specific
20 against TGF-beta binding-protein, or against a specific TGF-beta family member, if they bind with a K_a of greater than or equal to 10⁷M⁻¹, preferably greater than or equal to 10⁸M⁻¹, and do not bind to other TGF-beta binding-proteins, or, bind with a K_a of less than or equal to 10⁶M⁻¹. Furthermore, antibodies of the present invention should block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

25 The affinity of a monoclonal antibody or binding partner, as well as inhibition of binding can be readily determined by one of ordinary skill in the art (*see* Scatchard, *Ann. N.Y. Acad. Sci.* 51:660-672, 1949).

Briefly, polyclonal antibodies may be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows,
30 various fowl, rabbits, mice, or rats. Typically, the TGF-beta binding-protein or unique peptide thereof of 13-20 amino acids (preferably conjugated to keyhole limpet hemocyanin by cross-linking with glutaraldehyde) is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections, along with an adjuvant such as Freund's complete or incomplete adjuvant. Following several

booster immunizations, samples of serum are collected and tested for reactivity to the protein or peptide. Particularly preferred polyclonal antisera will give a signal on one of these assays that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the protein, larger quantities of
5 antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.

Monoclonal antibodies may also be readily generated using conventional techniques (see U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993, see also *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988, which are also incorporated
10 herein by reference).

Briefly, within one embodiment a subject animal such as a rat or mouse
15 is immunized with TGF-beta binding-protein or portion thereof as described above. The protein may be admixed with an adjuvant such as Freund's complete or incomplete adjuvant in order to increase the resultant immune response. Between one and three weeks after the initial immunization the animal may be reimmunized with another booster immunization, and tested for reactivity to the protein utilizing assays described
20 above. Once the animal has reached a plateau in its reactivity to the injected protein, it is sacrificed, and organs which contain large numbers of B cells such as the spleen and lymph nodes are harvested.

Cells which are obtained from the immunized animal may be immortalized by infection with a virus such as the Epstein-Barr virus (EBV) (see
25 Glasky and Reading, *Hybridoma* 8(4):377-389, 1989). Alternatively, within a preferred embodiment, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibody. Suitable myeloma lines include, for example, NS-1 (ATCC No. TIB 18), and P3X63 - Ag 8.653 (ATCC No. CRL 1580).

Following the fusion, the cells may be placed into culture plates
30 containing a suitable medium, such as RPMI 1640, or DMEM (Dulbecco's Modified Eagles Medium) (JRH Biosciences, Lenexa, Kansas), as well as additional ingredients, such as fetal bovine serum (FBS, i.e., from Hyclone, Logan, Utah, or JRH Biosciences). Additionally, the medium should contain a reagent which selectively
35 allows for the growth of fused spleen and myeloma cells such as HAT (hypoxanthine, aminopterin, and thymidine) (Sigma Chemical Co., St. Louis, Missouri). After about

seven days, the resulting fused cells or hybridomas may be screened in order to determine the presence of antibodies which are reactive against TGF-beta binding-protein (depending on the antigen used), and which block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

5 A wide variety of assays may be utilized to determine the presence of antibodies which are reactive against the proteins of the present invention, including for example countercurrent immuno-electrophoresis, radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, western blots, immunoprecipitation, inhibition or competition assays, and
10 sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Following several clonal dilutions and reassays, a hybridoma producing antibodies reactive against the desired protein may be isolated.

Other techniques may also be utilized to construct monoclonal
15 antibodies (see William D. Huse et al., "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281, December 1989; see also L. Sastry et al., "Cloning of the Immunological Repertoire in *Escherichia coli* for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library," *Proc. Natl. Acad. Sci. USA*
20 86:5728-5732, August 1989; see also Michelle Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," *Strategies in Molecular Biology* 3:1-9, January 1990). These references describe a commercial system available from Stratagene (La Jolla, California) which enables the production of antibodies through recombinant techniques. Briefly, mRNA is isolated from a B cell
25 population, and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the λ ImmunoZap(H) and λ ImmunoZap(L) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (see Huse et al., *supra*; see also Sastry et al., *supra*). Positive plaques may subsequently be converted to a non-lytic plasmid which allows high level expression of
30 monoclonal antibody fragments from *E. coli*.

Similarly, portions or fragments, such as Fab and Fv fragments, of antibodies may also be constructed utilizing conventional enzymatic digestion or recombinant DNA techniques to incorporate the variable regions of a gene which encodes a specifically binding antibody. Within one embodiment, the genes which
35 encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using nucleotide primers for the variable region. These primers

may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources. Stratagene (La Jolla, California) sells primers for mouse and human variable regions including, among others, primers for V_{Ha}, V_{Hb}, V_{Hc}, V_{Hd}, C_{H1}, V_L and C_L regions. These primers may be utilized to amplify heavy
5 or light chain variable regions, which may then be inserted into vectors such as ImmunoZAP™ H or ImmunoZAP™ L (Stratagene), respectively. These vectors may then be introduced into *E. coli*, yeast, or mammalian-based systems for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the V_H and V_L domains may be produced (see Bird et al., *Science* 242:423-426,
10 1988). In addition, such techniques may be utilized to change a "murine" antibody to a "human" antibody, without altering the binding specificity of the antibody.

Once suitable antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor
15 Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques.

c. Mutant TGF-beta binding-proteins

As described herein and below in the Examples (e.g., Examples 8 and
20 9), altered versions of TGF-beta binding-protein which compete with native TGF-beta binding-protein's ability to block the activity of a particular TGF-beta family member should lead to increased bone density. Thus, mutants of TGF-beta binding-protein which bind to the TGF-beta family member but do not inhibit the function of the TGF-beta family member would meet the criteria. The mutant versions must effectively
25 compete with the endogenous inhibitory functions of TGF-beta binding-protein.

d. Production of proteins

Although various genes (or portions thereof) have been provided herein, it should be understood that within the context of the present invention, reference to one or more of these genes includes derivatives of the genes that are substantially
30 similar to the genes (and, where appropriate, the proteins (including peptides and polypeptides) that are encoded by the genes and their derivatives). As used herein, a nucleotide sequence is deemed to be "substantially similar" if: (a) the nucleotide sequence is derived from the coding region of the above-described genes and includes, for example, portions of the sequence or allelic variations of the sequences discussed

above, or alternatively, encodes a molecule which inhibits the binding of TGF-beta binding-protein to a member of the TGF-beta family, (b) the nucleotide sequence is capable of hybridization to nucleotide sequences of the present invention under moderate, high or very high stringency (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1989); or (c) the DNA sequences are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b). Further, the nucleic acid molecule disclosed herein includes both complementary and non-complementary sequences, provided the sequences otherwise meet the criteria set forth herein. Within the context of the present invention, high stringency means standard hybridization conditions (e.g., 5XSSPE, 0.5% SDS at 65°C, or the equivalent).

The structure of the proteins encoded by the nucleic acid molecules described herein may be predicted from the primary translation products using the hydrophobicity plot function of, for example, P/C Gene or Intelligenetics Suite (Intelligenetics, Mountain View, California), or according to the methods described by Kyte and Doolittle (*J. Mol. Biol.* 157:105-132, 1982).

Proteins of the present invention may be prepared in the form of acidic or basic salts, or in neutral form. In addition, individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions, or additions may be made to the amino acid or nucleic acid sequences, the net effect of which is to retain or further enhance or decrease the biological activity of the mutant or wild-type protein. Moreover, due to degeneracy in the genetic code, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid sequence.

Other derivatives of the proteins disclosed herein include conjugates of the proteins along with other proteins or polypeptides. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal fusion proteins which may be added to facilitate purification or identification of proteins (see U.S. Patent No. 4,851,341, see also, Hopp et al., *Bio/Technology* 6:1204, 1988.) Alternatively, fusion proteins such as Flag/TGF-beta binding-protein be constructed in order to assist in the identification, expression, and analysis of the protein.

Proteins of the present invention may be constructed using a wide variety of techniques described herein. Further, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following

ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific (or segment specific) mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (*Gene* 42:133, 1986); Bauer et al. (*Gene* 37:73, 1985); Craik (*BioTechniques*, January 1985, 12-19); Smith et al. (*Genetic Engineering: Principles and Methods*, Plenum Press, 1981); and Sambrook et al. (*supra*). Deletion or truncation derivatives of proteins (e.g., a soluble extracellular portion) may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, 1989).

Mutations which are made in the nucleic acid molecules of the present invention preferably preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, that would adversely affect translation of the mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed mutants screened for indicative biological activity. Alternatively, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Nucleic acid molecules which encode proteins of the present invention may also be constructed utilizing techniques of PCR mutagenesis, chemical mutagenesis (Drinkwater and Klinedinst, *PNAS* 83:3402-3406, 1986), by forced nucleotide misincorporation (e.g., Liao and Wise *Gene* 88:107-111, 1990), or by use of randomly mutagenized oligonucleotides (Horwitz et al., *Genome* 3:112-117, 1989).

The present invention also provides for the manipulation and expression of the above described genes by culturing host cells containing a vector capable of expressing the above-described genes. Such vectors or vector constructs include either synthetic or cDNA-derived nucleic acid molecules encoding the desired protein, which

are operably linked to suitable transcriptional or translational regulatory elements. Suitable regulatory elements may be derived from a variety of sources, including bacterial, fungal, viral, mammalian, insect, or plant genes. Selection of appropriate regulatory elements is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of regulatory elements include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a transcriptional terminator, and a ribosomal binding sequence, including a translation initiation signal.

Nucleic acid molecules that encode any of the proteins described above may be readily expressed by a wide variety of prokaryotic and eukaryotic host cells, including bacterial, mammalian, yeast or other fungi, viral, insect, or plant cells. Methods for transforming or transfecting such cells to express foreign DNA are well known in the art (see, e.g., Itakura et al., U.S. Patent No. 4,704,362; Hinnen et al., *Proc. Natl. Acad. Sci. USA* 75:1929-1933, 1978; Murray et al., U.S. Patent No. 4,801,542; Upshall et al., U.S. Patent No. 4,935,349; Hagen et al., U.S. Patent No. 4,784,950; Axel et al., U.S. Patent No. 4,399,216; Goeddel et al., U.S. Patent No. 4,766,075; and Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, 1989; for plant cells see Czako and Marton, *Plant Physiol.* 104:1067-1071, 1994; and Paszkowski et al., *Biotech.* 24:387-392, 1992).

Bacterial host cells suitable for carrying out the present invention include *E. coli*, *B. subtilis*, *Salmonella typhimurium*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, as well as many other bacterial species well known to one of ordinary skill in the art. Representative examples of bacterial host cells include DH5 α (Stratagene, LaJolla, California).

Bacterial expression vectors preferably comprise a promoter which functions in the host cell, one or more selectable phenotypic markers, and a bacterial origin of replication. Representative promoters include the β -lactamase (penicillinase) and lactose promoter system (see Chang et al., *Nature* 275:615, 1978), the T7 RNA polymerase promoter (Studier et al., *Meth. Enzymol.* 185:60-89, 1990), the lambda promoter (Elvin et al., *Gene* 87:123-126, 1990), the *trp* promoter (Nichols and Yanofsky, *Meth. in Enzymology* 101:155, 1983) and the *tac* promoter (Russell et al., *Gene* 20:231, 1982). Representative selectable markers include various antibiotic resistance markers such as the kanamycin or ampicillin resistance genes. Many plasmids suitable for transforming host cells are well known in the art, including among others, pBR322 (see Bolivar et al., *Gene* 2:95, 1977), the pUC plasmids pUC18,

pUC19, pUC118, pUC119 (see Messing, *Meth. in Enzymology* 101:20-77, 1983 and Vieira and Messing, *Gene* 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, California).

Yeast and fungi host cells suitable for carrying out the present invention include, among others, *Saccharomyces pombe*, *Saccharomyces cerevisiae*, the genera *Pichia* or *Kluyveromyces* and various species of the genus *Aspergillus* (McKnight et al., U.S. Patent No. 4,935,349). Suitable expression vectors for yeast and fungi include, among others, YCp50 (ATCC No. 37419) for yeast, and the amdS cloning vector pV3 (Turnbull, *Bio/Technology* 7:169, 1989), YRp7 (Struhl et al., *Proc. Natl. Acad. Sci. USA* 76:1035-1039, 1978), YEpl3 (Broach et al., *Gene* 8:121-133, 1979), pJDB249 and pJDB219 (Beggs, *Nature* 275:104-108, 1978) and derivatives thereof.

Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., *J. Biol. Chem.* 255:12073-12080, 1980; Alber and Kawasaki, *J. Mol. Appl. Genet.* 1:419-434, 1982) or alcohol dehydrogenase genes (Young et al., in *Genetic Engineering of Microorganisms for Chemicals*, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, *Meth. Enzymol.* 101:192-201, 1983). Examples of useful promoters for fungi vectors include those derived from *Aspergillus nidulans* glycolytic genes, such as the *adh3* promoter (McKnight et al., *EMBO J.* 4:2093-2099, 1985). The expression units may also include a transcriptional terminator. An example of a suitable terminator is the *adh3* terminator (McKnight et al., *ibid.*, 1985).

As with bacterial vectors, the yeast vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include *leu2* (Broach et al., *ibid.*), *ura3* (Botstein et al., *Gene* 8:17, 1979), or *his3* (Struhl et al., *ibid.*). Another suitable selectable marker is the *cat* gene, which confers chloramphenicol resistance on yeast cells.

Techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (*ibid.*), Hinnen et al. (*Proc. Natl. Acad. Sci. USA* 75:1929-1933, 1978), Yelton et al. (*Proc. Natl. Acad. Sci. USA* 81:1740-1747, 1984), and Russell (*Nature* 301:167-169, 1983). The genotype of the host cell may contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art.

Protocols for the transformation of yeast are also well known to those of ordinary skill in the art. For example, transformation may be readily accomplished either by preparation of spheroplasts of yeast with DNA (see Hinnen et al., *PNAS USA* 75:1929, 1978) or by treatment with alkaline salts such as LiCl (see Itoh et al., *J. Bacteriology* 153:163, 1983). Transformation of fungi may also be carried out using polyethylene glycol as described by Cullen et al. (*Bio/Technology* 5:369, 1987).

Viral vectors include those which comprise a promoter that directs the expression of an isolated nucleic acid molecule that encodes a desired protein as described above. A wide variety of promoters may be utilized within the context of the present invention, including for example, promoters such as MoMLV LTR, RSV LTR, Friend MuLV LTR, adenoviral promoter (Ohno et al., *Science* 265:781-784, 1994), neomycin phosphotransferase promoter/enhancer, late parvovirus promoter (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), Herpes TK promoter, SV40 promoter, metallothionein IIa gene enhancer/promoter, cytomegalovirus immediate early promoter, and the cytomegalovirus immediate late promoter. Within particularly preferred embodiments of the invention, the promoter is a tissue-specific promoter (see e.g., WO 91/02805; EP 0,415,731; and WO 90/07936). Representative examples of suitable tissue specific promoters include neural specific enolase promoter, platelet derived growth factor beta promoter, bone morphogenic protein promoter, human alpha1-chimaerin promoter, synapsin I promoter and synapsin II promoter. In addition to the above-noted promoters, other viral-specific promoters (e.g., retroviral promoters (including those noted above, as well as others such as HIV promoters), hepatitis, herpes (e.g., EBV), and bacterial, fungal or parasitic (e.g., malarial) -specific promoters may be utilized in order to target a specific cell or tissue which is infected with a virus, bacteria, fungus or parasite.

Mammalian cells suitable for carrying out the present invention include, among others COS, CHO, SaOS, osteosarcomas, KS483, MG-63, primary osteoblasts, and human or mammalian bone marrow stroma. Mammalian expression vectors for use in carrying out the present invention will include a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters include viral promoters and cellular promoters. Bone specific promoters include the bone sialo-protein and the promoter for osteocalcin. Viral promoters include the cytomegalovirus immediate early promoter (Boshart et al., *Cell* 41:521-530, 1985), cytomegalovirus immediate late promoter, SV40 promoter (Subramani et al., *Mol. Cell. Biol.* 1:854-864, 1981), MMTV LTR, RSV LTR, metallothionein-1, adenovirus E1a. Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), a

mouse V_K promoter (Bergman et al., *Proc. Natl. Acad. Sci. USA* 81:7041-7045, 1983; Grant et al., *Nucl. Acids Res.* 15:5496, 1987) and a mouse V_H promoter (Loh et al., *Cell* 33:85-93, 1983). The choice of promoter will depend, at least in part, upon the level of expression desired or the recipient cell line to be transfected.

5 Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable
10 polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, *ibid.*), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., *Nuc. Acids Res.* 9:3719-3730, 1981). The expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and
15 the RNA splice sites. Preferred vectors may also include enhancer sequences, such as the SV40 enhancer. Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable expression vectors can be obtained from commercial sources (*e.g.*, Stratagene, La Jolla, California).

 Vector constructs comprising cloned DNA sequences can be introduced
20 into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann et al., *EMBO J.* 1:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley and Sons,
25 Inc., NY, 1987). To identify cells that have stably integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable selectable marker. Preferred amplifiable
30 selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (*Mammalian Cell Technology*, Butterworth Publishers, Stoneham, Massachusetts,

 Mammalian cells containing a suitable vector are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest.
35 Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an

amplifiable, selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level.

5 Cells that satisfy these criteria can then be cloned and scaled up for production.

Protocols for the transfection of mammalian cells are well known to those of ordinary skill in the art. Representative methods include calcium phosphate mediated transfection, electroporation, lipofection, retroviral, adenoviral and protoplast fusion-mediated transfection (*see* Sambrook et al., *supra*). Naked vector constructs can

10 also be taken up by muscular cells or other suitable cells subsequent to injection into the muscle of a mammal (or other animals).

Numerous insect host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of baculoviruses as vectors for expressing heterologous DNA sequences in insect cells has

15 been reviewed by Atkinson et al. (*Pestic. Sci.* 28:215-224, 1990).

Numerous plant host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of *Agrobacterium rhizogenes* as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (*J. Biosci. (Bangalore)* 11:47-58, 1987).

20 Within related aspects of the present invention, proteins of the present invention may be expressed in a transgenic animal whose germ cells and somatic cells contain a gene which encodes the desired protein and which is operably linked to a promoter effective for the expression of the gene. Alternatively, in a similar manner transgenic animals may be prepared that lack the desired gene (*e.g.*, "knock-out" mice).

25 Such transgenics may be prepared in a variety of non-human animals, including mice, rats, rabbits, sheep, dogs, goats and pigs (*see* Hammer et al., *Nature* 315:680-683, 1985, Palmiter et al., *Science* 222:809-814, 1983, Brinster et al., *Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985, Palmiter and Brinster, *Cell* 41:343-345, 1985, and U.S. Patent Nos. 5,175,383, 5,087,571, 4,736,866, 5,387,742, 5,347,075, 5,221,778, and

30 5,175,384). Briefly, an expression vector, including a nucleic acid molecule to be expressed together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs, for example, by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples. It is preferred that the introduced DNA be incorporated into the germ line of the animal so

35 that it is passed on to the animal's progeny. Tissue-specific expression may be achieved through the use of a tissue-specific promoter, or through the use of an

inducible promoter, such as the metallothionein gene promoter (Palmiter et al., 1983, *ibid*), which allows regulated expression of the transgene.

Proteins can be isolated by, among other methods, culturing suitable host and vector systems to produce the recombinant translation products of the present invention. Supernatants from such cell lines, or protein inclusions or whole cells where the protein is not excreted into the supernatant, can then be treated by a variety of purification procedures in order to isolate the desired proteins. For example, the supernatant may be first concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit. Following concentration, the concentrate may be applied to a suitable purification matrix such as, for example, an anti-protein antibody bound to a suitable support. Alternatively, anion or cation exchange resins may be employed in order to purify the protein. As a further alternative, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps may be employed to further purify the protein. Other methods of isolating the proteins of the present invention are well known in the skill of the art.

A protein is deemed to be "isolated" within the context of the present invention if no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by Coomassie blue staining. Within other embodiments, the desired protein can be isolated such that no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by silver staining.

3. Nucleic Acid Molecules

Within other aspects of the invention, nucleic acid molecules are provided which are capable of inhibiting TGF-beta binding-protein binding to a member of the TGF-beta family. For example, within one embodiment antisense oligonucleotide molecules are provided which specifically inhibit expression of TGF-beta binding-protein nucleic acid sequences (*see generally*, Hirashima et al. in *Molecular Biology of RNA: New Perspectives* (M. Inouye and B. S. Dudock, eds., 1987 Academic Press, San Diego, p. 401); *Oligonucleotides: Antisense Inhibitors of Gene Expression* (J.S. Cohen, ed., 1989 MacMillan Press, London); Stein and Cheng, *Science* 261:1004-1012, 1993; WO 95/10607; U.S. Patent No. 5,359,051; WO 92/06693; and EP-A2-612844). Briefly, such molecules are constructed such that they are complementary to, and able to form Watson-Crick base pairs with, a region of transcribed TGF-beta binding-protein mRNA sequence. The resultant double-stranded

nucleic acid interferes with subsequent processing of the mRNA, thereby preventing protein synthesis (see Example 10).

Within other aspects of the invention, ribozymes are provided which are capable of inhibiting the TGF-beta binding-protein binding to a member of the TGF-beta family. As used herein, "ribozymes" are intended to include RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity. The catalytic strand cleaves a specific site in a target RNA at greater than stoichiometric concentration. A wide variety of ribozymes may be utilized within the context of the present invention, including for example, the hammerhead ribozyme (for example, as described by Forster and Symons, *Cell* 48:211-220, 1987; Haseloff and Gerlach, *Nature* 328:596-600, 1988; Walbot and Bruening, *Nature* 334:196, 1988; Haseloff and Gerlach, *Nature* 334:585, 1988); the hairpin ribozyme (for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al., European Patent Publication No. 0 360 257, published March 26, 1990); and *Tetrahymena* ribosomal RNA-based ribozymes (see Cech et al., U.S. Patent No. 4,987,071). Ribozymes of the present invention typically consist of RNA, but may also be composed of DNA, nucleic acid analogs (e.g., phosphorothioates), or chimerics thereof (e.g., DNA/RNA/RNA).

4. Labels

The gene product or any of the candidate molecules described above and below, may be labeled with a variety of compounds, including for example, fluorescent molecules, toxins, and radionuclides. Representative examples of fluorescent molecules include fluorescein, *Phycobili* proteins, such as phycoerythrin, rhodamine, Texas red and luciferase. Representative examples of toxins include ricin, abrin diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, *Shigella* toxin, and *Pseudomonas* exotoxin A. Representative examples of radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I-131, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. In addition, the antibodies described above may also be labeled or conjugated to one partner of a ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein.

Methods for conjugating or labeling the molecules described herein with the representative labels set forth above may be readily accomplished by one of ordinary skill in the art (see Trichothecene Antibody Conjugate, U.S. Patent No. 4,744,981; Antibody Conjugate, U.S. Patent No. 5,106,951; Fluorogenic Materials and

Labeling Techniques, U.S. Patent No. 4,018,884; Metal Radionuclide Labeled Proteins for Diagnosis and Therapy, U.S. Patent No. 4,897,255; and Metal Radionuclide Chelating Compounds for Improved Chelation Kinetics, U.S. Patent No. 4,988,496; *see also* Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wilchek (eds.), Academic Press, New York, p. 30, 1974; *see also* Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988).

PHARMACEUTICAL COMPOSITIONS

As noted above, the present invention also provides a variety of pharmaceutical compositions, comprising one of the above-described molecules which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents.

In addition, the pharmaceutical compositions of the present invention may be prepared for administration by a variety of different routes. In addition, pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients or diluents (*e.g.*, water, saline or PBS) which may be necessary to reconstitute the pharmaceutical composition.

METHODS OF TREATMENT

The present invention also provides methods for increasing the mineral content and mineral density of bone. Briefly, numerous conditions result in the loss of bone mineral content, including for example, disease, genetic predisposition, accidents which result in the lack of use of bone (*e.g.*, due to fracture), therapeutics which effect bone resorption, or which kill bone forming cells and normal aging. Through use of the molecules described herein which inhibit the TGF-beta binding-protein binding to a

TGF-beta family member such conditions may be treated or prevented. As utilized herein, it should be understood that bone mineral content has been increased, if bone mineral content has been increased in a statistically significant manner (*e.g.*, greater than one-half standard deviation), at a selected site.

5 A wide variety of conditions which result in loss of bone mineral content may be treated with the molecules described herein. Patients with such conditions may be identified through clinical diagnosis utilizing well known techniques (see, *e.g.*, Harrison's Principles of Internal Medicine, McGraw-Hill, Inc.). Representative examples of diseases that may be treated included dysplasias, wherein there is abnormal
10 growth or development of bone. Representative examples of such conditions include achondroplasia, cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher's, hypophosphatemic rickets, Marfan's, multiple hereditary exotoses, neurofibromatosis, osteogenesis imperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, fractures, periodontal disease, pseudoarthrosis and pyogenic osteomyelitis.

15 Other conditions which may be treated or prevented include a wide variety of causes of osteopenia (*i.e.*, a condition that causes greater than one standard deviation of bone mineral content or density below peak skeletal mineral content at youth). Representative examples of such conditions include anemic states, conditions caused steroids, conditions caused by heparin, bone marrow disorders, scurvy,
20 malnutrition, calcium deficiency, idiopathic osteoporosis, congenital osteopenia or osteoporosis, alcoholism, chronic liver disease, senility, postmenopausal state, oligomenorrhea , amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, transient regional osteoporosis and osteomalacia.

25 Within one aspect of the present invention, bone mineral content or density may be increased by administering to a warm-blooded animal a therapeutically effective amount of a molecule which inhibits the TGF-beta binding-protein binding to a TGF-beta family member. Examples of warm-blooded animals that may be treated include both vertebrates and mammals, including for example horses, cows, pigs,
30 sheep, dogs, cats, rats and mice. Representative examples of therapeutic molecules include ribozymes, ribozyme genes, antisense oligonucleotides and antibodies (*e.g.*, humanized antibodies).

Within other aspects of the present invention, methods are provided for increasing bone density, comprising the step of introducing into cells which home to
35 bone a vector which directs the expression of a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family, and administering the

vector containing cells to a warm-blooded animal. Briefly, cells which home to bone may be obtained directly from the bone of patients (e.g., cells obtained from the bone marrow such as CD34+, osteoblasts, osteocytes, and the like), from peripheral blood, or from cultures.

5 A vector which directs the expression of a molecule that inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family is introduced into the cells. Representative examples of suitable vectors include viral vectors such as herpes viral vectors (e.g., U.S. Patent No. 5,288,641), adenoviral vectors (e.g., WO 94/26914, WO 93/9191; Kolls et al., *PNAS* 91(1):215-219, 1994; Kass-Eisler et al.,
10 *PNAS* 90(24):11498-502, 1993; Guzman et al., *Circulation* 88(6):2838-48, 1993; Guzman et al., *Cir. Res.* 73(6):1202-1207, 1993; Zabner et al., *Cell* 75(2):207-216, 1993; Li et al., *Hum Gene Ther.* 4(4):403-409, 1993; Caillaud et al., *Eur. J. Neurosci.* 5(10):1287-1291, 1993; Vincent et al., *Nat. Genet.* 5(2):130-134, 1993; Jaffe et al., *Nat. Genet.* 1(5):372-378, 1992; and Levrero et al., *Gene* 101(2):195-202, 1991), adeno-
15 associated viral vectors (WO 95/13365; Flotte et al., *PNAS* 90(22):10613-10617, 1993), baculovirus vectors, parvovirus vectors (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), pox virus vectors (Panicali and Paoletti, *PNAS* 79:4927-4931, 1982; and Ozaki et al., *Biochem. Biophys. Res. Comm.* 193(2):653-660, 1993), and retroviruses (e.g., EP 0,415,731; WO 90/07936; WO 91/0285, WO 94/03622; WO 93/25698;
20 WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218). Viral vectors may likewise be constructed which contain a mixture of different elements (e.g., promoters, envelope sequences and the like) from different viruses, or non-viral sources. Within various embodiments, either the viral vector itself, or a viral particle which contains the viral vector may be utilized in the methods and compositions
25 described below.

Within other embodiments of the invention, nucleic acid molecules which encode a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family themselves may be administered by a variety of techniques, including, for example, administration of asialosomucoid (ASOR)
30 conjugated with poly-L-lysine DNA complexes (Cristano et al., *PNAS* 92:122-126, 1993), DNA linked to killed adenovirus (Curiel et al., *Hum. Gene Ther.* 3(2):147-154, 1992), cytofectin-mediated introduction (DMRIE-DOPE, Vical, California), direct DNA injection (Acsadi et al., *Nature* 352:815-818, 1991); DNA ligand (Wu et al., *J. of Biol. Chem.* 264:16985-16987, 1989); lipofection (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1989); liposomes (Pickering et al., *Circ.* 89(1):13-21, 1994; and
35 Wang et al., *PNAS* 84:7851-7855, 1987); microprojectile bombardment (Williams

et al., *PNAS* 88:2726-2730, 1991); and direct delivery of nucleic acids which encode the protein itself either alone (Vile and Hart, *Cancer Res.* 53: 3860-3864, 1993), or utilizing PEG-nucleic acid complexes.

Representative examples of molecules which may be expressed by the
5 vectors of present invention include ribozymes and antisense molecules, each of which are discussed in more detail above.

Determination of increased bone mineral content may be determined directly through the use of X-rays (e.g., Dual Energy X-ray Absorptometry or "DEXA"), or by inference through bone turnover markers (osteoblast specific alkaline
10 phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; see Comier, C., *Curr. Opin. in Rheu.* 7:243, 1995), or markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma tartrate-resistant acid phosphatases and galactosyl hydroxylysine; see Comier, *supra*). The amount of bone mass may also be calculated from body weights, or
15 utilizing other methods (see Guinness-Hey, *Metab. Bone Dis. and Rel. Res.* 5:177-181, 1984).

As will be evident to one of skill in the art, the amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient, and so forth.
20 Typically, the compositions may be administered by a variety of techniques, as noted above.

The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE 1

SCLEROSTEOSIS MAPS TO THE LONG ARM OF HUMAN CHROMOSOME 17

Genetic mapping of the defect responsible for sclerosteosis in humans localized the gene responsible for this disorder to the region of human chromosome 17 that encodes a novel TGF-beta binding-protein family member. In sclerosteosis, skeletal bone displays a substantial increase in mineral density relative to that of unaffected individuals. Bone in the head displays overgrowth as well. Sclerosteosis patients are generally healthy although they may exhibit variable degrees of syndactyly at birth and variable degrees of cranial compression and nerve compression in the skull.

Linkage analysis of the gene defect associated with sclerosteosis was conducted by applying the homozygosity mapping method to DNA samples collected from 24 South African Afrikaaner families in which the disease occurred. (Sheffield et al., 1994, *Human Molecular Genetics* 3:1331-1335. "Identification of a Bardet-Biedl syndrome locus on chromosome 3 and evaluation of an efficient approach to homozygosity mapping"). The Afrikaaner population of South Africa is genetically homogeneous; the population is descended from a small number of founders who colonized the area several centuries ago, and it has been isolated by geographic and social barriers since the founding. Sclerosteosis is rare everywhere in the world outside the Afrikaaner community, which suggests that a mutation in the gene was present in the founding population and has since increased in numbers along with the increase in the population. The use of homozygosity mapping is based on the assumption that DNA mapping markers adjacent to a recessive mutation are likely to be homozygous in affected individuals from consanguineous families and isolated populations.

A set of 371 microsatellite markers (Research Genetics, Set 6) from the autosomal chromosomes was selected to type pools of DNA from sclerosteosis patient samples. The DNA samples for this analysis came from 29 sclerosteosis patients in 24 families, 59 unaffected family members and a set of unrelated control individuals from the same population. The pools consisted of 4-6 individuals, either affected individuals, affected individuals from consanguineous families, parents and unaffected siblings, or unrelated controls. In the pools of unrelated individuals and in most of the pools with affected individuals or family members analysis of the markers showed several allele sizes for each marker. One marker, D17S1299, showed an indication of homozygosity: one band in several of the pools of affected individuals.

All 24 sclerosteosis families were typed with a total of 19 markers in the region of D17S1299 (at 17q12-q21). Affected individuals from every family were shown to be homozygous in this region, and 25 of the 29 individuals were homozygous for a core haplotype; they each had the same alleles between D17S1787 and D17S930. The other four individuals had one chromosome which matched this haplotype and a second which did not. In sum, the data compellingly suggested that this 3 megabase region contained the sclerosteosis mutation. Sequence analysis of most of the exons in this 3 megabase region identified a nonsense mutation in the novel TGF-beta binding-protein coding sequence (C>T mutation at position 117 of Sequence ID No. 1 results in a stop codon). This mutation was shown to be unique to sclerosteosis patients and carriers of Afrikaaner descent. The identity of the gene was further confirmed by identifying a mutation in its intron (A>T mutation at position +3 of the intron) which results in improper mRNA processing in a single, unrelated patient with diagnosed sclerosteosis.

15

EXAMPLE 2

TISSUE-SPECIFICITY OF TGF-BETA BINDING-PROTEIN GENE EXPRESSION

A. Human Beer Gene Expression by RT-PCR:

First-strand cDNA was prepared from the following total RNA samples using a commercially available kit ("Superscript Preamplification System for First-Strand cDNA Synthesis", Life Technologies, Rockville, MD): human brain, human liver, human spleen, human thymus, human placenta, human skeletal muscle, human thyroid, human pituitary, human osteoblast (NHOst from Clonetics Corp., San Diego, CA), human osteosarcoma cell line (Saos-2, ATCC# HTB-85), human bone, human bone marrow, human cartilage, vervet monkey bone, saccharomyces cerevisiae, and human peripheral blood monocytes. All RNA samples were purchased from a commercial source (Clontech, Palo Alto, CA), except the following which were prepared in-house: human osteoblast, human osteosarcoma cell line, human bone, human cartilage and vervet monkey bone. These in-house RNA samples were prepared using a commercially available kit ("TRI Reagent", Molecular Research Center, Inc., Cincinnati, OH).

PCR was performed on these samples, and additionally on a human genomic sample as a control. The sense Beer oligonucleotide primer had the sequence 5'-CCGGAGCTGGAGAACAACAAG-3' (SEQ ID NO:19). The antisense Beer oligonucleotide primer had the sequence 5'-GCACTGGCCGGAGCACACC-3' (SEQ

ID NO:20). In addition, PCR was performed using primers for the human beta-actin gene, as a control. The sense beta-actin oligonucleotide primer had the sequence 5'-AGGCCAACCGCGAGAAGATGA CC -3' (SEQ ID NO:21). The antisense beta-actin oligonucleotide primer had the sequence 5'-GAAGT CCAGGGCGACGTAGCA-3' (SEQ ID NO:22). PCR was performed using standard conditions in 25 ul reactions, with an annealing temperature of 61 degrees Celsius. Thirty-two cycles of PCR were performed with the Beer primers and twenty-four cycles were performed with the beta-actin primers.

Following amplification, 12 ul from each reaction were analyzed by agarose gel electrophoresis and ethidium bromide staining. See Figure 2A.

B. RNA In-situ Hybridization of Mouse Embryo Sections:

The full length mouse *Beer* cDNA (Sequence ID No. 11) was cloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA) in the antisense and sense direction using the manufacturer's protocol. ³⁵S-alpha-GTP-labeled cRNA sense and antisense transcripts were synthesized using in-vitro transcription reagents supplied by Ambion, Inc (Austin, TX). In-situ hybridization was performed according to the protocols of Lyons et al. (*J. Cell Biol.* 111:2427-2436, 1990).

The mouse *Beer* cRNA probe detected a specific message expressed in the neural tube, limb buds, blood vessels and ossifying cartilages of developing mouse embryos. Panel A in Figure 3 shows expression in the apical ectodermal ridge (aer) of the limb (l) bud, blood vessels (bv) and the neural tube (nt). Panel B shows expression in the 4th ventricle of the brain (4). Panel C shows expression in the mandible (ma) cervical vertebrae (cv), occipital bone (oc), palate (pa) and a blood vessel (bv). Panel D shows expression in the ribs (r) and a heart valve (va). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos.

ba=branchial arch, h=heart, te=telencephalon (forebrain), b=brain, f=frontonasal mass, g=gut, h=heart, j=jaw, li=liver, lu=lung, ot=otic vesicle, ao=, sc=spinal cord, skm=skeletal muscle, ns=nasal sinus, th=thymus, to=tongue, fl=forelimb, di=diaphragm

EXAMPLE 3

35 EXPRESSION AND PURIFICATION OF RECOMBINANT BEER PROTEIN

A. Expression in COS-1 Cells:

The DNA sequence encoding the full length human Beer protein was amplified using the following PCR oligonucleotide primers: The 5' oligonucleotide primer had the sequence 5'-**AAGCTTGGTACCATGCAGCTCCCAC**-3' (SEQ ID NO:23) and contained a HindIII restriction enzyme site (in bold) followed by 19 nucleotides of the *Beer* gene starting 6 base pairs prior to the presumed amino terminal start codon (ATG). The 3' oligonucleotide primer had the sequence 5'-**AAGCTTCTACTTGTCATCGTCGTCCT** TGTAGTCGTAGGCGTTCTCCAGCT-3' (SEQ ID NO:24) and contained a HindIII restriction enzyme site (in bold) followed by a reverse complement stop codon (CTA) followed by the reverse complement of the FLAG epitope (underlined, Sigma-Aldrich Co., St. Louis, MO) flanked by the reverse complement of nucleotides coding for the carboxy terminal 5 amino acids of the Beer. The PCR product was TA cloned ("Original TA Cloning Kit", Invitrogen, Carlsbad, CA) and individual clones were screened by DNA sequencing. A sequence-verified clone was then digested by HindIII and purified on a 1.5% agarose gel using a commercially available reagents ("QIAquick Gel Extraction Kit", Qiagen Inc., Valencia, CA). This fragment was then ligated to HindIII digested, phosphatase-treated pcDNA3.1 (Invitrogen, Carlsbad, CA) plasmid with T4 DNA ligase. DH10B *E. coli* were transformed and plated on LB, 100 µg/ml ampicillin plates. Colonies bearing the desired recombinant in the proper orientation were identified by a PCR-based screen, using a 5' primer corresponding to the T7 promoter/priming site in pcDNA3.1 and a 3' primer with the sequence 5'- GCACTGGCCGGAGCACACC-3' (SEQ ID NO:25) that corresponds to the reverse complement of internal BEER sequence. The sequence of the cloned fragment was confirmed by DNA sequencing.

COS-1 cells (ATCC# CRL-1650) were used for transfection. 50 µg of the expression plasmid pcDNA-Beer-Flag was transfected using a commercially available kit following protocols supplied by the manufacturer ("DEAE-Dextran Transfection Kit", Sigma Chemical Co., St. Louis, MO). The final media following transfection was DMEM (Life Technologies, Rockville, MD) containing 0.1% Fetal Bovine Serum. After 4 days in culture, the media was removed. Expression of recombinant BEER was analyzed by SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody (Sigma-Aldrich Co., St. Louis, MO). Purification of recombinant BEER protein was performed using an anti-FLAG M2 affinity column ("Mammalian Transient Expression System", Sigma-Aldrich Co., St. Louis, MO). The column profile was analyzed via SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody.

B. Expression in SF9 insect cells:

The human *Beer* gene sequence was amplified using PCR with standard conditions and the following primers:

Sense primer: 5'-GTCGTCGGATCCATGGGGTGGCAGGCGTTCAAGAATGAT-3'
5 (SEQ ID NO:26)

Antisense primer: 5'-GTCGTCAAGCTTCTACTTGTCATCGTCCTTGTAGTCGTA
GGCGTTCTCCAGCTCGGC-3' (SEQ ID NO:27)

The resulting cDNA contained the coding region of Beer with two modifications. The N-terminal secretion signal was removed and a FLAG epitope tag
10 (Sigma) was fused in frame to the C-terminal end of the insert. BamHI and HindIII cloning sites were added and the gene was subcloned into pMelBac vector (Invitrogen) for transfer into a baculoviral expression vector using standard methods.

Recombinant baculoviruses expressing Beer protein were made using the Bac-N-Blue transfection kit (Invitrogen) and purified according to the manufacturers
15 instructions.

SF9 cells (Invitrogen) were maintained in TNM_FH media (Invitrogen) containing 10% fetal calf serum. For protein expression, SF9 cultures in spinner flasks were infected at an MOI of greater than 10. Samples of the media and cells were taken daily for five days, and Beer expression monitored by western blot using an anti-FLAG
20 M2 monoclonal antibody (Sigma) or an anti-Beer rabbit polyclonal antiserum.

After five days the baculovirus-infected SF9 cells were harvested by centrifugation and cell associated protein was extracted from the cell pellet using a high salt extraction buffer (1.5 M NaCl, 50 mM Tris pH 7.5). The extract (20 ml per 300 ml culture) was clarified by centrifugation, dialyzed three times against four liters of
25 Tris buffered saline (150 mM NaCl, 50 mM Tris pH 7.5), and clarified by centrifugation again. This high salt fraction was applied to Hitrap Heparin (Pharmacia; 5 ml bed volume), washed extensively with HEPES buffered saline (25 mM HEPES 7.5, 150 mM NaCl) and bound proteins were eluted with a gradient from 150 mM NaCl to 1200 mM NaCl. Beer elution was observed at approximately 800 mM NaCl. Beer
30 containing fractions were supplemented to 10% glycerol and 1 mM DTT and frozen at -80 degrees C.

EXAMPLE 4

35 PREPARATION AND TESTING OF POLYCLONAL ANTIBODIES TO BEER, GREMLIN, AND
DAN

A. Preparation of antigen:

The DNA sequences of Human *Beer*, Human *Gremlin*, and Human *Dan* were amplified using standard PCR methods with the following oligonucleotide primers:

5 H. Beer

Sense: 5' -GACTTGGATCCCAGGGGTGGCAGGCGTTC- 3' (SEQ ID NO:28)

Antisense 5' -AGCATAAGCTTCTAGTAGGCGTTCTCCAG- 3' (SEQ ID NO:29)

H. Gremlin

Sense: 5' -GACTTGGATCCGAAGGGAAAAAGAAAGGG- 3' (SEQ ID NO:30)

10 Antisense: 5' -AGCATAAGCTTTTAATCCAAATCGATGGA- 3' (SEQ ID NO:31)

H. Dan

Sense: 5' -ACTACGAGCTCGGCCCCACCACCCATCAACAAG- 3' (SEQ ID NO:32)

Antisense: 5' -ACTTAGAAGCTTTCAGTCCTCAGCCCCCTCTTCC-3' (SEQ ID NO:33)

15 In each case the listed primers amplified the entire coding region minus the secretion signal sequence. These include restriction sites for subcloning into the bacterial expression vector pQE-30 (Qiagen Inc., Valencia, CA) at sites BamHI/HindIII for Beer and Gremlin, and sites SacI/HindIII for Dan. pQE30 contains a coding sequence for a 6x His tag at the 5' end of the cloning region. The completed constructs
20 were transformed into *E. coli* strain M-15/pRep (Qiagen Inc) and individual clones verified by sequencing. Protein expression in M-15/pRep and purification (6xHis affinity tag binding to Ni-NTA coupled to Sepharose) were performed as described by the manufacturer (Qiagen, The QIAexpressionist).

The *E. coli*-derived Beer protein was recovered in significant quantity
25 using solubilization in 6M guanidine and dialyzed to 2-4M to prevent precipitation during storage. Gremlin and Dan protein were recovered in higher quantity with solubilization in 6M guanidine and a post purification guanidine concentration of 0.5M.

B. Production and testing of polyclonal antibodies:

30 Polyclonal antibodies to each of the three antigens were produced in rabbit and in chicken hosts using standard protocols (R & R Antibody, Stanwood, WA; standard protocol for rabbit immunization and antisera recovery; Short Protocols in Molecular Biology. 2nd edition. 1992. 11.37- 11.41. Contributors Helen M. Cooper and Yvonne Paterson; chicken antisera was generated with Strategic Biosolutions,
35 Ramona, CA).

Rabbit antisera and chicken egg IgY fraction were screened for activity

via Western blot. Each of the three antigens was separated by PAGE and transferred to 0.45um nitrocellulose (Novex, San Diego, CA). The membrane was cut into strips with each strip containing approximately 75 ng of antigen. The strips were blocked in 3% Blotting Grade Block (Bio-Rad Laboratories, Hercules, CA) and washed 3 times in 1X Tris buffer saline (TBS) /0.02% TWEEN buffer. The primary antibody (preimmunization bleeds, rabbit antisera or chicken egg IgY in dilutions ranging from 1:100 to 1:10,000 in blocking buffer) was incubated with the strips for one hour with gentle rocking. A second series of three washes 1X TBS/0.02%TWEEN was followed by an one hour incubation with the secondary antibody (peroxidase conjugated donkey anti-rabbit, Amersham Life Science, Piscataway, NJ; or peroxidase conjugated donkey anti-chicken, Jackson ImmunoResearch, West Grove, PA). A final cycle of 3X washes of 1X TBS/0.02%TWEEN was performed and the strips were developed with Lumi-Light Western Blotting Substrate (Roche Molecular Biochemicals, Mannheim, Germany).

15

C. Antibody cross-reactivity test:

Following the protocol described in the previous section, nitrocellulose strips of Beer, Gremlin or Dan were incubated with dilutions (1:5000 and 1:10,000) of their respective rabbit antisera or chicken egg IgY as well as to antisera or chicken egg Igy (dilutions 1:1000 and 1:5000) made to the remaining two antigens. The increased levels of nonmatching antibodies was performed to detect low affinity binding by those antibodies that may be seen only at increased concentration. The protocol and duration of development is the same for all three binding events using the protocol described above. There was no antigen cross-reactivity observed for any of the antigens tested.

25

EXAMPLE 5

INTERACTION OF BEER WITH TGF-BETA SUPER-FAMILY PROTEINS

The interaction of Beer with proteins from different phylogenetic arms of the TGF- β superfamily were studied using immunoprecipitation methods. Purified TGF β -1, TGF β -2, TGF β -3, BMP-4, BMP-5, BMP-6 and GDNF were obtained from commercial sources (R&D systems; Minneapolis, MN). A representative protocol is as follows. Partially purified Beer was dialyzed into HEPES buffered saline (25 mM HEPES 7.5, 150 mM NaCl). Immunoprecipitations were done in 300 ul of IP buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1mM EDTA, 1.4 mM β -mercaptoethanol, 0.5 % triton X 100, and 10% glycerol). 30 ng recombinant human BMP-5 protein (R&D

35

systems) was applied to 15 ul of FLAG affinity matrix (Sigma; St Louis MO)) in the presence and absence of 500 ng FLAG epitope-tagged Beer. The proteins were incubated for 4 hours @ 4°C and then the affinity matrix-associated proteins were washed 5 times in IP buffer (1 ml per wash). The bound proteins were eluted from the affinity matrix in 60 microliters of 1X SDS PAGE sample buffer. The proteins were resolved by SDS PAGE and Beer associated BMP-5 was detected by western blot using anti-BMP-5 antiserum (Research Diagnostics, Inc) (see Figure 5).

BEER Ligand Binding Assay:

FLAG-Beer protein (20 ng) is added to 100 ul PBS/0.2% BSA and adsorbed into each well of 96 well microtiter plate previously coated with anti-FLAG monoclonal antibody (Sigma; St Louis MO) and blocked with 10% BSA in PBS. This is conducted at room temperature for 60 minutes. This protein solution is removed and the wells are washed to remove unbound protein. BMP-5 is added to each well in concentrations ranging from 10 pM to 500 nM in PBS/0.2% BSA and incubated for 2 hours at room temperature. The binding solution is removed and the plate washed with three times with 200ul volumes of PBS/0.2% BSA. BMP-5 levels are then detected using BMP-5 anti-serum via ELISA (F.M. Ausubel et al (1998) Current Protocols in Mol Biol. Vol 2 11.2.1-11.2.22). Specific binding is calculated by subtracting non-specific binding from total binding and analyzed by the LIGAND program (Munson and Podbard, Anal. Biochem., 107, p220-239, (1980).

In a variation of this method, Beer is engineered and expressed as a human Fc fusion protein. Likewise the ligand BMP is engineered and expressed as mouse Fc fusion. These proteins are incubated together and the assay conducted as described by Mellor et al using homogeneous time resolved fluorescence detection (G.W. Mellor et al., *J of Biomol Screening*, 3(2) 91-99, 1998).

EXAMPLE 6

SCREENING ASSAY FOR INHIBITION OF TGF-BETA BINDING-PROTEIN BINDING TO TGF-BETA FAMILY MEMBERS

The assay described above is replicated with two exceptions. First, BMP concentration is held fixed at the K_d determined previously. Second, a collection of antagonist candidates is added at a fixed concentration (20 uM in the case of the small organic molecule collections and 1 uM in antibody studies). These candidate molecules (antagonists) of TGF-beta binding-protein binding include organic

compounds derived from commercial or internal collections representing diverse chemical structures. These compounds are prepared as stock solutions in DMSO and are added to assay wells at $\leq 1\%$ of final volume under the standard assay conditions. These are incubated for 2 hours at room temperature with the BMP and Beer, the solution removed and the bound BMP is quantitated as described. Agents that inhibit 40% of the BMP binding observed in the absence of compound or antibody are considered antagonists of this interaction. These are further evaluated as potential inhibitors based on titration studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity. Comparable specificity control assays may also be conducted to establish the selectivity profile for the identified antagonist through studies using assays dependent on the BMP ligand action (e.g. BMP/BMP receptor competition study).

15

EXAMPLE 7

INHIBITION OF TGF-BETA BINDING-PROTEIN LOCALIZATION TO BONE MATRIX

Evaluation of inhibition of localization to bone matrix (hydroxyapatite) is conducted using modifications to the method of Nicolas (Nicolas, V. *Calcif Tissue Int* 57:206, 1995). Briefly, ^{125}I -labelled TGF-beta binding-protein is prepared as described by Nicolas (*supra*). Hydroxyapatite is added to each well of a 96 well microtiter plate equipped with a polypropylene filtration membrane (Polyfiltroninc, Weymouth MA). TGF-beta binding-protein is added to 0.2% albumin in PBS buffer. The wells containing matrix are washed 3 times with this buffer. Adsorbed TGF-beta binding-protein is eluted using 0.3M NaOH and quantitated.

25

Inhibitor identification is conducted via incubation of TGF-beta binding-protein with test molecules and applying the mixture to the matrix as described above. The matrix is washed 3 times with 0.2% albumin in PBS buffer. Adsorbed TGF-beta binding-protein is eluted using 0.3 M NaOH and quantitated. Agents that inhibit 40% of the TGF-beta binding-protein binding observed in the absence of compound or antibody are considered bone localization inhibitors. These inhibitors are further characterized through dose response studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity.

30

EXAMPLE 8

CONSTRUCTION OF TGF-BETA BINDING-PROTEIN MUTANT

A. Mutagenesis:

A full-length TGF-beta binding-protein cDNA in pBluescript SK serves
5 as a template for mutagenesis. Briefly, appropriate primers (see the discussion
provided above) are utilized to generate the DNA fragment by polymerase chain
reaction using Vent DNA polymerase (New England Biolabs, Beverly, MA). The
polymerase chain reaction is run for 23 cycles in buffers provided by the manufacturer
using a 57°C annealing temperature. The product is then exposed to two restriction
10 enzymes and after isolation using agarose gel electrophoresis, ligated back into pRBP4-
503 from which the matching sequence has been removed by enzymatic digestion.
Integrity of the mutant is verified by DNA sequencing.

B. Mammalian Cell Expression and Isolation of Mutant TGF-beta binding-protein:

15 The mutant TGF-beta binding-protein cDNAs are transferred into the
pcDNA3.1 mammalian expression vector described in EXAMPLE 3. After verifying
the sequence, the resultant constructs are transfected into COS-1 cells, and secreted
protein is purified as described in EXAMPLE 3.

20

EXAMPLE 9

ANIMAL MODELS -I

GENERATION OF TRANSGENIC MICE OVEREXPRESSING THE *BEER* GENE

The ~200 kilobase (kb) BAC clone 15G5, isolated from the CITB mouse
25 genomic DNA library (distributed by Research Genetics, Huntsville, AL) was used to
determine the complete sequence of the mouse *Beer* gene and its 5' and 3' flanking
regions. A 41 kb *Sall* fragment, containing the entire gene body, plus ~17 kb of 5'
flanking and ~20 kb of 3' flanking sequence was sub-cloned into the *Bam*HI site of the
SuperCosI cosmid vector (Stratagene, La Jolla, CA) and propagated in the *E. coli* strain
30 DH10B. From this cosmid construct, a 35 kb *Mlu*I - *Avi*II restriction fragment
(Sequence No. 6), including the entire mouse *Beer* gene, as well as 17 kb and 14 kb of
5' and 3' flanking sequence, respectively, was then gel purified, using conventional
means, and used for microinjection of mouse zygotes (DNX Transgenics; US Patent
No. 4,873,191). Founder animals in which the cloned DNA fragment was integrated
35 randomly into the genome were obtained at a frequency of 5-30% of live-born pups.
The presence of the transgene was ascertained by performing Southern blot analysis of

genomic DNA extracted from a small amount of mouse tissue, such as the tip of a tail. DNA was extracted using the following protocol: tissue was digested overnight at 55°C in a lysis buffer containing 200 mM NaCl, 100 mM Tris pH8.5, 5 mM EDTA, 0.2% SDS and 0.5 mg/ml Proteinase K. The following day, the DNA was extracted once with phenol/chloroform (50:50), once with chloroform/isoamylalcohol (24:1) and precipitated with ethanol. Upon resuspension in TE (10mM Tris pH7.5, 1 mM EDTA) 8-10 ug of each DNA sample were digested with a restriction endonuclease, such as EcoRI, subjected to gel electrophoresis and transferred to a charged nylon membrane, such as HyBondN+ (Amersham, Arlington Heights, IL). The resulting filter was then hybridized with a radioactively labelled fragment of DNA deriving from the mouse *Beer* gene locus, and able to recognize both a fragment from the endogenous gene locus and a fragment of a different size deriving from the transgene. Founder animals were bred to normal non-transgenic mice to generate sufficient numbers of transgenic and non-transgenic progeny in which to determine the effects of *Beer* gene overexpression. For these studies, animals at various ages (for example, 1 day, 3 weeks, 6 weeks, 4 months) are subjected to a number of different assays designed to ascertain gross skeletal formation, bone mineral density, bone mineral content, osteoclast and osteoblast activity, extent of endochondral ossification, cartilage formation, etc. The transcriptional activity from the transgene may be determined by extracting RNA from various tissues, and using an RT-PCR assay which takes advantage of single nucleotide polymorphisms between the mouse strain from which the transgene is derived (129Sv/J) and the strain of mice used for DNA microinjection [(C57BL5/J x SJL/J)F2].

ANIMAL MODELS – II

25 DISRUPTION OF THE MOUSE BEER GENE BY HOMOLOGOUS RECOMBINATION

Homologous recombination in embryonic stem (ES) cells can be used to inactivate the endogenous mouse *Beer* gene and subsequently generate animals carrying the loss-of-function mutation. A reporter gene, such as the *E. coli* β -galactosidase gene, was engineered into the targeting vector so that its expression is controlled by the endogenous *Beer* gene's promoter and translational initiation signal. In this way, the spatial and temporal patterns of *Beer* gene expression can be determined in animals carrying a targeted allele.

The targeting vector was constructed by first cloning the drug-selectable phosphoglycerate kinase (PGK) promoter driven *neomycin-resistance* gene (*neo*) cassette from pGT-N29 (New England Biolabs, Beverly, MA) into the cloning vector pSP72 (Promega, Madison, WI). PCR was used to flank the PGK*neo* cassette with

bacteriophage P1 loxP sites, which are recognition sites for the P1 Cre recombinase (Hoess et al., PNAS USA, 79:3398, 1982). This allows subsequent removal of the neo-resistance marker in targeted ES cells or ES cell-derived animals (US Patent 4,959,317). The PCR primers were comprised of the 34 nucleotide (ntd) loxP
 5 sequence, 15-25 ntd complementary to the 5' and 3' ends of the PGKneo cassette, as well as restriction enzyme recognition sites (BamHI in the sense primer and EcoRI in the anti-sense primer) for cloning into pSP72. The sequence of the sense primer was 5'-

AATCTGGATCCATAACTTCGTATAGCATACATTATACGAAGTTATCTGCAG
 10 GATTCGAGGGCCCCT-3' (SEQ ID NO:34); sequence of the anti-sense primer was 5'-AATCTGAATTCCACCGGTGTTAATTAAATAACTTCGT
 ATAATGTATGCTATACGAAGTTATAGATCTAGAG TCAGCTTCTGA-3' (SEQ ID NO:35).

The next step was to clone a 3.6 kb XhoI-HindIII fragment, containing
 15 the *E. coli* β -galactosidase gene and SV40 polyadenylation signal from pSV β (Clontech, Palo Alto, CA) into the pSP72-PGKneo plasmid. The "short arm" of homology from the mouse *Beer* gene locus was generated by amplifying a 2.4 kb fragment from the BAC clone 15G5. The 3' end of the fragment coincided with the translational initiation site of the *Beer* gene, and the anti-sense primer used in the PCR
 20 also included 30 ntd complementary to the 5' end of the β -galactosidase gene so that its coding region could be fused to the Beer initiation site in-frame. The approach taken for introducing the "short arm" into the pSP72- β gal-PGKneo plasmid was to linearize the plasmid at a site upstream of the β -gal gene and then to co-transform this fragment with the "short arm" PCR product and to select for plasmids in which the PCR product
 25 was integrated by homologous recombination. The sense primer for the "short arm" amplification included 30 ntd complementary to the pSP72 vector to allow for this recombination event. The sequence of the sense primer was 5'-ATTAGGTGACACT ATAGAACTCGAGCAGCTGAAGCTTAACCACATGGTGGCTCACAACCAT-3' (SEQ ID NO:36) and the sequence of the anti-sense primer was 5'-
 30 AACGACGGCCAGTGAATCCGTA ATCATGGTCATGCTGCCAGGTGGAGGAGGGCA-3' (SEQ ID NO:37).

The "long arm" from the *Beer* gene locus was generated by amplifying a 6.1 kb fragment from BAC clone 15G5 with primers which also introduce the rare-cutting restriction enzyme sites SgrAI, FseI, AscI and PacI. Specifically, the sequence
 35 of the sense primer was 5'-ATTACCACCGGTGACACCCGCTTCCTGACAG-3' (SEQ ID NO:38); the sequence of the anti-sense primer was 5'-

ATTACTTAATTAAACATGGCGCGCCAT

ATGGCCGGCCCCCTAATTGCGGCGCATCGTTAATT-3' (SEQ ID NO:39). The resulting PCR product was cloned into the TA vector (Invitrogen, Carlsbad, CA) as an intermediate step.

5 The mouse *Beer* gene targeting construct also included a second selectable marker, the *herpes simplex virus I thymidine kinase* gene (HSVTK) under the control of rous sarcoma virus long terminal repeat element (RSV LTR). Expression of this gene renders mammalian cells sensitive (and inviable) to gancyclovir; it is therefore a convenient way to select against neomycin-resistant cells in which the
10 construct has integrated by a non-homologous event (US Patent 5,464,764). The RSVLTR-HSVTK cassette was amplified from pPS1337 using primers that allow subsequent cloning into the FseI and Ascl sites of the "long arm"-TA vector plasmid. For this PCR, the sequence of the sense primer was 5'-
15 ATTACGGCCGGCCGCAAAGGAATTCAAGA TCTGA-3' (SEQ ID NO:40); the sequence of the anti-sense primer was 5'-ATTACGGCGCGCCCCCTC
ACAGGCCGCACCCAGCT-3' (SEQ ID NO:41).

 The final step in the construction of the targeting vector involved cloning the 8.8 kb SgrAI-Ascl fragment containing the "long arm" and RSVLTR-HSVTK gene into the SgrAI and Ascl sites of the pSP72-"short arm"- β gal-PGKneo
20 plasmid. This targeting vector was linearized by digestion with either Ascl or PacI before electroporation into ES cells.

EXAMPLE 10

25 ANTISENSE-MEDIATED BEER INACTIVATION

 17-nucleotide antisense oligonucleotides are prepared in an overlapping format, in such a way that the 5' end of the first oligonucleotide overlaps the translation initiating AUG of the Beer transcript, and the 5' ends of successive oligonucleotides occur in 5 nucleotide increments moving in the 5' direction (up to 50 nucleotides
30 away), relative to the Beer AUG. Corresponding control oligonucleotides are designed and prepared using equivalent base composition but redistributed in sequence to inhibit any significant hybridization to the coding mRNA. Reagent delivery to the test cellular system is conducted through cationic lipid delivery (P.L. Felgner, *Proc. Natl. Acad. Sci. USA* 84:7413, 1987). 2 ug of antisense oligonucleotide is added to 100 ul of
35 reduced serum media (Opti-MEM I reduced serum media; Life Technologies, Gaithersburg MD) and this is mixed with Lipofectin reagent (6 ul) (Life Technologies,

Gaithersburg MD) in the 100 ul of reduced serum media. These are mixed, allowed to complex for 30 minutes at room temperature and the mixture is added to previously seeded MC3T3E21 or KS483 cells. These cells are cultured and the mRNA recovered. Beer mRNA is monitored using RT-PCR in conjunction with Beer specific primers. In
5 addition, separate experimental wells are collected and protein levels characterized through western blot methods described in Example 4. The cells are harvested, resuspended in lysis buffer (50 mM Tris pH 7.5, 20 mM NaCl, 1mM EDTA, 1% SDS) and the soluble protein collected. This material is applied to 10-20 % gradient denaturing SDS PAGE. The separated proteins are transferred to nitrocellulose and
10 the western blot conducted as above using the antibody reagents described. In parallel, the control oligonucleotides are added to identical cultures and experimental operations are repeated. Decrease in Beer mRNA or protein levels are considered significant if the treatment with the antisense oligonucleotide results in a 50% change in either instance compared to the control scrambled oligonucleotide. This methodology enables
15 selective gene inactivation and subsequent phenotype characterization of the mineralized nodules in the tissue culture model.

SEQUENCES

Sequence ID No. 1: Human BEER cDNA (complete coding region plus 5' and 3' UTRs)

5
AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCCC
CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAACAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACCACCCCTTTGAGACCAAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTTCACCCGCTACGTGACCGAT
10 GGGCCGTGCCGCAGCGCCAAGCCGGTCACCGAGCTGGTGTGCTCCGGCCAGTGCGGCCCGGGCGCGCCTGCTGCCCAACGC
CATCGGCCGCGGCAAGTGGTGGCGACCTAGTGGGCCCCGACTTCCGCTGCATCCCCGACCGCTACCGCGCGCAGCGCGTGC
AGCTGCTGTGTCCCGGTGGTGAAGGCGCCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACC
CGCTTCCACAACCAAGTCCGAGCTCAAGGACTTCGGGACCGAGGCCGCTCGGCCCGAGAAGGGCCGGAAGCCGCGGCCCGG
CGCCCCGAGCGCCAAAGCCAACCAGGCCGAGCTGGAGAAGCCCTACTAGAGCCCCGCGCGCCCTCCCCACCGGCGGGC
15 GCCCCGGCCCTGAACCGCGCCCCACATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTTATTGTAAATGCCTGC
AAGCCAGGGCAGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCCGGCAAGGCCCCCTCAGCCCGCCAGCTG
AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTACAGACACTGAGCCACGCAGCCCCGCTCTGGGGCCGCTACCT
TTGCTGGTCCCACTTCCAGAGGAGGCAGAAATGGAAGCATTTTACCGCCCTGGGGTTTTAAGGGAGCGGTGTGGGAGTGG
GAAAGTCCAGGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
20 CCAGAGCACAAGACTGGGGGCACTGTAGATGTGGTTTCTAGTCCTGGCTCTGCCACTAAGTTGCTGTGTAACTTGAAC
TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAAATGAATG
CAGTTGCATTGATTCAAGTGCCTAAGGTCACTTCCAGAATTGAGAGTTGTGATGCTCTCTCTGACAGCCAAAGATGAAAAA
CAAACAGAAAAAAGTAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
25 CTTCCAGCCTGGCTTCCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGGTGGTGGGAGGGATAGAAATCATATCCGCCCAACTTCCCAAAGAGCAGCATCCCTCCCCCG
ACCCATAGCCATGTTTTAAAGTCACCTTCCGAAGAGAAGTGAAAGGTTCAAGGACACTGGCCTTGACAGGCCGAGGGAGC
AGCCATCACAACTCACAGACCAGCACATCCCTTTTGAACACCGCCTTCTGCCCACCACTCACGGACACATTTCTGCCT
AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAAATATTATTGGGGGAAAACTACAAGT
30 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGAAGAAATCATTTCCAGACAACCTC
TTACTTTCTGTGTAGTTTTTAATTGTTAAAAAAGTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
GGTCGTTTTTTTGGCAATTCTTCCACGTGGGACTTGTCCACAAGAATGAAAGTAGTGGTTTTTAAAGAGTTAAGTTACAT
ATTTATTTTCTCACTTAAGTTATTTATGCAAAAGTTTTTCTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAAGACAATGAATCATGACCGAAAG
35

WO 00/32773

PCT/US99/27990

69

Sequence ID No. 2: Human BEER protein (complete sequence)

MQLFLALCLVCLLVHTAFRVVEGQGWQAFKNDATETIIPELGEYPEPPFELENNKTMNRAENGGRFPHPHFETKDVSEYSC
 RELHFTRYVTDGFCSRSAKPVTELVCSGQCGPARLLENAIGRGKWWRFSGDFRCIPDRYRAQRVQLLCFGGEAPRARKVR
 5 LVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY

Sequence ID No. 3: Human Beer cDNA containing Sclerosteosis nonsense
 10 **mutation**

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
 CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCTAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCC
 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAACAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
 15 CTCCCCACCACCCCTTTGAGACCAAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTTCACCCGCTACGTGACCGAT
 GGGCCGTGCCGCGAGCGCCAAGCCGGTCACCGAGCTGGTGTGCTCCGGCCAGTGCGGCCCGGCGCGCCTGCTGCCCAACGC
 CATCGGCCGCGGCAAGTGGTGGCGACCTAGTGGGCCCGACTTCCGCTGCATCCCCGACCGCTACCGCGCGCAGCGCGTGC
 AGCTGCTGTGTCCCGGTGGTGGAGCGCCGCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACC
 CGCTTCCACAACCAAGTCCGAGCTCAAGGACTTCGGGACCGAGGCGGCTCGGCCGCGAGAAGGGCCGGAAGCCGCGGCCCGG
 20 CGCCCGGAGCGCCAAAGCCAACCAGGCCGAGCTGGAGAACGCCTACTAGAGCCCGCCGCGCCCCCTCCCCACCGGCGGGC
 GCCCCGGGCCCTGAACCCGCGCCCCACATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTTATTGTAATGCCTGC
 AACCCAGGGCAGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCCGCAAGGCCCCCTCAGCCCGCCAGCTG
 AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTCACAGACACTGAGCCACGCAGCCCCGCTCTGGGGCCGCTACCT
 TTGCTGGTCCCACTTCAGAGGAGGCAGAAATGGAAGCATTTTCACCGCCCTGGGGTTTTAAGGGAGCGGTGTGGGAGTGG
 25 GAAAGTCCAGGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
 CCAGAGCACAAGACTGGGGGCAACTGTAGATGTGGTTTCTAGTCCTGGCTCTGCCACTAACTTGCTGTGTAACTTGAAC
 TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
 TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAATGAATG
 CAGTTGCATTGATTCAAGTGCCTCAAGTCACTTCCAGAATTCAGAGTTGTGATGCTCTCTTCTGACAGCCAAAGATGAAAAA
 30 CAAACAGAAAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
 CTTCCCAGCCTGGCTTCCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
 AAAGGAGAGGGTCCGAGGGTGGTGGGAGGGATAGAAATCACATCCGCCCAACTTCCCAAGAGCAGCATCCCTCCCCCG
 ACCCATAGCCATGTTTTAAAGTCACCTTCCGAAGAGAAGTGAAAGGTTCAAGGACACTGGCCTTGCAAGGCCGAGGGAGC
 AGCCATCACAACTCACAGACCAGCACATCCCTTTTGAGACACCGCCTTCTGCCACCCTCACGGACACATTTCTGCCT
 35 AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAATATTATTGGGGGAAAAACTACAAGT
 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGAAGATCATTTCCAGACAACCTC

WO 00/32773

PCT/US99/27990

70

TTACTTTCTGTGTAGTTTTTAATTGTTAAAAAAGTTTTTAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
GGTCGTTTTTTTGGCAATCTTCCACGTGGGACTTGTCCACAAGAATGAAAGTAGTGGTTTTTAAGAGTTAAGTTACAT
ATTTATTTCTCACTTAAGTTATTTATGCAAAAGTTTTCTTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAAGACAATGAATCATGACCGAAAG

5

Sequence ID No. 4: Truncated Human Beer protein from Sclerosteosis

MQLFALCLVCLLVHTAFRVVEG*

10

Sequence ID No. 5: Human BEER cDNA encoding protein variant (V10I)

15 AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCATCTGC
CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCCG
CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACCACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACCTCACCCGCTACGTGACCGAT
GGGCGGTGCCGCGAGCGCAAGCCGGTCACCGAGCTGGTGTGCTCCGSCAGTGGGCCCCGGCGCGCCTGCTGCCCAACGC
20 CATCGGCCGCGGCAAGTGGTGGCGACCTAGTGGGCCCGACTTCCGCTGCATCCCGACCGCTACCGCGCGCAGCGCGTGC
AGCTGCTGTGTCCCGGTGGTGAAGCGCCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACC
CGCTTCCACAACCAGTCGGAGCTCAAGGACTTCGGGACCGAGGCCGCTCGGCCGCGAAGGGCCGGAAGCCGCGGCCCGG
CGCCCGGAGCGCCAAAGCCAACCAGGCCGAGCTGGAGAACGCCTACTAGAGCCCGCCCGCGCCCTCCCCACCGGCGGGC
GCCCCGGCCCTGAACCCGCGCCCCACATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTCATTGTAAATGCCTGC
25 AACCCAGGGCAGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCCGGAAGGCCCCCTCAGCCCGCCAGCTG
AGGGGTCCCACGGGGCAGGGGAGGGAATTGAGAGTCACAGACACTGAGCCACGCAGCCCCGCCTCTGGGGCCGCTACCT
TTGCTGGTCCCACTTCAGAGGAGGCAGAAATGGAAGCATTTTCACCGCCCTGGGGTTTTAAGGGAGCGGTGTGGGAGTGG
GAAAGTCCAGGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
CCAGAGCACAAAGACTGGGGGCAACTGTAGATGTGGTTTCTAGTCCTGGCTCTGCCACTAACTTGCTGTGTAACTTGAAC
30 TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAAATGAATG
CAGTTGCATTGATTCAGTGCCAAGGTCACTTCCAGAATTCAGAGTTGTGATGCTCTTCTGACAGCCAAAGATGAAAAA
CAACAGAAAAAAGTAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
CTTCCCAGCCTGGCTTCCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
35 AAAGGAGAGGGTCCGAGGGTGGTGGGAGGGATAGAAATCACATCCGCCCCAACTTCCCAAAGAGCAGCATCCCTCCCCCG
ACCCATAGCCATGTTTTAAAGTCACCTTCCGAAGAGAAGTGAAAGGTTCAAGGACACTGGCCTTGCAGGCCCGAGGGAGC

WO 00/32773

PCT/US99/27990

71

AGCCATCAGAACTCACAGACCAGCACATCCCTTTTGAGACACCGCCTTCTGCCACCCTCACGGACACATTTCTGCCT
 AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAATATTATTGGGGGAAAACTACAAGT
 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGGAAAATCATTTCAGACAACCTC
 TTACTTTCTGTGTAGTTTTTAATTGTTAAAAAAAAGTTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
 5 GGTCTTTTTTTGGCAATTCTCCACGTGGGACTTGTCACACAAGAATGAAAGTAGTGGTTTTTAAAGAGTTAAGTTACAT
 ATTTATTTTCTCACTTAAGTTATTTATGCAAAAGTTTTTCTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
 CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAAGACAATGAATCATGACCGAAAG

10 Sequence ID No. 6: Human BEER protein variant (V10I)

MQFLALCLICLLVHTAFRVVEGQGWQAFKNDATETIIRELGEYFEFFFELENNKTMNRAENGGRFPFHFFETKDVSEYSC
 RELHFTRYVTDGFCRSAKEVTELVCSGQCGEARLLENAIGRGKWWRESGFDFRCIPDRYRAQRVQLLCFGEAPRARKVR
 LVASCKCKRLTRFHNQSELKDFGTEAARFPQGRKRFERARSAKANQAELENAY

15

Sequence ID No. 7: Human Beer cDNA encoding protein variant (P38R)

20 AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
 CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCCG
 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
 CTCCCCACCACCCCTTTGAGACCAAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTTCACCCGCTACGTGACCGAT
 GGGCCGTGCCGACGCGCAAGCCGGTCACCGAGCTGGTGTGCTCCGGCCAGTGCGGCCCGGCGCGCCTGCTGCCCAACGC
 25 CATCGGCCGCGGCAAGTGGTGGCGACCTAGTGGGCCCCACTTCCGCTGCATCCCCGACCGCTACCGCGCGCAGCGCGTGC
 AGCTGCTGTGTCCCGGTGGTGGAGCGCCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACC
 CGCTTCCACAACCAAGTCCGAGCTCAAGGACTTCGGGACCGAGGCCGCTCGGCCGAGAAAGGGCCGGAAGCCGCGGCCCCG
 CGCCCGGAGCGCCAAAGCCAACAGGCCGAGCTGGAGAACGCCTACTAGAGCCCGCCGCGCCCTCCCCACCGGCGGGC
 GCCCCGGCCCTGAACCCGCGCCCCACATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTTATTGTAAATGCCTGC
 30 AACCAGGGCAGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCCGGCAAGGCCCCCTCAGCCCGCCAGCTG
 AGGGGTCCCACGGGGCAGGGGAGGGAATTGAGAGTCACAGACACTGAGCCACGCAGCCCCGCCTCTGGGGCCGCTACCT
 TTGCTGGTCCCACTTCAGAGGAGGCAGAAATGGAAGCATTTTCACCGCCCTGGGGTTTTAAGGGAGCGGTGTGGGAGTGG
 GAAAGTCCAGGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
 CCAGAGCACAAGACTGGGGGCACTGTAGATGTGGTTTCTAGTCCTGGCTCTGCCACTAATTGCTGTGTAACTTGAAC
 35 TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
 TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAATGAATG

CAGTTGCATTGATTCAAGTCCAGGTCCTTCCAGAAATTCAGAGTTGTGATGCTCTCTTCTGACAGCCAAAGATGAAAAA
CAACACAGAAAAAAGTAAAGAGTCTATTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
CTTCCCAGCCTGGCTTCCCCGGATGTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGGTGGTGGGAGGGATAGAAATCACATCCGCCCCAACTTCCCAAAGAGCAGCATCCCTCCCCCG
5 ACCCATAGCCATGTTTTAAAGTCACCTTCCGAAGAGAAGTGAAAGGTTCAAGGACACTGGCCTTGCAGGCCCCGAGGGAGC
AGCCATCACAACTCACAGACCAGCACATCCCTTTTGAGACACCGCCTTCTGCCCACCACTCACGGACACATTTCTGCCT
AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAATATTATTGGGGGAAAACTACAAGT
GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGAAAATCATTTCCAGACAACCTC
TTACTTTCTGTGTAGTTTTTAATTGTTAAAAAAGTTTTTAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
10 GGTCTTTTTTTGGCAATTCTTCCAGTGGGACTTGTCCACAAGAATGAAAGTAGTGGTTTTTAAAGAGTTAAGTTACAT
ATTTATTTTCTCACTTAAGTTATTTATGCAAAGTTTTTCTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAAGACAATGAATCATGACCGAAAG

15 **Sequence ID No. 8: Human Beer protein variant (P38R)**

MQLELALCLVCLLVHTAFRVVEGQGWQAFKNDATETIIRELGEYPEFFPELENNKTMNRAENGGRPFPHFFETKDVSEYSC
RELHFTRYVTDGFCRSAKFVTELVCSGQCGFARLLPNAIGRGKWWRFSGFDFRCIPDRYRAQRVQLLCFGGEAFRARKVR
LVASCKCKRLTRFHNQSELKDFGTEAARFQKGRKFRPRARSAKANQAELENAY

20

Sequence ID No. 9: Vervet BEER cDNA (complete coding region)

25 ATGCAGCTCCCACTGGCCCTGTGTCTTGTCTGCCTGCTGGTACACGCAGCCTTCCGTGTAGTGGAGGGCCAGGGGTGGCA
GGCCTTCAAGAATGATGCCACGGAAATCATCCCCGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAACA
AGACCATGAACCGGGCGGAGAATGGAGGGCGGCCTCCCCACCACCCCTTTGAGACCAAAGACGTGTCCGAGTACAGCTGC
CGAGAGCTGCACTTACCCGCTACGTGACCGATGGGCCGTGCCGCAGCGCCAAGCCAGTCACCGAGTTGGTGTGCTCCGG
CCAGTGCGGCCCCGGCACGCCTGCTGCCCAACGCCATCGGCCGCGGCAAGTGGTGGCGCCGAGTGGGCCCCGACTTCCGCT
30 GCATCCCCGACCGCTACCGCGCGCAGCGTGTGCAGCTGCTGTGTCCCGGTGGTGCCGCGCCGCGCGCGCAAGGTGCGC
CTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACCCGCTTCCACAACCAGTCGGAGCTCAAGGACTTCGGTCCCCGAGGCCGC
TCGGCCGCGAGAAGGGCCGGAAGCCGCGGCCCGCGCCCGGGGGGCCAAAGCCAATCAGGCCGAGCTGGAGAACGCCTACT
AG

35

Sequence ID No. 10: Vervet BEER protein (complete sequence)

WO 00/32773

PCT/US99/27990

73

MQLFALCLVCLLVHAAFRVVEGQGWQAFKNDATETIIIFELGEYFEFFPELENNKTMNRAENGGRFFHHFFETKDVSEYSC
RELHETRYVTDGFCSRSAKFVTELVCSGQCGPARLLFNALGRGKWWRFSGPDFRCIFDRYRAQRVQLLCFGGAAFRARKVR
LVASCKCKRLTRFHNQSELKDFGPAAARFQKGRKPRFRARGAKANQAELENAY

5

Sequence ID No. 11: Mouse BEER cDNA (coding region only)

10 ATGCAGCCCTCACTAGCCCCGTGCCTCATCTGCCTACTTGTGCACGCTGCCTTCTGTGCTGTGGAGGGCCAGGGGTGSCA
AGCCTTCAGGAATGATGCCACAGAGGTCATCCCAGGGCTTGAGAGTACCCCGAGCCTCCTCCTGAGAACACCAGACCA
TGAACCGGGCGGAGAATGGAGGCAGACCTCCCCACCATCCCTATGACGCCAAAGGTGTGTCCGAGTACAGCTGCCGCGAG
CTGCACTACACCCGCTTCTGACAGACGGCCCATGCCGCAGCGCCAAAGCGGTACCGAGTTGGTGTGCTCCGGCCAGTG
CGGCCCCGCGCGGCTGCTGCCCAACGCCATCGGGCGCGTGAAGTGGTGGCGCCCGAACGGACCGGATTTCCGCTGCATCC
15 CGGATCGCTACCGCGCGCAGCGGGTGCAGCTGCTGTGCCCCGGGGGCGCGCGCCGCGCTCGCGCAAGGTGCGTCTGGTG
GCCTCGTGCAAGTGCAAGCGCCTCACCCGCTTCCACAACCAGTGGAGCTCAAGGACTTCGGGCGGAGACCGCGCGGCC
GCAGAAGGGTCGCAAGCCGCGGCCCGGCGCCCCGGGGAGCCAAAGCCAAACCAGGCGGAGCTGGAGAACCCCTACTAGAG

20 **Sequence ID No. 12: Mouse BEER protein (complete sequence)**

MQPSLAPCLICLLVHAAFCAVEGQGWQAFRNDATETVIIFGLGEYFEFFPENNTMNRANENGGRFFHHFFYDAKDVSEYSCRE
LHYTRFLTDGFCSRSAKFVTELVCSGQCGPARLLFNALGRVKWWRFNGEDFRCIFDRYRAQRVQLLCFGGAAAPRSRKVRLV
ASCKCKRLTRFHNQSELKDFGPETARFQKGRKPRFGARGAKANQAELENAY

25

Sequence ID No. 13: Rat BEER cDNA (complete coding region plus 5' UTR)

30 GAGGACCGAGTGCCCTTCTCCTTCTGGCACCATGCAGCTCTCACTAGCCCCTTGCCCTGCCTGCCTGCTTGTACATGCA
GCCTTCGTTGCTGTGGAGAGCCAGGGGTGGCAAGCCTTCAAGAATGATGCCACAGAAATCATCCCGGGACTCAGAGAGTA
CCCAGAGCCTCCTCAGGAAGTAGAGAACACCAGACCATGAACCGGGCCGAGAACGGAGGCAGACCCCCCACCATCCTT
ATGACACCAAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTACACCCGCTTCGTGACCGACGGCCCGTGCCGCAGT
GCCAAGCCGGTCACCGAGTTGGTGTGCTCGGGCCAGTGCGGCCCCGCGCGGCTGCTGCCCAACGCCATCGGGCGCGTGAA
35 GTGGTGGCGCCCCGAACGGACCCGACTTCCGCTGCATCCCGGATCGCTACCGCGCGCAGCGGGTGCAGCTGCTGTGCCCCG
GCGGCGCGGCGCCGCGCTCGCGCAAGGTGCGTCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACCCGCTTCCACAACCAG

WO 00/32773

PCT/US99/27990

74

TCGGAGCTCAAGGACTTCGGACCTGAGACCGCGCGCGCCGAGAGGGTCGCAAGCCGCGGCCCCGCGCCCGGGGATCCAA
AGCCAACCAGGCGGAGCTGGAGAACGCCTACTAG

5 **Sequence ID No. 14: Rat BEER protein (complete sequence)**

MQLSLAFCLACLLVHAAFVAVESQGWQAFKNDTEIIIFGLREYFEFFQELENNQTMNRAENGGRFFHHEYDTKDVSEYSC
RELHYTREVTGDFCRSAKPVTELVCSGQCGFARLLPNAIGRVKWWRENGDFRCIFDRYRAQRVQLLCFGGAAFRSRKVR
LVASCKCKRLTRFHNQSELKDFGPEFETARFQKGRKPRFRARGAKANQAELENAY

10

Sequence ID No. 15: Bovine BEER cDNA (partial coding sequence)

15 AGAATGATGCCACAGAAATCATCCCCGAGCTGGGCGAGTACCCCGAGCCTCTGCCAGAGCTGAACAACAAGACCATGAAC
CGGGCGGAGAACGGAGGGAGACCTCCCCACCACCCCTTTGAGACCAAAGACGCCTCCGAGTACAGCTGCCGGGAGCTGCA
CTTACCCGCTACGTGACCGATGGGCGGTGCCGCGAGCGCCAAGCCGGTCACCGAGCTGGTGTGCTCGGGCCAGTGCSGCC
CGGCGCGCCTGCTGCCCCAACGCCATCGGCGCGGGCAAGTGGTGGCGCCCAAGCGGGCCCGACTTCCGCTGCATCCCCGAC
CGCTACCGCGCGCAGCGGGTGAGCTGTTGTGTCTGGCGGCGCGGCGCCGCGCGCGCGCAAGGTGCGCCTGGTGGCCTC
20 GTGCAAGTGCAAGCGCCTCACTCGCTTCCACAACCAAGTCCGAGCTCAAGGACTTCGGGCCCCGAGGCCGCGCGGCGCGCAAA
CGGGCGGGAAGCTGCGGCCCCGCGCCCCGGGGCACCAAAGCCAGCCGGGGCCGA

25 **Sequence ID No. 16: Bovine BEER protein (partial sequence -- missing
signal sequence and last 6 residues)**

NDATEIIPELGEYFEPLPELNNKTMNRAENGGRFFHHFFETKDASEYSCRELHFTRYVTDGFCRSAPVTELVCSGQCGF
ARLLPNAIGRGKWWRPSPGDFRCIFDRYRAQRVQLLCFGGAAFRARKVRLVASCKCKRLTRFHNQSELKDFGPEAAREFQT
GRKLRPRARGTKASRA

30

**Sequence ID No. 17: MluI - AvIII restriction fragment used to make mouse Beer
transgene**

35

CGCGTTTGGTGAGCAGCAATATTGCGCTTCGATGAGCCTTGGCGTTGAGATTGATACCTCTGCTGCACAAAAGGCAATC

WO 00/32773

PCT/US99/27990

75

GACCGAGCTGGACCAGCGCATTCGTGACACCGTCTCCTTCGAACTTATTCGCAATGGAGTGTCAATTCATCAAGGACNGCC
TGATCGCAAATGGTGCTATCCACGCAGCGGCAATCGAAAACCTCAGCCGGTGACCAATATCTACAACATCAGCCTTGGT
ATCCTGCGTGATGAGCCAGCGCAGAACAAGGTAACCGTCAGTGCCGATAAGTTCAAAGTTAAACCTGGTGTGATACCAA
CATTGAAACGTTGATCGAAAACGCGCTGAAAACGCTGCTGAATGTGCGGCGCTGGATGTCACAAAGCAAATGGCAGCAG
5 ACAAGAAAGCGATGGATGAACTGGCTTCCTATGTCCGCACGGCCATCATGATGGAATGTTTCCCCGGTGGTGTATCTGG
CAGCAGTGCCGTCGATAGTATGCAATTGATAATTATTATCATTTGCGGGTCCTTCCGGCGATCCGCCTTGTTACGGGGC
GGCGACCTCGCGGGTTTTCGCTATTTATGAAAATTTTCCGGTTTAAGGCGTTTCCGTTCTTCTTCGTCATAACTTAATGT
TTTTATTTAAATACCTCTGAAAAGAAAGGAAACGACAGGTGCTGAAGCGAGCTTTTTGGCCTCTGTCGTTTCTTTTC
TCTGTTTTTGTCCGTGGAATGAACAATGGAAGTCAACAAGCAGAGCTTATCGATGATAAGCGGTCAAACATGAGAAT
10 TCGCGGCCGCATAATACGACTCACTATAGGGATCGACGCCTACTCCCCGCGCATGAAGCGGAGGAGCTGGACTCCGCATG
CCCAGAGACGCCCCCAACCCCCAAAGTGCCCTGACCTCAGCCTCTACCAAGCTCTGGCTTGGGCTTGGGCGGGGTCAAGGC
TACCACGTTCTCTTAACAGGTGGCTGGGCTGTCTCTTGGCCGCGCGTCACTGTGACAGCTGCCTAGTTCTGCAGTGAGGTC
ACCGTGGAATGTCTGCCTTCGTTGCCATGGCAACGGGATGACGTTACAATCTGGGTGTGGAGCTTTTCTGTCCGTGTCA
GGAAATCCAAATACCTAAAATACCTAGAAGAGGAAGTAGCTGAGCCAAAGCTTTCTGGCTTCTCCAGATAAAGTTTG
15 ACTTAGATGGAAAAAACAAATGATAAAGACCCGAGCCATCTGAAAATTCCTCCTAATTGCACCACTAGGAAATGTGTA
TATTATTGAGCTCGTATGTGTTCTTATTTTAAAAGAAAACCTTTAGTCATGTTATTAATAAGAATTTCTCAGCAGTGGGA
GAGAACCAATATTAACACCAAGATAAAAGTTGGCATGATCCACATTGCAGGAAGATCCACGTTGGGTTTTCATGAATGTG
AAGACCCCATTTATTAAGTCCTAAGCTCTGTTTTTGCACACTAGGAAGCGATGGCCGGGATGGCTGAGGGGCTGTAAGG
ATCTTTCAATGTCTTACATGTGTGTTTCTGTCTGACCTAGGACCTGCTGCCTAGCCTGCAGCAGAGCCAGAGGGGTT
20 TCACATGATTAGTCTCAGACACTTGGGGGCAGGTTGCATGTAAGTGCATCGCTTATTTCCATACGGAGCACCTACTATGTG
TCAAACACCATATGGTGTTCACTCTTCAGAACGGTGGTGGTCATCATGGTGCATTTGCTGACGGTTGGATTGGTGGTAGA
GAGCTGAGATATATGGACGCACTCTTCAGCATTCTGTCAACGTGGCTGTGCATTCTTGCTCCTGAGCAAGTGGCTAAACA
GACTCACAGGGTCAGCCTCCAGCTCAGTCGCTGCATAGTCTTAGGGAACCTCTCCAGTCCTCCCTACCTCAACTATCCA
AGAAGCCAGGGGGCTTGGCGGTCTCAGGAGCCTGCTTGCTGGGGGACAGGTTGTTGAGTTTTATCTGCAGTAGGTTGCCT
25 AGGCATAGTGTGAGGACTGATGGCTGCCTTGGAGAACACATCCTTTGCCCTCTATGCAAATCTGACCTTGACATGGGGGC
GCTGCTCAGCTGGGAGGATCAACTGCATACCTAAAGCCAAGCCTAAAGCTTCTTCGTCCACCTGAAACTCCTGGACCAAG
GGGCTTCCGGCACATCCTCTCAGGCCAGTGAGGGAGTCTGTGTGAGCTGCACTTTCCAATCTCAGGGCGTGAGAGGCAGA
GGGAGGTGGGGCAGAGCCTTGACGCTCTTCCCTCCCATCTGGACAGCGCTCTGGCTCAGCAGCCCATATGAGCACAGGC
ACATCCCCACCCACCCACCTTTCTGTCTGTCAGAAATTTAGGCTCTGTTACGGGGGGGGGGGGGGGGGGGGCAGTCC
30 TATCCTCTCTTAGGTAGACAGGACTCTGCAGGAGACACTGCTTTGTAAGATACTGCAGTTTAAATTTGGATGTTGTGAGG
GGAAAGCGAAGGGCCTCTTTGACCATTCAAGTCAAGGTACCTTCTAACTCCCATCGTATTGGGGGGCTACTCTAGTGCTAG
ACATTGCAGAGAGCCTCAGAACTGTAGTTACCAGTGTGGTAGGATTGATCCTTCAGGGAGCCTGACATGTGACAGTTCCA
TTCTTCACCCAGTCACCGAACATTTATTCAGTACCTACCCCGTAACAGGCACCGTAGCAGGTAAGTGGGGACGGACCACT
CAAAGAACTGACAGACCGAAGCCTTGGAATATAAACACCAAGCATCAGGCTCTGCCAACAGAACTCTTTAACTCA
35 GGCCCTTTAACTCAGGACCCCAACCCCAAGCAGTTGGCACTGCTATCCACATTTTACAGAGAGGAAAACTA
GGCACAGGACGATATAAGTGGCTTGCTTAAGCTTGTCTGCATGGTAAATGGCAGGGCTGGATTGAGACCCAGACATTCCA

WO 00/32773

PCT/US99/27990

76

ACTCTAGGGTCTATTTTCTTTTTCTCGTTGTTTGAATCTGGGTCTTACTGGGTAACTCAGGCTAGCCTCACACTCAT
ATCCTTCTCCCATGGCTTACGAGTGCTAGGATTCCAGGTGTGTGCTACCATGTCTGACTCCCTGTAGCTTGTCTATACCA
TCCTCACAAACATAGGAATTGTGATAGCAGCACACACACCCGGAAGGAGCTGGGGAAATCCCACAGAGGGCTCCGCAGGATG
ACAGGCGAATGCCTACACAGAAGGTGGGGAAGGGAAGCAGAGGGAACAGCATGGGCGTGGGACCACAAGTCTATTTGGGG
5 AAGCTGCCGGTAACCGTATATGGCTGGGGTGAGGGGAGAGGTCATGAGATGAGGCAGGAAGAGCCACAGCAGGCAGCGGG
TACGGGCTCCTTATTGCCAAGAGGCTCGGATCTTCCTCCTCTTCCTCCTTCCGGGGCTGCCTGTTTCTATTTCCACCACTG
CCTCCCATCCAGGTCTGTGGCTCAGGACATCACCCAGCTGCAGAACTGGGCATCACCCACGTCCTGAATGCTGCCGAGG
GCAGGTCCTTCATGCACGTCAACACCAGTGCTAGCTTCTACGAGGATTCTGGCATCACCTACTTGGGCATCAAGGCCAAT
GATACGCAGGAGTTCAACCTCAGTGCTTACTTTGAAAGGGCCACAGATTTTATTGACCAGGCGCTGGCCCATAAAATGG
10 TAAGGAACGTACATTCCGGCACCCATGGAGCGTAAGCCCTCTGGGACCTGCTTCCTCCAAAGAGGGCCCCACTTGAAAAA
GGTTCAGAAAGATCCCAAATATGCCACCAACTAGGGATTAAGTGTCTACATGTGAGCCGATGGGGGCCACTGCATAT
ASTCTGTGCCATAGACATGACAATGGATAATAATATTTTACAGACAGAGAGCAGGAGTTAGGTAGCTGTGCTCCTTTCCCTT
TAATTGAGTGTGCCATTTTATTTTATTCATGTATGTGTATACATGTGTGTGCACACATGCCATAGGTTGATACTGAACACC
GTCTTCAATCGTTCCCCACCCACCTTATTTTTTGAGGCAGGGTCTCTTCCCTGATCCTGGGGCTCATTGGTTTATCTAG
15 GCTGCTGGCCAGTGAGCTCTGGAGTTCTGCTTTTCTCTACCTCCCTAGCCCTGGGACTGCAGGGGCATGTGCTGGGCCAG
GCTTTTATGTGCGGTTGGGGATCTGAACTTAGGTCCCTAGGCCTGAGCACCGTAAAGACTCTGCCACATCCCCAGCCTGT
TTGAGCAAGTGAACCATCCCCAGAATCCCCCAGTGGGGCTTTCCTACCCTTTTATTGGCTAGGCATTCTAGAGTGGTC
ACCTCGCCAGAGGAATGAGTGGCCACGACTGGCTCAGGGTCAGCAGCCTAGAGATACTGGGTAAAGTCTTCTGCGGCTC
GCTCCCTGCAGCCGCAGACAGAAAGTAGGACTGAATGAGAGCTGGCTASTGGTCAGACAGGACAGAAGGCTGAGAGGGTC
20 ACAGGGCAGATGTCAGCAGAGCAGACAGGTTCTCCCTCTGTGGGGGAGGGGTGGCCCACTGCAGGTGTAATTGGCCTTCT
TTGTGCTCCATAGAGGCTTCTGGGTACACAGCAGCTTCCCTGTCTGTGATTCCCAAAGAGAACTCCCTACCACTGGA
CTTACAGAAGTTCTATTGACTGGTGTAACGGTTCAACAGCTTTGGCTCTTGGTGGACGGTGCATACTGCTGTATCAGCTC
AAGAGCTCATTACGAATGAACACACACACACACACACACACACACACACACAGCTAATTTGATATGCCTTAACTA
GCTCAGTGACTGGGCATTTCTGAACATCCCTGAAGTTAGCACACATTTCCCTCTGGTGTTCCTGGCTTAACACCTTCTAA
25 ATCTATATTTTATCTTTGCTGCCCTGTTACCTTCTGAGAAGCCCCCTAGGGCCACTTCCCTTCGCACCTACATTGCTGGAT
GGTTTCTCTCCTGCAGCTCTTAAATCTGATCCCTCTGCCTCTGAGCCATGGGAACAGCCCAATAACTGAGTTAGACATAA
AAACGTCTCTAGCCAAAATTCAGCTAAATTTAGACAATAAATCTTACTGGTTGTGGAATCCTTAAGATTCTTCATGACC
TCCTTCACATGGCACGAGTATGAAGCTTTATTACAATTGTTTATTGATCAAATAACTCATAAAAGCCAGTTGTCTTTC
ACCTGCTCAAGGAAGGAACAAAATTCATCCTTAACTGATCTGTGCACCTTGCACAATCCATACGAATATCTTAAGAGTAC
30 TAAGATTTTGGTTGTGAGAGTCACATGTTACAGAATGTACAGCTTTGACAAGGTGCATCCTTGGGATGCCGAAGTGACCT
GCTGTTCCAGCCCCCTACCTTCTGAGGCTGTTTTGGAAGCAATGCTCTGGAAGCAACTTTAGGAGGTAGGATGCTGGAAC
AGCGGGTCACTTCAGCATCCCGATGACGAATCCCGTCAAAGCTGTACATTCTGTAACAGACTGGGAAAGCTGCAGACTTT
AAGGCCAGGGCCCTATGGTCCCTCTTAATCCCTGTACACCCCAACCCGAGCCCTTCTCCTCCAGCCGTTCTGTGCTTCTC
ACTCTGGATAGATGGAGAACACGGCCTTGCTAGTTAAAGGAGTGAGGCTTCACCCCTTCTCACATGGCAGTGGTTGGTCAT
35 CCTCATTCAGGGAACCTCTGGGGCATTCTGCCTTTACTTCTCTTTTTGGACTACAGGGAATATATGCTGACTTGTTTTGA
CCTTGTGTATGGGGAGACTGGATCTTTGGTCTGGAATGTTTCCTGCTAGTTTTTCCCATCCTTTGGCAAACCTATCTA

WO 00/32773

PCT/US99/27990

78

GGCAGCGTGTGAGCTGCCTGGTGTGGGTGCTGGGAACCAACTTGAATCTAAAGCAAGCACTTTTAACTGCTGAGGCAGC
 TCTCAGTACCCCTTCTTCATTTCTCCGCTGGGTTCATTGTATGGACACATGTAGCTAGAATATCTTGCTTATCTAATTA
 TGTACATTGTTTTGTGCTAAGAGAGAGTAATGCTCTATAGCCTGAGCTGGCCTCAACCTTGCCATCCTCCTGCCTCAGCC
 TCCTCCTCCTGAGTGCTAGGATGACAGGCGAGTGGTAACTTACATGGTTTCATGTTTTGTTCAAGACTGAAGGATAACAT
 5 TCATACAGAGAAGGTCTGGSTCACAAAGTGTGCAGTTCAGTGAATGGCACAACCCGTGATCAAGAAACAAAACACTCAGGGG
 CTGGAGAGATGGCACTGACTGCTCTTCCAGAGGTCCGGAGTTCAATTCCCAGCAACCACATGGTGGCTCACAGCCATCTA
 TAACGAGATCTGACGCCCTCTTCTGGTGTGTCTGAAGACAGCTACAGTGTACTCACATAAAATAAATAAATCTTTAAAC
 ACACACACACACACAATTACCACCCCAGAAAGCCCCACTCCATGTTCCCTCCCACGTCTCTGCCTACAGTACTCCCAGGTT
 ACCACTGTTCAAGGCTTCTAACAACCTGGTTTACTTGGGCCTCTTTCTGCTCTGTGGAGCCACACATTTGTGTGCCTCAT
 10 ACACGTTCTTTCTAGTAAGTTGCATATTACTCTGCSTTTTACATGTATTTATTTATTGTAGTTGTGTGTGCGTGTGGSC
 CCATGCATGGCACAGTGTGTGGGGATGTGAGAGTATTGTGAACAGGGGACAGTTCTTTTCTTCAATCATGTGGGTTCAG
 AGGTTGAACTCAGGTCATCATGTGTGGCAGCAAATGCCTTTACCCACTGAGACATCTCCATATTCTTTTTTTTTCCCTG
 AGGTGGGGGCTTGTTCATAGCCCCAACTGGCTTTGCACTTGCAGTTCAAAGTGAAGTCCCTGTCTCCACCTCTTAGAGTA
 TTGGAATTACGATGTGTACTACCACACCTGACTGGATCATTAAATCTTTGATGGGGGCGGGGAAGCGCACATGCTGCAGG
 15 TGAAGGGATGACTGGACTGGACATGAGCGTGGAGCCAGAGAACAGCTTCAGTCTAATGCTCTCCCACTGAGCTATTTTC
 GGTTCGCCAGAGAACAACCTTACAGAAAGTTCTCAGTGCCATGTGGATTGCGGGTTGGAGTTCAACTCATCAGCTTGACAT
 TGGCTCCTCTACCCACTGAGCCTTCTCACTACTCTCTACCTAGATCATTAAATCTTTTTTAAAGACTTATTAGGGGGC
 TGGAGAGATGGCTCAGCCGTTAAGAGCACCGAATGCCCTTCCAGAGSTCCTGAGTTCAATTCCCAGCATGCCATTGCTGG
 GCAGTAGGGGGCGCAGGTGTTCAACGTGAGTAGCTGTTGCCAGTTTCCGCGGTGGAGAACCTCTTGACACCCTGCTGTC
 20 CCTGGTCATTCTGGGTGGGTGCATGGTGATATGCTTGTGTATGGAAGACTTTGACTGTTACAGTGAAGTTGGGCTTCCA
 CAGTTACCACGTCTCCCTGTTTCTTGCAGGCCGGGTGCTTGTCCATTGCCGCGAGGGCTACAGCCGCTCCCCAACGCTA
 GTTATCGCCTACCTCATGATGCGGCAGAAGATGGACGTCAAGTCTGCTCTGAGTACTGTGAGGCAGAATCGTGAGATCGG
 CCCCACGATGGCTTCTGGCCCCAATCTGCCAGCTCAATGACAGACTAGCCAAGGAGGGCAAGGTGAAACTCTAGGGTG
 CCCACAGCCTCTTTTGCAGAGGTCTGACTGGGAGGGCCCTGGCAGCCATGTTTAGGAAACACAGTATACCCACTCCCTGC
 25 ACCACCAGACACGTGCCACATCTGTCCCACTCTGGTCCTCGGGGGCCACTCCACCCTTAGGGAGCACATGAAGAAGCTC
 CCTAAGAAGTTCTGCTCCTTAGCCATCCTTTCTGTAATTTATGTCTCTCCCTGAGGTGAGGTTCAAGTTTATGTCCCTG
 TCTGTGGCATAGATACATCTCAGTGACCCAGGGTGGGAGGGCTATCAGGGTGCATGGCCCCGGGACACGGGCACTCTTCAT
 GACCCCTCCCCACCTGGGTCTTCCCTGTGTGGTCCAGAACCACGAGCCTGGTAAAGGAACTATGCAAACACAGGCCCTG
 ACCTCCCCATGTCTGTTCCCTGGTCCTCACAGCCCGACACGCCCTGCTGAGGCAGACGAATGACATTAAGTTCTGAAGCAG
 30 AGTGGAGATAGATTAGTGAAGTATTTCCAAAAAGAGGAAAAAAGGCTGCATTTTAAATTATTTCTTAGAATTAA
 AGATACTACATAGGGGCCCTTGGGTAAGCAAATCCATTTTTCCAGAGGCTATCTTGATTCTTTGGAATGTTTAAAGTGT
 GCCTTGCCAGAGAGCTTACGATCTATATCTGCTGCTTCAGAGCCTTCCCTGAGGATGGCTCTGTTCCCTTGCTTGTTAGA
 AGAGCGATGCCTTGGGCAGGGTTTCCCCCTTTTCAGAATACAGGGTGTAAGTCCAGCCTATTACAAACAAACAAACAAA
 CAAACAAACAAAGGACCTCCATTTGGAGAATTGCAAGGATTTTATCCTGAATTATAGTGTGGTGAGTTCAAGTCATCAC
 35 GCCAAGTGCTTGCCATCCTGGTTGCTATTCTAAGAATAATTAGGAGGAGGAACCTAGCCAATTGCAGCTCATGTCCGTGG
 GTGTGTGCACGGGTGCATATGTTGGAAGGGGTGCCTGTCCCCTTGGGGACAGAAGGAAAAATGAAAGGCCCTCTGCTCAC

WO 00/32773

PCT/US99/27990

79

CCTGGCCATTTACGGGAGGCTCTGCTGGTTCACGGTGTCTGTGCAGGATCCTGAACTGACTCGCTGGACAGAAACGAG
ACTTGGCGGCACCATGAGAATGGAGAGAGAGAGAGCAAGAAAGAAACAGCCTTTAAAAGAACTTTCTAAGGGTGGTTTT
TGAACCTCGCTGGACCTTGTATGTGTGCACATTTGCCAGAGATTGAACATAATCCTCTTGGGACTTCACGTTCTCATTAT
TTGTATGTCTCCGGGGTCACGCAGAGCCGTGAGCCACCACCCAGCACCCGGCACATAGGCGTCTCATAAAAGCCCATT
5 TATGAGAACCAGAGCTGTTTGAGTACCCCGTGTATAGAGAGAGTGTGTGCTGGGGCACC CGGATCCCAGCAGCCTGGT
TGCCTGCCTGTAGGATGTCTTACAGGAGTTTGCAGAGAAACCTTCCTTGGAGGGAAAGAAATATCAGGGATTTTTTGTGA
ATATTTCAAATTCAGCTTTAAGTGTAAAGACTCAGCAGTGTTCATGGTTAAGGTAAGGAACATGCCTTTTCCAGAGCTGCT
GCAAGAGGCAGGAGAAGCAGACCTGTCTTAGGATGTCACTCCAGGGTAAAGACCTCTGATCACAGCAGGAGCAGAGCTG
TGCAGCCTGGATGGTCATTGTCCCCTATTCTGTGTGACCACAGCAACCCTGGTCACATAGGGCTGGTCATCCTTTTTTTT
10 TTTTTTTTTTTTTTTTTTTTTTGGCCAGAATGAAGTGACCATAGCCAAAGTTGTGTACCTCAGTCTTTAGTTTCCAAGCGGCT
CTCTTGCTCAATACAATGTGCATTTCAAATAACACTGTAGAGTTGACAGAACTGGTTCATGTGTTATGAGAGAGGAAAA
GAGAGGAAAGAACAAAACAAAACAAAACACCACAAACCAAAAACATCTGGGCTAGCCAGGCATGATTGCAATGTCTACAG
GCCCAGTTCATGAGAGGCAGAGACAGGAAGACCGCCGAAGGTCAAGGATAGCATGGTCTACGTATCGAGACTCCAGCCA
GGGCTACGGTCCCAAGATCCTAGGTTTTGGATTTTGGGCTTTGGTTTTTGAGACAGGGTTTCTCTGTGTAGCCCTGGCTG
15 TCCTGGAACCTCGCTCTGTAGACCAGGCTGGCCTCAACTTAGAGATCTGCCTGACTCTGCCTTTGAGGGCTGGGACGAAT
GCCACCACTGCCCAACTAAGATTCCATTAAAAAAGTTCAAGATAATTAAGAGTTGCCAGCTCGTTAAAGCTAA
GTAGAAGCAGTCTCAGGCCTGCTGCTTGAGGCTGTTCTTGGCTTGACCTGAAATCTGCCCCAACAGTGTCCAAGTGCA
CATGACTTTGAGCCATCTCCAGAGAAGGAAGTGAAAATTGTGGCTCCCCAGTCGATTGGGACACAGTCTCTCTTTGTCTA
GGTAACACATGGTGACACATAGCATTGAACTCTCCACTCTGAGGGTGGGTTTCCCTCCCCCTGCCTCTTCTGGGTTGGTC
20 ACCCCATAGGACAGCCACAGGACAGTCACTAGCACCTACTGGAAACCTCTTGTGGGAACATGAAGAAAGAGCCTTTGGG
AGATTCCCTGGCTTTCCATTAGGGCTGAAAGTACAACGGTTCTTGGTTGGCTTTGCCTCGTGTATAAACTAGCTACTA
TTCTTCAGGTAAATACCGATGTTGTGGAAAAGCCAACCCCGTGGCTGCCCGTGAGTAGGGGGTGGGGTTGGGAATCCTG
GATAGTGTCTATCCATGGAAAGTGGTGGAATAGGAATTAAGGGTGTCCCCCCCCCAACCTCTTCTCAGACCCAG
CCACTTTCTATGACTTATAAACATCCAGGTAAAAATTACAAACATAAAAATGGTTTCTCTTCTCAATCTTCTAAAGTCTG
25 CCTGCCTTTTCCAGGGGTAGGTCTGTTTCTTTGCTGTTCTATTGTCTTGAGAGCACAGACTAACACTTACCAAATGAGGG
AACTCTTGGCCATACTAAGGCTCTTCTGGGCTCCAGCACTCTTAAGTTATTTAAGAATTCTCACTTGGCCTTTAGCAC
ACCCGCCACCCCAAGTGGGTGTGGATAATGCCATGGCCAGCAGGGGGCACTGTTGAGGCGGGTGCCTTTCCACCTTAAG
TTGCTTATAGTATTTAAGATGCTAAATGTTTTAATCAAGAGAAGCACTGATCTTATAATACGAGGATAAGAGATTTTCTC
ACAGGAAATTGTCTTTTTCATAATTCTTTTACAGGCTTTGTCTGATCGTAGCATAGAGAGAATAGCTGGATATTTAACT
30 TGTATTCCATTTTCTCTGCCAGCGTTAGGTTAACTCCGTAAAAAGTGATTCAAGTGGACCGAAGAGGCTCAGAGGGCAGG
GGATGGTGGGGTGGGCAGAGCACTGTACCTGCCAGGCATGGGAGGTCTGCCATCCGGGAGGAAAAGGAAAGTTTAGC
CTCTAGTCTACCACCACTGTTAACGCACTCTAAAGTTGTAACCAAAATAAATGTCTTACATTACAAAGACGTCTGTTTTG
TGTTTCCTTTTGTGTGTTTGGGCTTTTTATGTGTGCTTTATAACTGCTGTGGTGGTGCTGTTGTAGTTTTGAGGTAGGA
TCTCAGGCTGGCCTTGAACCTCTGATCGCCTGCCCTGCCCTGCCCTGCCCTGTCCCTGCCTCCAAGTGCTAGGACT
35 AAAAGCACATGCCACCACACCACTACAGCATTTTTCTAACATTTAAAAATAATCACCTAGGGGCTGGAGAGAGGGTTCCA
GCTAAGAGTGCACACTGCTCTTGGGTAGGACCTGAGTTTAGTTCCCAGAACCTATACTGGGTGGCTCCAGGTCCAGAGGA

WO 00/32773

PCT/US99/27990

80

TCCAGGACCTCTGGCCTCCATGGGCATCTGCTCTTAGCACATACCCACATACAGATACACACATAAAAATAAAATGAAGC
CTTTAAAAACCTCCTAAAACCTAGCCCTTGGAGGTACGACTCTGGAAAGCTGGCATACTGTGTAAGTCCATCTCATGGTG
TTCTGGCTAACGTAAGACTTACAGAGACAGAAAAGAACTCAGGGTGTGCTGGGGGTGGGATGGAGGAAGAGGGATGAGT
AGGGGGAGCACGGGGAACTTGGGCAGTGAATAATTCTTTTCAGGACACTAGAGGAGGATAAATACCAGTCATTGCACCCAC
5 TACTGGACAACCTCCAGGGAATTATGCTGGGTGAAAAGAGAGGCCCCAGGTATTGGCTGCATTGGCTGCATTTGCGTAAC
ATTTTTTTAAATTGAAAAGAAAAAGATGTAAATCAAGTTAGATGAGTGGTTGCTGTGAGCTGAGAGCTGGGGTGAGTGA
GACATGTGGACAACCTCCATCAAAAAGCGACAGAAAGAGCGGGCTGTGGTGACAGCTACCTCTAATCTCCACCTCCGGGAG
GTGATCAAGGTTAGCCCTCAGCTAGCCTGTGGTGATGAGACCTGTTTCAAAAACCTTTAATAAGAAATAATGAAAAA
GACATCAGGGCAGATCCTTGGGGCCAAAGGCGGACAGGCGAGTCTCGTGGTAAGGTCTGTAGAGCGGATGCATGAGCA
10 CGTGCCGCAGGCATCATGAGAGAGCCCTAGGTAAGTAAGGATGGATGTGAGTGTGTGGCGTGGGCGCACTGCACGTCCT
GGCTGTGGTGCTGGACTGGCATCTTTGGTGAGCTGTGGAGGGGAAATGGGTAGGGAGATCATAAATCCCTCCGAATTAT
TTCAAGAACTGTCTATTACAATTATCTCAAAATATTAATAAAAAAGAAATTAATAAAACAAAAACCTATCCAGGTGTG
GTGGTGTGCACCTATAGCCACGGGCACTTGGAAAGCTGAGCAAGAGGATGGCGAGTTTGAAGGTATCTGGGGCTGTACA
GCAAGACCGTCTGCCCCAAACCAACCAACAGCAACCCATTATGTACACAAGAGTGTATATAGTGAGCGGCCTCGCT
15 GAGAGCATGGGGTGGGGTGGGGTGGGGGACAGAAATATCTAAACTGCAGTCAATAGGGATCCACTGAGACCTGGGGC
TTGACTGCAGCTTAACCTTGGGAATGATAAGGGTTTTGTGTTGAGTAAAAGCATCGATTACTGACTTAACCTCAAATGA
AGAAAAAGAAAAAAGAAAAACAACAAAGCCAAACCAAGGGGCTGGTGAGATGGCTCAGTGGGTAAAGACACCCGACTGC
TCTTCCGAAGGTCCAGAGTTCAPATCCCAGCAACCACATGGTGGCTCACAACCATCTGTAACGAGATATGATGCCCTCTT
CTGGTGTGTCTGAAGACAGCTACAGTGTACTTACATATAATAAATAAATCTTAAAAAAGCCAAA
20 CCGAGCAACCAGGCCCCCAACAGAGGACAGGACGAGCGGAGGACACGAGCCATCCTGTGAAAAGGCAGGGCTACC
CATGGGCGGAGGAGGGTCCAGAGAGATAGGCTGGTAAGCTCAGTTTCTCTGTATACCCTTTTCTTGTGACACTACTTC
AATTACAGATAAAATAACAAATAAACAATACTAGAGCCTGGCCACTCTCTGCTCGCTTGATTTTCTGTTACGTCCAG
CAGGTGGCGGAAGTGTTCAGGAACAGATCGCATCATTAGGTGGCCAGCATAATCTCCCATCAGCAGGTGGTGCTGTGA
GAACCATTTATGGTGCTCACAGAATCCCGGGCCAGGAGCTGCCCTCTCCCAAGTCTGGAGCAATAGGAAAGCTTTCTGGC
25 CCAGACAGGGTTAACAGTCCACATTCCAGAGCAGGGGAAAGGAGACTGGAGGTACAGACAAAAGGGCCAGCTTCTAAC
AACTTCACAGCTCTGGTAGGAGAGATAGATCACCCCAACAATGGCCACAGCTGGTTTTGTCTGCCCCGAAGGAACTGA
CTTAGGAAGCAGGTATCAGAGTCCCTTCCCTGAGGGGACTTCTGTCTGCCTTGTAAGCTGTGAGAGCAGCTGCATTGAT
GTGTGGGTGACAGAAGATGAAAAGGAGGACCCAGGCAGATCGCCACAGATGGACCGGCCACTTACAAGTCGAGGCAGGTG
GCAGAGCCTTGCAAGCTCTGCAGGTGGACGACACTGATTCATTACCCAGTTAGCATACCACAGCGGGCTAGGCGGACC
30 ACAGCCTCCTTCCCAGTCTTCCCTCCAGGGCTGGGGAGTCTCCAACCTTCTGTCTCAGTGCAGCTTCCGCCAGCCCCCTCC
TCCTTTTGACCTCAGGTGTGAACCCTCCCTCCTCTCCTTCTCCCTGTGGCATGGCCCTCCTGCTACTGCAGGCTGAGCA
TTGGATTTCTTTGTGCTTAGATAGACCTGAGATGGCTTTCTGATTTATATATATATATCCATCCCTTGGATCTTACATCT
AGGACCCAGAGCTGTTTGTGATACCATAAGAGGCTGGGGAGATGATATGGTAAGAGTGCTTGCTGTACAAGCATGAAGAC
ATGAGTTCGAATCCCCAGCAACCATGTGGAAAAATAACCTTCTAACCTCAGAGTTGAGGGGAAAGGCAGGTGGATTCTGG
35 GGGCTTACTGGCCAGCTAGCCAGCCTAACCTAAATGTCTCAGTCAGAGATCCTGTCTCAGGGAATAACTTGGGAGAATGA
CTGAGAAAGACACCTCCTCAGGTCTCCCATGCACCCACACAGACACACGGGGGGGGGTAATGTAATAAGCTAAGAAATA

WO 00/32773

PCT/US99/27990

81

ATGAGGGAAATGATTTTTTGTCTAAGAAATGAAATTCTGTGTGGCCGCAAGAAGCCTGGCCAGGGAAGGAAGTGCCTTTG
GCACACCAGCCTATAAGTCACCATGAGTTCCCTGGCTAAGAATCACATGTAATGGAGCCCAGGTCCCTCTTGCCTGGTGG
TTGCCTCTCCCACTGGTTTTTGAAGAGAAATTCAGAGAGATCTCCTTGGTCAGAATTGTAGGTGCTGAGCAATGTGGAGC
TGGGGTCAATGGGATTCTTTAAAGGCATCCTTCCCAGGGCTGGGTCACTTCAATAGTAGGGTGCTTGACAGCAAGC
5 GTGAGACCCTAGGTTAGAGTCCCCAGAATCTGCCCCCAACCCCCCAAAAAGGCATCCTTCTGCCTCTGGGTGGGTGGGGG
GAGCAAACACCTTTAACTAAGACCATTAGCTGGCAGGGSTAACAAATGACCTTGGCTAGAGGAATTTGGTCAAGCTGGAT
TCCGCCTTCTGTAGAAGCCCCACTTGTTCCTTTGTTAAGCTGGCCACAGTTTGTGTTTGAATGCCTGAGGGGGCCAG
GGAGCCAGACAATTAAAAGCCAAGCTCATTTTGATATCTGAAAACACAGCCTGACTGCCCTGCCGTGGGAGGTACTGG
GAGAGCTGGCTGTGTCCCTGCCTCACCACGCCCCCCCCCCCCAACACAGACTCCTCGGGTCACTGGGAGGTGCCAGCAG
10 CAATTTGGAAGTTTACTGAGCTTGAGAAGTCTTGGGAGGGCTGACGCTAAGCACACCCCTTCTCCACCCCCCCCCACCCC
ACCCCCGTGAGGAGGAGGGTGAGGAAACATGGGACCAGCCCTGCTCCAGCCCGTCTTATTGGCTGGCATGAGGCAGAGG
GGGCTTTAAAAGGCAACCGTATCTAGGCTGGACACTGGAGCCTGTGCTACCGAGTGCCCTCCTCCACCTGGCAGCATGC
AGCCCTCACTAGCCCCGTGCCTCATCTGCCTACTTGTGCAGCTGCCTTCTGTGCTGTGGAGGGCCAGGGGTGGCAAGCC
TTCAGGAATGATGCCACAGAGGTATCCCAGGGCTTGGAGAGTACCCCGAGCCTCCTCCTGAGAPCAACCAGACCATGAA
15 CCGGGCGGAGAATGGAGGCAGACCTCCCCACCATCCCTATGACGCCAAAGGTACGGGATGAAGAAGCACATTAGTGGGGG
GGGGGGTCTGGGAGGTGACTGGGGTGGTTTTAGCATCTTCTTCAGAGGTTGTGTGGGTGGCTAGCCTCTGCTACATCA
GGGACAGGGACACATTTGCCTGGAAGAATACTAGCACAGCATTAGAACCTGGAGGGCAGCATTGGGGGGTGGTAGAGAGC
ACCCAAGGCAGGGTGGAGGCTGAGGTGAGCCGAAGCTGGCATTAAACAGGGCATGGGCTTGTATGATGGTCCAGAGAATC
TCCTCCTAAGGATGAGGACACAGGTGAGATCTAGCTGCTGACCAGTGGGGAAGTGATATGGTGAGGCTGGATGCCAGATG
20 CCATCCATGGCTGTACTATATCCACATGACCACCACATGAGGTAAAGAAGGCCCCAGCTTGAGATGGAGAAACCGAGA
GGCTCCTGAGATAAAGTCACCTGGGAGTAAGAAGAGCTGAGACTGGAAGCTGGTTTGATCCAGATGCAAGGCAACCTAG
ATTGGGTTTGGGTGGGAACCTGAAGCCAGGAGGAATCCCTTTAGTTCCCCCTTGCCCAGGGTCTGCTCAATGAGCCCAGA
GGGTTAGCATTAAAAGAACAGGGTTTGTAGGTGGCATGTGACATGAGGGGCAGCTGAGTGAAATGTCCCCTGTATGAGCA
CAGGTGGCACCACTTGCCCTGAGCTTGACCCCTGACCCAGCTTTGCCTCATTCCTGAGGACAGCAGAACTGTGGAGGC
25 AGAGCCAGCACAGAGAGATGCCTGGGGTGGGGGTGGGGGTATCACGCACGGAAGTACAGCAATGAATGGGGTGGGGTGG
CAGCTGGAGGGACACTCCAGAGAAATGACCTTGCTGGTCACCATTTGTGTGGGAGGAGAGCTCATTTTCCAGCTTGCCAC
CACATGCTGTCCCTCCTGTCTCCTAGCCAGTAAGGGATGTGGAGGAAAGGGCCACCCCAAAGGAGCATGCAATGCAGTCA
CGTTTTTGCAGAGGAAGTGCTTGACCTAAGGGCACTATTCTTGGAAGCCCCAAAAGTCTCCTTCCCTGGGCAAACAGG
CCTCCCCACATACCACCTCTGCAGGGGTGAGTAAATTAAGCCAGCCACAGAAGGGTGGCAAGGCCTACACCTCCCCCT
30 GTTGTGCCCCCCCCCCCCCGTGAAGGTGCATCCTGGCCTCTGCCCTCTGGCTTTGGTACTGGGATTTTTTTTTTCTT
TTATGTCATATTGATCCTGACACCATGGAACCTTTTGGAGGTAGACAGGACCCACACATGGATTAGTTAAAAGCCTCCCAT
CCATCTAAGCTCATGGTAGGAGATAGAGCATGTCCAAGAGAGGAGGGCAGGCATCAGACCTAGAAGATATGGCTGGGCAT
CCAACCCAATCTCCTTCCCCGGAGAACAGACTCTAAGTCAGATCCAGCCACCCCTTGAGTAACCAGCTCAAGGTACACAGA
ACAAGAGAGTCTGGTATACAGCAGGTGCTAAACAAATGCTTGTGGTAGCAAAAGCTATAGGTTTGGGTGAGAACTCCGA
35 CCCAAGTCGCGAGTGAAGAGCGAAAGGCCCTCTACTCGCCACCGCCCCCGCCCCCACCTGGGGTCTTATAACAGATCACTT
TCACCCTTGCGGGAGCCAGAGAGCCCTGGCATCCTAGGTAGCCCCCCCCCGCCCCCCCCCGCAAGCAGCCCAGCCCTGCC

WO 00/32773

PCT/US99/27990

82

TTTGGGGCAAGTTCTTTTCTCAGCCTGGACCTGTGATAATGAGGGGGTTGGACGCGCGCCTTTGGTCGCTTTCAAGTCT
AATGAATTCTTATCCCTACCACCTGCCCTTCTACCCCGCTCCTCCACAGCAGCTGTCCTGATTTATTACCTTCAATTAC
CTCCACTCCTTTCTCCATCTCCTGGGATACCGCCCTGTCCCAGTGGCTGGTAAAGGAGCTTAGGAAGGACCAGAGCCAG
GTGTGGCTAGAGGCTACCAGGCAGGGCTGGGGATGAGGAGCTAAACTGGAAGAGTGTGTTGGTTAGTAGGCACAAAGCCTT
5 GGGTGGGATCCCTAGTACCGGAGAAGTGSAGATGGGCGCTGAGAAGTTCAAGACCATCCATCCTTAACACAGCCAGT
TTGAGGCCAGCCTGGGCTACATAAAAACCCAATCTCAAAGCTGCCAATTCTGATTCTGTGCCACGTAGTGCCCGATGTA
ATAGTGGATGAAGTCGTTGAATCCTGGGGCAACCTATTTTACAGATGTGGGGAAAAGCAACTTTAAGTACCCTGCCACAG
GATCACAAGAAAGTAAGTGACAGAGCTCCAGTGTTCATCCCTGGGTTCCAAGGACAGGGAGAGAGAAGCCAGGGTGGG
ATCTCACTGCTCCCGGTGCCTCCTTCTATAATCCATACAGATTGAAAGCGCAGGGCAGGTTTGGAAAAGAGAGAAG
10 GGTGGAAGGAGCAGACCAGTCTGGCCTAGGCTGCAGCCCTCACGCATCCCTCTCTCCGCAGATGTGTCCGAGTACAGCT
GCCGCGAGCTGCACTACACCCGCTTCTGACAGACGGCCCATGCCGACGCGCAAGCCGGTCACCGAGTTGGTGTGCTCC
GGCCAGTGGGCCCCGCGCGGCTGCTGCCCAACGCCATCGGGCGCGTGAAGTGGTGGCGCCCGAACGGACCGGATTTCCG
CTGCATCCCGGATCGCTACCGCGCGCAGCGGGTGCAGCTGCTGTGCCCCGGGGGCGCGCGCGCGCTCGCGCAAGGTGC
GTCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACCCGCTTCCACAACCAAGTCGGAGCTCAAGGACTTCGGGCCGGAGACC
15 GCGCGGCCGCAGAAGGGTCGCAAGCCGCGGCCCGGCGCCCGGGGAGCCAAAGCCAACCAAGGCGGAGCTGGAGAACGCCTA
CTAGAGCGAGCCCGCGCCTATGCAGCCCCGCGCGATCCGATTCTGTTTTAGTGTAAAGCCTGCAGCCCAGGCCAGGGGT
GCCAAACTTTCCAGACCGTGTGGAGTTCCAGCCCAAGTAGAGACCGCAGGTCTTCTGCCCGCTGCGGGGATGGGGAGG
GGGTGGGGTTCCCGCGGGCCAGGAGAGGAAGCTTGAGTCCAGACTCTGCCTAGCCCCGGGTGGGATGGGGGTCTTTCTA
CCCTCGCCGGACCTATACAGGACAAGGCAGTGTTCACCTTAAAGGGAAGGGAGTGTGGAACGAAAGACCTGGGACTGG
20 TTATGGACGTACAGTAAGATCTACTCCTTCCACCCAAATGTAAAGCCTGCGTGGGCTAGATAGGGTTTCTGACCCTGACC
TGGCCACTGAGTGTGATGTTGGGCTACGTGGTTCTCTTTTGGTACGGTCTTCTTTGTAAAATAGGGACCGGAACCTCTGCT
GAGATTCCAAGGATTGGGGTACCCCGTGTAGACTGGTGAGAGAGAGGAGAACAGGGGAGGGGTAGGGGAGAGATTGTGG
TGGGCAACCGCCTAGAAGAAGCTGTTTGTGGCTCCAGCCTCGCCGCTCAGAGGTTTGGCTTCCCCACTCCTTCCTC
TCAAATCTGCCTTCAAATCCATATCTGGGATAGGGAAGGCCAGGGTCCGAGAGATGGTGGAAGGGCCAGAAATCACACTC
25 CTGGCCCCCGAAGAGCAGTGTCCCGCCCCAACTGCCTTGTATATTGTAAAGGGATTTTCTACACAACAGTTTAAGGT
CGTTGGAGGAACTGGGCTTGCCAGTCACTCCCATCCTTGTCCCTTGCCAGGACACCACCTCCTGCCTGCCACCCACGG
ACACATTTCTGTCTAGAAACAGAGCGTCGTGCTGCTGCTCTGAGACAGCATATCTTACATTAAAAGAATAATACGGG
GGGGGGGGCGGAGGGCGCAAGTGTATACATATGCTGAGAAGCTGTCAGGCGCCACAGCACCACCCACAATCTTTTGT
AAATCATTTCCAGACACCTCTTACTTTCTGTGTAGATTTTAATTGTTAAAGGGGAGGAGAGAGAGCGTTTGTAAACAGAA
30 GCACATGGAGGGGGGGGTAGGGGGGTGGGGCTGGTGAGTTTGGCGAACTTCCATGTGAGACTCATCCACAAGACTGA
AAGCCGCGTTTTTTTTTTAAGAGTTCAGTGACATATTTATTTTCTCATTTAAGTTATTTATGCCAACATTTTTTCTTG
TAGAGAAAGGCAGTGTTAATATCGCTTGTGAAGCACAAAGTGTGTGTGGTTTTTTGTTTTTTGTTTTTTCCCCGACCAGA
GGCATTGTTAATAAAGACAATGAATCTCGAGCAGGAGGCTGTGGTCTTGTGTTTGTCAACCACACACAATGTCTCGCCACT
GTCATCTCACTCCCTTCCCTTGGTCACAAGACCCAAACCTTGACAACACCTCCGACTGCTCTCTGGTAGCCCTTGTGGCA
35 ATACGTGTTTCTTTGAAAAGTCACATTCATCTTTCTTTTGCAAACCTGGCTCTCATTCCCCAGCTGGGTCTCGTCAT
ACCCTCACCCAGCCTCCCTTTAGCTGACCACTCTCCACACTGTCTTCCAAAAGTGCACGTTTACCGAGCCAGTTCCCT

WO 00/32773

PCT/US99/27990

83

GGTCCAGGTCATCCCATTGCTCCTCCTTGCTCCAGACCCTTCTCCCACAAAGATGTTTCATCTCCCACTCCATCAAGCCCC
AGTGGCCCTGCGGCTATCCCTGTCTCTTCAGTTAGCTGAATCTACTTGCTGACACCACATGAATTCCTTCCCCTGTCTTA
AGGTTTCATGGAACCTCTTGCTGCCCTGAACCTTCCAGGACTGTCCCAGCGTCTGATGTGTCTCTCTCTTGTAAGCCC
CACCCCACTATTTGATTCCCAATTCTAGATCTTCCCTTGTTTCATTCCCTTACGGGATAGTGTCTCATCTGGCCAAGTCCT
5 GCTTGATATTGGGATAAATGCAAAGCCAAGTACAATTGAGGACCAGTTTCATCATTGGGCCAAGCTTTTTCAAATGTGAA
TTTTACACCTATAGAAGTGTAAGCCCTTCCAAAGCAGAGGCAATGCCTGGCTCTTCCCTTCAACATCAGGGCTCCTGCTT
TATGGGTCTGGTGGGGTAGTACATTCATAAACCACACTAGGGGTGTGAAAGCAAGATGATTGGGAGTTGAGGGCCAAT
CTTGGCTATGAGGCCCTGTCTCAACCTCTCCTCCCTCCCTCCAGGGTTTTGTTTTGTTTTGTTTTTTGATTTGAAACTG
CAACACTTTAAATCCAGTCAAGTGCATCTTTGCGTGAGGGGAACCTCTATCCCTAATATAAGCTTCCATCTTGATTTGTGT
10 ATGTGCACACTGGGGGTTGAACCTGGGCCTTTGTACCTGCCGGGCAAGCTCTCTACTGCTCTAAACCCAGCCCTCACTGG
CTTTCTGTTTCAACTCCCAATGAATTCCTTAAATGAATTATCAATATCATGTCTTTGAAAAATACCATTGAGTGCTGCT
GGTGTCCCTGTGGTTCCAGATTCCAGGAAGGACTTTTCAGGGAATCCAGGCATCCTGAAGAATGTCTTAGAGCAGGAGGC
CATGGAGACCTTGGCCAGCCCCACAAGGCAGTGTGGTGCAGAGGGTGAGGATGGAGGCAGGCTTGCAATTGAAGCTGAGA
CAGGGTACTCAGGATTAAAAAGCTTCCCCCAAAACAATTCCAAGATCAGTTCTGTGACTTGACCTGTTCACTATGCA
15 GAGCCCAGTGGGCATAGGTGAAGACACCGGTTGTACTGTCTACTACTGTGCTTCAGAGCCGGCAGAGACAAATAAT
GTTATGGTGACCCAGGGGACAGTGATTCCAGAAGGAACACAGAAGAGAGTGTGCTAGAGGCTGCCTGAAGGAGAAGGG
GTCCCAGACTCTCTAAGCAAAGACTCCACTCACATAAAGACACAGGCTGAGCAGAGCTGGCCGTGGATGCAGGGAGCCCA
TCCACCATCCTTTAGCATGCCCTTGATTCCCATCACATGCCAGGGATGAGGGGCATCAGAGAGTCCAAGTGATGCCCAA
ACCCAAACACACCTAGGACTTGCTTTCTGGGACAGACAGATGCAGGAGAGACTAGGTTGGGCTGTGATCCCATTACCACA
20 AAGAGGGGAAAAACAAAAACAAACAAACAAACAAAAAAACAAACAAACAAAAAAACCCCAAGGTCCAAATTGTA
GGTCAGGTTAGAGTTTATTTATGGAAAGTTATATTCTACCTCCATGGGGTCTACAAGGCTGGCGCCCATCAGAAAGAACA
AACAACAGGCTGATCTGGGAGGGGTGGTACTCTATGGCAGGGAGCACGTGTGCTTGGGGTACAGCCAGACACGGGGCTTG
TATTAATCACAGGGCTTGTTAATAGGCTGAGAGTCAAGCAGACAGAGAGACAGAAGGAAACACACACACACACACACA
CACACACACACACACACACATGCACACACCACTCACTTCTCACTCGAAGAGCCCCCTACTTACATTCTAAGAACAACC
25 ATTCCTCCTCATAAAGGAGACAAAGTTGCAGAAACCCAAAGAGCCACAGGGTCCCCACTCTCTTTGAAATGACTTGGAC
TTGTTGCAGGGAAGACAGAGGGGTCTGCAGAGGCTTCTGGGTGACCCAGAGCCACAGACACTGAAATCTGGTGCTGAGA
CCTGTATAAACCCCTCTTCCACAGGTTCCCTGAAAGGAGCCACATTCCCCAACCCCTGTCTCCTGACCACTGAGGATGAGA
GCACCTGGGCCTTCCCCATTCTTGGAGTGACCCCTGGTTTCCCCATCTGAGGGCACATGAGGTCTCAGGTCTTGGGAAAG
TTCCACAAGTATTGAAAGTGTCTTGTGTTTGTGATTAAATTTAGGTGTATGAGTGCTTTTGCTTGAATATATGCCT
30 GTGTAGCATTTACAAGCCTGGTGCCTGAGGAGATCAGAAGATGGCATCAGATACCCTGGAACTGGACTTGACAGACAGTTA
TGAGCCACTGTGTGGGTGCTAGGAACAGAACCTGGATCCTCCGGAAGAGCAGACAGCCAGCGCTCTTAGCCACTAAGCCA
TCACTGAGGTTCTTTCTGTGGCTAAAGAGACAGGAGACAAAGGAGAGTTTCTTTTAGTCAATAGGACCATGAATGTTCCCT
CGTAACGTGAGACTAGGGCAGGGTGATCCCCCAGTGACACCGATGGCCCTGTGTAGTTATTAGCAGCTCTAGTCTTATTC
CTTAATAAGTCCCAGTTTGGGGCAGGAGATATGTATTCCCTGCTTTGAAGTGGCTGAGGTCCAGTTATCTACTTCCAAGT
35 ACTTGTTTCTCTTCTGGAGTTGGGGAAGCTCCCTGCCTGCCTGTAAATGTGTCCATTCTTCAACCTTAGACAAGATCAC
TTTCCCTGAGCAGTCAGGCCAGTCCAAAGCCCTTCAATTTAGCTTTTATAAGGAACACCCCTTTTGTGGGTGGAGGTAG

[illegible]

WO 00/32773

PCT/US99/27990

87

CTGTAGCAGCCCTCCGCTGAGGGGCTCCAGGTGGGCGCCCAAGGTGCTGCAGTGGGAGCCACATGAGAGGTGATGTCTTG
 GAGTCACCTCGGGTACCATTGTTTAGGGAGGTGGGGATTGTGGTGTGGAGACAGGCAGCCTCAAGGATGCTTTTCAACA
 ATGGTTGATGAGTTGGAATAAAACAGGGGCCATCACACTGGCTCCCATAGCTCTGGGCTTGCCAGCTTCCACATCTGCC
 CCCCACCCCTGTCTGGCACCAGCTCAAGCTCTGTGATTCTACACATCCAAAAGAGGAAGAGTAGCCTACTGGGCATGCC
 5 ACCTCTTCTGGACCATCAGGTGAGAGTGTGGCAAGCCCTAGGCTCCTGTCCAGGATGCAGGGCTGCCAGATAGGATGCTC
 AGCTATCTCCTGAGCTGGAACTATTTTAGGAATAAGGATTATGCCCGCCCGGGGTGGCCAGCACCCAGCAGCCTGTGC
 TTGCGTAAAAGCAAGTGCTGTTGATTTATCTAAAAACAGAGCCGTGGACCCACCCACAGGACAAGTATGATGCATCTGT
 TTCATGTATCTGAAAAGCGACACAACCATTTTTTACATCATGGCATCTTCCTAACCCCATTCCTTTTTTGTGTTTTT
 TTGAGACAGGGTTTCTCTGTGTAGTCCTGGCTGTCTGGAACCTCACTTTGTAGACCAGGCTGGCCTCGAACTCAGAAATC
 10 CTGGGATTAAAGGTGTGTGCCACCACGCCCGGCCCTAACCCCATTCCTAATGGTGATCCAGTGGTTGAAATTTTCGGGCC
 ACACACATGTCCATTAGGGATTAGCTGCTGTCTTCTGAGCTACCTGGTACAATCTTTATCCCCTGGGGCCTGGGCTCCTG
 ATCCCTGACTCGGGCCCGATCAAGTCCAGTTCCTGGGCCCGATCAAGTCCAGTTCCTGGGCCCGAACAAGTCCAGTCCCT
 AGCTCGATTAGCTCATCCTGGCTCCCTGGCCTGTTCTTACTTACACTCTTCCCCTTGCTCTGGACTTGTTGCTTTCTTTA
 CTCAAGTTGTCTGCCACAGTCCCTAAGCCACCTCTGTAAGACAATAAGATAATACTTCCCTCAAGCACGGAAAGTCCTG
 15 AGTCACCACACCCTCTGGAGGTGTGTGGACACATGTTTCATGCGTGTGGTTGCGCTTACGTACGTGTGC

Sequence ID No. 18: Human Beer Genomic Sequence (This gene has two exons, at positions 161-427 abd 3186-5219).

20 tagaggagaa gtctttgggg agggtttgct ctgagcacac ccctttccct ccctccgggg 60
 ctgagggaaa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120
 25 agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180
 ggtggcgtgc cctcctctgg ctggtaccat gcagctccca ctggccctgt gtctcgtctg 240
 cctgctggta cacacagcct tccgtgtagt ggagggccag gggtaggcagg cgttcaagaa 300
 30 tgatgccacg gaaatcatcc ccgagctcgg agagtacccc gagcctccac cggagctgga 360
 gaacaacaag accatgaacc gggcggagaa cggagggcgg cctccccacc acccctttga 420
 35 gaccaaaggt atgggggtgga ggagagaatt cttagtaaaa gatcctgggg aggtttttaga 480

WO 00/32773

PCT/US99/27990

88

aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg 540
ccagcactgg tcgaggaaca gtcttgccctg gaggtggggg aagaatggct cgctggtgca 600
5 gccttcaa at tcaggtgcag aggcattgagg caacagacgc tggtagagagc ccagggcagg 660
gaggacgctg gggtaggtgag ggtatggcat cagggcatca gaacaggctc aggggctcag 720
aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgctc cagctgctgg 780
10 taccactggg aaggggaaca ggtaaggag cctcccatcc acagaacagc acctgtgggg 840
caccggacac tctatgctgg tggtaggtgt cccaccaca cagaccaca tcatggaatc 900
15 cccaggaggt gaacccccag ctggaagggg aagaaacagg ttccaggcac tcagtaactt 960
ggtagtgaga agagctgagg tgtgaacctg gtttgatcca actgcaagat agccctgggtg 1020
tgtggggggg tgtgggggac agatctccac aaagcagtgg ggaggaaggc cagagaggca 1080
20 cccctgcagt gtgcattgcc catggcctgc ccaggagct ggcacttgaa ggaatgggag 1140
ttttcggcac agtttttagcc cctgacatgg gtgcagctga gtccaggccc tggaggggag 1200
25 agcagcatcc tctgtgcagg agtagggaca tctgtcctca gcagccacc cagtcccaac 1260
cttgccctcat tccaggggag ggagaaggaa gaggaaccct gggttcctgg tcaggcctgc 1320
acagagaagc ccaggtgaca gtgtgcatct ggctctataa ttggcaggaa tcctgaggcc 1380
30 atgggggagc ctgaaatgac acttcagact aagagcttcc ctgtcctctg gccattatcc 1440
aggtggcaga gaagtccact gccagggctc ctggacccca gccctccccg cctcacaacc 1500
35 tgtagggact atgggggtgct aaaaagggca actgcatggg aggccagcca ggaccctccg 1560

WO 00/32773

PCT/US99/27990

89

tcttcaaaat ggaggacaag ggcgcctccc cccacagctc cccttctagg caaggtcagc 1620
tgggctccag cgactgcctg aagggctgta aggaacccaa acacaaaatg tccaccttgc 1680
5 tggactccca cgagaggcca cagccccctga ggaagccaca tgctcaaaac aaagtcatga 1740
tctgcagagg aagtgcctgg cctagggggcg ctattctcga aaagccgcaa aatgccccct 1800
tccctgggca aatgcccccc tgaccacaca cacattccag ccctgcagag gtgaggatgc 1860
10 aaaccagccc acagaccaga aagcagcccc agacgatggc agtggccaca tctccccctgc 1920
tgtgcttgct cttcagagtg ggggtggggg gtggccttct ctgtcccctc tctggtttgg 1980
15 tcttaagact atttttcatt ctttcttgct acattggaac tatccccatg aaaccttttg 2040
gggtggactg gtactcacac gacgaccagc tatttaaaaa gctcccaccc atctaagtcc 2100
accataggag acatgggtcaa ggtgtgtgca ggggatcagg ccaggcctcg gagcccaatc 2160
20 tctgcctgcc cagggagtat caccatgagg cgcccattca gataacacag aacaagaaat 2220
gtgcccagca gagagccagg tcaatgtttg tggcagctga acctgtaggt tttgggtcag 2280
25 agctcagggc ccctatggta ggaaagtaac gacagtaaaa agcagccctc agtcccatcc 2340
cccagcccag cctcccatgg atgctcgaac gcagagcctc cactcttgcc ggagccaaaa 2400
ggtgctggga ccccagggaa gtggagtccg gagatgcagc ccagcctttt gggcaagttc 2460
30 ttttctctgg ctgggcctca gtattctcat tgataatgag ggggttggac aactgcctt 2520
tgattccttt caagtctaata gaattcctgt cctgatcacc tccccttcag tccctcgcct 2580
35 ccacagcagc tgccctgatt tattaccttc aattaacctc tactcctttc tccatcccct 2640

WO 00/32773

PCT/US99/27990

90

gtccacccct cccaagtggc tggaaaagga atttgggaga agccagagcc aggcagaagg 2700

tgtgctgagt acttaccctg cccaggccag ggaccctgcg gcacaagtgt ggcttaaata 2760

5 ataagaagac cccagaagag aatgataat aataatacat aacagccgac gctttcagct 2820

atatgtgcca aatgggtattt tctgcattgc gtgtgtaatg gattaactcg caatgcttgg 2880

ggcggcccat ttgagagaca ggaagaagag agaggtaag gaacttgccc aagatgacac 2940

10 ctgcagtgag cgatggagcc ctggtgtttg aaccccagca gtcatttggc tccgagggga 3000

cagggcgccg aggagagctt tccaccagct ctagagcatc tgggaccttc ctgcaataga 3060

15 tgttcagggg caaaagcctc tggagacagg cttggcaaaa gcagggctgg ggtggagaga 3120

gacgggcccg tccagggcag gggtagccag gcgggcccgc accctcacgc gcgcctctct 3180

ccacagacgt gtccgagtag agctgccgcg agctgcactt caccgctac gtgaccgatg 3240

20 ggccgtgccg cagcgccaag ccggtcaccg agctgggtgtg ctccggccag tgcggcccgg 3300

cgcgctgct gcccaacgcc atcggccgcg gcaagtgggtg gcgacctagt gggcccgaact 3360

25 tccgctgcat ccccgaccgc taccgcgcg agcgcggtgca gctgctgtgt cccggtgggtg 3420

aggcgccgcg cgcgcgcaag gtgcgcttgg tggcctcgtg caagtgcgaag cgcctcacc 3480

gcttccacaa ccagtcggag ctcaaggact tcgggaccga ggccgctcgg ccgcagaagg 3540

30 gccggaagcc gcggccccgc gccgggagcg ccaaagccaa ccaggccgag ctggagaacg 3600

cctactagag cccgcccgcg cccctcccca ccggcgggcg ccccgccct gaaccgcgcg 3660

35 cccacatttc tgcctctgc gcgtgggttg attgtttata tttcattgta aatgcctgca 3720

WO 00/32773

PCT/US99/27990

91

acccagggca gggggctgag accttccagg ccctgaggaa tcccgggcgc cggcaaggcc 3780
ccctcagcc cgccagctga ggggtccac ggggcagggg agggaattga ggtcacaga 3840
5 cactgagcca cgcagccccg cctctggggc cgcctacctt tgctgggtccc acttcagagg 3900
aggcagaaat ggaagcattt tcaccgccct ggggttttaa gggagcgggtg tgggagtggg 3960
aaagtccagg gactgggttaa gaaagttgga taagattccc ccttgcacct cgctgcccac 4020
10 cagaaagcct gaggcgtgcc cagagcacia gactgggggc aactgtagat gtgggtttcta 4080
gtcctggctc tgccactaac ttgctgtgta accttgaact acacaattct ccttcgggac 4140
15 ctcaatttcc actttgtaaa atgagggtgg aggtgggaat aggatctcga ggagactatt 4200
ggcatatgat tccaaggact ccagtgcctt ttgaatgggc agaggtgaga gagagagaga 4260
gaaagagaga gaatgaatgc agttgcattg attcagtgcc aaggtcactt ccagaattca 4320
20 gagttgtgat gctctcttct gacagccaaa gatgaaaaac aaacagaaaa aaaaaagtaa 4380
agagtctatt tatggctgac atatttacgg ctgacaaact cctggaagaa gctatgctgc 4440
25 ttcccagcct ggcttccccg gatgtttggc tacctccacc cctccatctc aaagaaataa 4500
catcatccat tggggtagaa aaggagaggg tccgaggggtg gtgggagggg tagaaatcac 4560
atccgccccca acttcccaaa gagcagcatc cctcccccca cccatagcca tgtttttaaag 4620
30 tcaccttccg aagagaagtg aaaggttcaa ggacactggc cttgcaggcc cgagggagca 4680
gccatcacia actcacagac cagcacatcc cttttgagac accgccttct gccaccact 4740
35 cacggacaca tttctgccta gaaaacagct tcttactgct cttacatgtg atggcatatc 4800

WO 00/32773

PCT/US99/27990

92

ttacactaaa agaattattat tgggggaaaa actacaagtg ctgtacatat gctgagaaac 4860
tgcagagcat aatagctgcc acccaaaaat ctttttgaaa atcattttcca gacaacctct 4920
5 tactttctgt gtagttttta attgttaaaa aaaaaaagtt ttaaacagaa gcacatgaca 4980
tatgaaagcc tgcaggactg gtcgtttttt tggcaattct tccacgtggg acttgtccac 5040
aagaatgaaa gtagtggttt ttaaagagtt aagttacata tttattttct cacttaagtt 5100
10 atttatgcaa aagtttttct tgtagagaat gacaatgtta atattgcttt atgaattaac 5160
agtctgttct tccagagtcc agagacattg ttaataaaga caatgaatca tgaccgaaag 5220
15 gatgtggtct cattttgtca accacacatg acgtcatttc tgtcaaagtt gacacccttc 5280
tcttggtcac tagagctcca accttggaac cacctttgac tgctctctgg tggcccttgt 5340
ggcaattatg tcttcctttg aaaagtcatg tttatccctt cctttccaaa cccagaccgc 5400
20 atttcttcac ccagggcatg gtaataacct cagccttgta tccttttagc agcctccctt 5460
ccatgctggc ttccaaaatg ctgtttctcat tgtatcactc cctgctcaa aagccttcca 5520
25 tagtcccccc ttgcccagga tcaagtgcag ttccctatc tgacatggga ggccttctct 5580
gcttgactcc cacctccac tccaccaagc ttcctactga ctccaaatgg tcatgcagat 5640
ccctgcttcc ttagtttgcc atccacactt agcaccceca ataactaatc ctctttcttt 5700
30 aggattcaca ttacttgta tctcttcccc taaccttcca gagatgttcc aatctcccat 5760
gatccctctc tcctctgagg ttccagcccc ttttgtctac accactactt tggttcctaa 5820
35 ttctgttttc catttgacag tcattcatgg aggaccagcc tggccaagtc ctgcttagta 5880

WO 00/32773

PCT/US99/27990

93

ctggcataga caacacaaag ccaagtacaa ttcaggacca gctcacagga aacttcatct 5940
tcttcgaagt gtggatttga tgcctcctgg gtagaaatgt aggatcttca aaagtgggcc 6000
5 agcctcctgc acttctctca aagtctcgcc tccccaaagg gtcttaatag tgctggatgc 6060
tagctgagtt agcatcttca gatgaagagt aaccctaaag ttactcttca gttgccctaa 6120
gggtgggatgg tcaactggaa agctttaaat taagtccagc ctaccttggg ggaaccacc 6180
10 cccacaaaga aagctgaggt ccctcctgat gacttgtcag tttaactacc aataaccac 6240
ttgaattaat catcatcatc aagtctttga taggtgtgag tgggtatcag tggccggtcc 6300
15 cttcctgggg ctccagcccc cgaggaggcc tcagtgagcc cctgcagaaa atccatgcat 6360
catgagtgtc tcagggccca gaatatgaga gcaggtagga aacagagaca tcttccatcc 6420
ctgagaggca gtgcggtcca gtgggtgggg acacgggctc tgggtcaggt ttgtgttggt 6480
20 tgtttgtttg ttttgagaca gagtctcgct ctattgccca ggctggagtg cagtgtcaca 6540
atctcggctt actgcaactt ctgccttccc ggattcaagt gattctcctg cctcagcctc 6600
25 cagagtagct gggattacag gtgcgtgcca ccacgcctgg ctaatttttg tatttttgat 6660
agagacgggg tttcaccatg ttggccaggc tagtctcgaa ctcttgacct caagtgatct 6720
gcctgcctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccaca cccagcccca 6780
30 ggttggtggt tgaatctgag gagactgaag caccaagggg ttaaagtgtt tgcccacagc 6840
catacttggg ctgagttcct tgccctaccc ctcaactgag ctgcttagaa cctggtgggc 6900
35 acatgggcaa taaccaggtc acactgtttt gtaccaagtg ttatgggaat ccaagatagg 6960

WO 00/32773

PCT/US99/27990

94

agtaatttgc tctgtggagg ggatgaggga tagtggtttag ggaaagcttc acaaagtggg 7020
tgttgcttag agattttcca ggtggagaag ggggcttcta ggcagaaggc atagcccaag 7080
5 caaagactgc aagtgcattg ctgctcatgg gtagaagaga atccaccatt cctcaacatg 7140
taccgagtcc ttgccatgtg caaggcaaca tgggggtacc aggaattcca agcaatgtcc 7200
aaacctaggg tctgctttct gggacctgaa gatacaggat ggatcagccc aggctgcaat 7260
10 cccattacca cgagggggaa aaaaacctga aggctaaatt gtaggtcggg ttagaggtta 7320
tttatggaaa gttatattct acctacatgg ggtctataag cctggcgcca atcagaaaag 7380
15 gaacaaacaa cagacctagc tgggaggggc agcattttgt ttagaggggc ggggcacatg 7440
ttctgggggt acagccagac tcagggttg tattaatagt ctgagagtaa gacagacaga 7500
gggatagaag gaaataggtc cctttctctc tctctctctc tctctctctc actctctctc 7560
20 tctctcacac acacacacag acacacacac acgctctgta ggggtctact tatgctccaa 7620
gtacaaatca ggccacattt acacaaggag gtaaaggaaa agaacgttgg aggagccaca 7680
25 ggaccccaaa attccctgtt ttccttgaat caggcaggac ttacgcagct gggaggggtg 7740
agagcctgca gaagccacct gcgagtaagc caagttcaga gtcacagaca ccaaagctg 7800
gtgccatgtc ccacaccgc ccacctcca cctgctcctt gacacagccc tgtgctccac 7860
30 aaccgggtc ccagatcatt gattatagct ctggggcctg caccgtcctt cctgccacat 7920
ccccaccca ttcttggaac ctgccctctg tcttctccct tgtccaaggg caggcaaggg 7980
35 ctgagctatt gggcagcttt gaccaacagc tgaggctcct tttgtggctg gagatgcagg 8040

WO 00/32773

PCT/US99/27990

95

aggcagggga atattcctct tagtcaatgc gaccatgtgc ctggtttgcc caggggtgggc 8100
tcgttttacac ctgtaggcca agcgtaatta ttaacagctc ccacttctac tctaaaaaat 8160
5 gacccaatct gggcagtaaa ttatatgggtg cccatgctat taagagctgc aacttgctgg 8220
gcgtgggtggc tcacacctgt aatcccagta ctttgggacg tcaaggcggg tggatcacct 8280
gaggtcacga gttagagact ggcctggcca gcatggcaaa accccatctt tactaaaaat 8340
10 acaaaaatta gcaaggcatg gtggcatgca cctgtaatcc caggtactcg ggaggctgag 8400
acaggagaat ggcttgaacc caggaggcag aggttgcagt gagccaagat tgtgccactg 8460
15 ccctccagcc ctggcaacag agcaagactt catctcaaaa gaaaaaggat actgtcaatc 8520
actgcaggaa gaaccaggt aatgaatgag gagaagagag gggctgagtc accatagtg 8580
cagcaccgac tcctgcagga aaggcgagac actgggtcat gggctactgaa gggtgccctg 8640
20 aatgacgttc tgcttttagag accgaacctg agccctgaaa gtgcatgcct gttcatgggt 8700
gagagactaa attcatcatt ccttggcagg tactgaatcc tttcttacgg ctgccctcca 8760
25 atgcccaatt tcctacaat tgtctgggggt gcctaagctt ctgcccacca agagggccag 8820
agctggcagc gagcagctgc aggtaggaga gataggtacc cataaggag gtgggaaaga 8880
gagatggaag gagaggggtg cagagcacac acctcccctg cctgacaact tcctgagggc 8940
30 tggatcatgcc agcagattta aggcggaggc aggggagatg gggcgggaga ggaagtgaaa 9000
aaggagaggg tggggatgga gaggaagaga gggatgatcat tcattcattc cattgctact 9060
35 gactggatgc cagctgtgag ccaggcacca ccctagctct gggcatgtgg ttgtaatctt 9120

WO 00/32773

PCT/US99/27990

96

ggagcctcat ggagctcaca gggagtgctg gcaaggagat ggataatgga cggataacaa 9180

ataaacattt agtacaatgt ccgggaatgg aaagttctcg aaagaaaaat aaagctggtg 9240

5 agcatataga cagccctgaa ggcggccagg ccaggcattt ctgaggaggt ggcatttgag 9300

c

9301

- 10 From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

WO 00/32773

PCT/US99/27990

1

SEQUENCE LISTING

5 <110> Brunkow, Mary E.
 Galas, David J.
 Kovacevich, Brian
 Mulligan, John T.
 Paeper, Bryan W.
 Van Ness, Jeffrey
 10 Winkler, David G.

15 <120> COMPOSITIONS AND METHODS FOR INCREASING
 BONE MINERALIZATION

<130> 240083.508

<140> US
 <141> 1999-11-24

20 <160> 41

<170> FastSEQ for Windows Version 3.0

25 <210> 1
 <211> 2301
 <212> DNA
 <213> Homo sapien

30 <400> 1

agagcctgtg ctactggaag gtggcgtgcc ctctctggc tggtagcatg cagctcccac 60
 tggccctgtg tctcgtctgc ctgctggtac acacagcctt ccgtgtagtg gagggccagg 120
 ggtggcaggc gttcaagaat gatgccacgg aaatcatccc cgagctcgga gagtaccccg 180
 agcctccacc ggagctggag aacaacaaga ccatgaaccg ggcggagAAC ggagggcggc 240
 35 ctccccacca cccctttgag accaaagacg tgtccgagta cagctgccgc gagctgcact 300
 tcacccgcta cgtgaccgat gggccgtgcc gcagcgccaa gccggtcacc gagctggtgt 360

WO 00/32773

PCT/US99/27990

2

gctccggcca gtgcggcccg gcgcgcctgc tgcccaacgc catcggccgc ggcaagtggc 420
 ggcgacctag tgggcccgcac ttccgctgca tccccgaccg ctaccgcgcg cagcgcgtgc 480
 agctgctgtg tcccgggtgt gaggcgcgcg gcgcgcgcaa ggtgcgcctg gtggcctcgt 540
 gcaagtgcaa gcgcctcacc cgcttccaca accagtcgga gctcaaggac ttcgggaccg 600
 5 aggccgctcg gccgcagaag ggccggaagc cgcggccccc cgcccggagc gccaaagcca 660
 accaggccga gctggagaac gcctactaga gcccgcccgc gccctcccc accggcgggc 720
 gcccggccc tgaacccgcg cccacattt ctgtcctctg cgcgtggttt gattgtttat 780
 atttcattgt aaatgcctgc aaccagggc agggggctga gaccttccag gccctgagga 840
 atcccgggcg ccggcaaggc cccctcagc ccgccagctg aggggtccca cggggcaggg 900
 10 gaggggaattg agagtcacag aactgagcc acgcagcccc gcctctgggg ccgcctacct 960
 ttgctgggtcc cacttcagag gaggcagaaa tggaagcatt ttcaccgccc tgggggtttta 1020
 agggagcggc gtgggagtg gaaagtccag ggactgggta agaaagtgtg ataagattcc 1080
 cccttgcacc tcgctgccc tcaaaaagcc tgaggcgtgc ccagagcaca agactggggg 1140
 caactgtaga tgtgggtttt agtcctggct ctgccactaa cttgctgtgt aaccttgaac 1200
 15 tacacaattc tccttcggga cctcaatttc cactttgtaa aatgagggtg gaggtgggaa 1260
 taggatctcg aggagactat tggcatatga ttccaaggac tccagtgcct tttgaatggg 1320
 cagaggtgag agagagagag agaaagagag agaataatg cagttgcatt gattcagtgc 1380
 caaggctcact tccagaattc agagttgtga tgctctcttc tgacagccaa agatgaaaaa 1440
 caaacagaaa aaaaaaagta aagagtctat ttatggctga catatttacg gctgacaaac 1500
 20 tcctggaaga agctatgctg ctcccagcc tggcttcccc ggatgtttgg ctacctccac 1560
 ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgagggt 1620
 ggtgggaggg atagaaatca catccgcccc aacttcccaa agagcagcat cctcccccgc 1680
 acccatagcc atgtttttaa gtcaccttcc gaagagaagt gaaagggtca aggacactgg 1740
 ccttgcaggc ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
 25 caccgccttc tgcccaccac tcacggacac atttctgcct agaaaacagc ttcttactgc 1860
 tcttacatgt gatggcatat cttacactaa aagaatatta ttgggggaaa aactacaagt 1920
 gctgtacata tgctgagaaa ctgcagagca taatagctgc cacccaaaaa tctttttgaa 1980
 aatcatttcc agacaacctc ttactttctg tgtagttttt aattgtttaa aaaaaaagt 2040
 tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtcgttttt ttggcaattc 2100
 30 ttccacgtgg gacttgtcca caagaatgaa agtagtggtt tttaaagagt taagttacat 2160
 atttattttc tcaacttaagt tatttatgca aaagtttttc ttgtagagaa tgacaatgtt 2220
 aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
 acaatgaatc atgaccgaaa g 2301

35

<210> 2

<211> 213

WO 00/32773

PCT/US99/27990

3

<212> PRT

<213> Homo sapien

<400> 2

5 Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
 1 5 10 15
 Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
 20 25 30
 Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 10 35 40 45
 Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 50 55 60
 Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 15 Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
 85 90 95
 Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
 100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
 20 115 120 125
 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 130 135 140
 Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 25 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 165 170 175
 Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
 30 195 200 205
 Leu Glu Asn Ala Tyr
 210

<210> 3

35

<211> 2301

<212> DNA

WO 00/32773

PCT/US99/27990

4

<213> Homo sapien

<400> 3

	agagcctgtg	ctactggaag	gtggcgtgcc	ctcctctggc	tggtaccatg	cagctcccac	60
5	tggccctgtg	tctcgtctgc	ctgctggtac	acacagcctt	ccgtgtagtg	gagggctagg	120
	ggtggcaggc	gttcaagaat	gatgccacgg	aaatcatccc	cgagctcggg	gagtaccccg	180
	agcctccacc	ggagctggag	aacaacaaga	ccatgaaccg	ggcggagaaac	ggagggcggc	240
	ctccccacca	cccctttgag	accaaagacg	tgtccgagta	cagctgccgc	gagctgcact	300
	tcacccgcta	cgtgaccgat	gggccgtgcc	gcagcgccaa	gccggtcacc	gagctggtgt	360
10	gctccggcca	gtgcggcccg	gcgcgcctgc	tgcccaacgc	catcggccgc	ggcaagtggg	420
	ggcgacctag	tgggcccgcg	ttccgctgca	tccccgaccg	ctaccgcgcg	cagcgcgctgc	480
	agctgctgtg	tcccgggtgg	gagggcgccg	gcgcgcgcaa	ggtgcgcctg	gtggcctcgt	540
	gcaagtgcaa	gcgcctcacc	cgcttccaca	accagtcgga	gctcaaggac	ttcgggaccg	600
	aggccgctcg	gccgcagaag	ggccggaagc	cgcgcccccg	cgccccggagc	gccaaagcca	660
15	accaggccga	gctggagaaac	gcctactaga	gcccgcgccg	gcccctcccc	accggcgggc	720
	gccccggccc	tgaacccgcg	ccccacattt	ctgtcctctg	cgcggtggtt	gattgtttat	780
	atttcattgt	aaatgcctgc	aaccacaggg	agggggctga	gaccttccag	gccctgagga	840
	atccccggcg	ccggcaaggc	ccccctcagc	ccgccagctg	aggggtccca	cggggcaggg	900
	gaggggaattg	agagtcacag	acactgagcc	acgcagcccc	gcctctgggg	ccgcctacct	960
20	ttgctgggtc	cacttcagag	gaggcagaaa	tgggaagcatt	ttcaccgccc	tgggggtttta	1020
	agggagcggt	gtgggagtgg	gaaagtccag	ggactgggtta	agaaagttag	ataagattcc	1080
	cccttgcacc	tcgctgcccc	tcagaaagcc	tgaggcgtgc	ccagagcaca	agactggggg	1140
	caactgtaga	tgtgggtttc	agtcctggct	ctgccactaa	cttgctgtgt	aaccttgaac	1200
	tacacaattc	tccttcggga	cctcaatttc	cactttgtaa	aatgaggggt	gaggtgggaa	1260
25	taggatctcg	aggagactat	tggcatatga	ttccaaggac	tccagtgcct	tttgaatggg	1320
	cagaggtgag	agagagagag	agaaagagag	agaatgaatg	cagttgcatt	gattcagtgc	1380
	caaggtcact	tccagaattc	agagttgtga	tgctctcttc	tgacagccaa	agatgaaaaa	1440
	caaacagaaa	aaaaaaagta	aagagtctat	ttatggctga	catattttac	gctgacaaac	1500
	tcctggaaga	agctatgctg	cttcccagcc	tggcttcccc	ggatgtttgg	ctacctccac	1560
30	ccctccatct	caaagaaata	acatcatcca	ttggggtaga	aaaggagagg	gtccgagggg	1620
	ggtgggaggg	atagaaatca	catccgcccc	aacttcccaa	agagcagcat	ccctcccccg	1680
	acccatagcc	atgtttttaa	gtcaccttcc	gaagagaagt	gaaagggttc	aggacactgg	1740
	ccttgcaggc	ccgagggagc	agccatcaca	aactcacaga	ccagcacatc	cctttttgaga	1800
	caccgccttc	tgcccaccac	tcacggacac	atttctgcct	agaaaacagc	ttcttactgc	1860
35	tccttacatgt	gatggcatat	cttacactaa	aagaatatta	ttgggggaaa	aactacaagt	1920
	gctgtacata	tgctgagaaa	ctgcagagca	taatagctgc	cacccaaaaa	tcctttttgaa	1980

WO 00/32773

PCT/US99/27990

5

aatcatttcc agacaacctc ttactttctg tgtagttttt aattgtttaa aaaaaaaagt 2040
 tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtcgttttt ttggcaattc 2100
 ttccacgtgg gacttgtcca caagaatgaa agtagtggtt tttaaagagt taagttacat 2160
 atttattttc tcacttaagt tatttatgca aaagtttttc ttgtagagaa tgacaatggt 2220
 5 aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
 acaatgaatc atgaccgaaa g 2301

<210> 4

<211> 23

10 <212> PRT

<213> Homo sapien

<400> 4

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
 15 1 5 10 15
 Ala Phe Arg Val Val Glu Gly
 20

<210> 5

20 <211> 2301

<212> DNA

<213> Homo sapien

<400> 5

25 agagcctgtg ctactggaag gtggcgtgcc ctctctggc tggtagcatg cagctccac 60
 tggccctgtg tctcatctgc ctgctggtac acacagcctt ccgtgtagtg gagggccagg 120
 ggtggcaggc gttcaagaat gatgccacgg aaatcatccg cgagctcgga gagtaccacg 180
 agcctccacc ggagctggag aacaacaaga ccatgaaccg ggcggagaac ggagggcggc 240
 ctccccacca cccctttgag accaaagacg tgtccgagta cagctgccgc gagctgcact 300
 30 tcaccgcta cgtgaccgat gggccgtgcc gcagcgcaa gccggtcacc gagctggtgt 360
 gctccggcca gtgcggcccg gcgcgcctgc tgcccaacgc catcggccgc ggcaagtgg 420
 ggcgacctag tgggcccgcac ttccgctgca tccccgaccg ctaccgcgcg cagcgcgtgc 480
 agctgctgtg tcccgggtggg gaggcgcgcg gcgcgcgcaa ggtgcgcctg gtggcctcgt 540
 gcaagtgcaa gcgcctcacc cgcttccaca accagtcgga gctcaaggac ttcgggaccg 600
 35 aggccgctcg gccgcagaag ggccggaagc cgcggccccc cgcccggagc gccaaagcca 660
 accaggccga gctggagaac gcctactaga gcccgcccgcc gccctcccc accggcgggc 720

WO 00/32773

PCT/US99/27990

6

gccccggccc tgaacccgcg cccacattt ctgtcctctg cgcgtgggtt gattgtttat 780
 atttcattgt aaatgcctgc aaccacagggc aggggggctga gaccttccag gccctgagga 840
 atccccgggcg ccggcaaggc cccctcagc ccgccagctg aggggtccca cggggcaggg 900
 gaggggaattg agagtcacag aactgagcc acgcagcccc gcctctgggg ccgcctacct 960
 5 ttgctgggtcc cacttcagag gaggcagaaa tggaagcatt ttcaccgccc tgggggtttta 1020
 agggagcggg gtgggagtg gaaagtccag ggactgggta agaaagttgg ataagattcc 1080
 cccttgccacc tcgctgcccc tcagaaagcc tgaggcgtgc ccagagcaca agactggggg 1140
 caactgtaga tgtgggtttct agtcctggct ctgccactaa cttgctgtgt aaccttgaac 1200
 tacacaattc tccttcggga cctcaatttc cactttgtaa aatgaggggt gaggtgggaa 1260
 10 taggatctcg aggagactat tggcatatga ttccaaggac tccagtgcct tttgaatggg 1320
 cagaggtgag agagagagag agaaagagag agaataatg cagttgcatt gattcagtgc 1380
 caaggtcact tccagaattc agagttgtga tgctctcttc tgacagccaa agatgaaaaa 1440
 caaacagaaa aaaaaaagta aagagtctat ttatgggtga catatttacg gctgacaaac 1500
 tcctggaaga agctatgctg cttcccagcc tggcttcccc ggatgtttgg ctacctccac 1560
 15 ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgagggg 1620
 ggtgggaggg atagaaatca catccgcccc aacttcccaa agagcagcat ccctcccccg 1680
 acccatagcc atgtttttaa gtcaccttcc gaagagaagt gaaaggttca aggacactgg 1740
 ccttgccaggc ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
 caccgccttc tgcccaccac tcacggacac atttctgcct agaaaacagc ttcttactgc 1860
 20 tcttacatgt gatggcatat cttacactaa aagaatatta ttgggggaaa aactacaagt 1920
 gctgtacata tgctgagaaa ctgcagagca taatagctgc cacccaaaaa tctttttgaa 1980
 aatcatttcc agacaacctc ttactttctg tgtagttttt aattgttaaa aaaaaaaagt 2040
 tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtcgttttt ttggcaattc 2100
 ttccacgtgg gacttgtcca caagaatgaa agtagtggtt tttaaagagt taagttacat 2160
 25 atttattttc tcaacttaagt tatttatgca aaagtttttc ttgtagagaa tgacaatgtt 2220
 aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
 acaatgaatc atgaccgaaa g 2301

<210> 6

30 <211> 213

<212> PRT

<213> Homo sapien

<400> 6

35 Met Gln Leu Pro Leu Ala Leu Cys Leu Ile Cys Leu Leu Val His Thr

1

5

10

15

WO 00/32773

PCT/US99/27990

7

Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
 20 25 30
 Ala Thr Glu Ile Ile Arg Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 5 Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 50 55 60
 Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
 10 85 90 95
 Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
 100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
 115 120 125
 15 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 130 135 140
 Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 20 165 170 175
 Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 25 Leu Glu Asn Ala Tyr
 210

<210> 7

<211> 2301

30

<212> DNA

<213> Homo sapien

<400> 7

agagcctgtg ctactggaag gtggcgtgcc ctctctggc tggtagcatg cagctccac 60
 35 tggccctgtg tctcgtctgc ctgctggtac acacagcctt ccgtgtagtg gagggccagg 120
 ggtggcaggc gttcaagaat gatgccacgg aaatcatccg cgagctcgga gaggaccccg 180

WO 00/32773

PCT/US99/27990

8

	agcctccacc	ggagctggag	aacaacaaga	ccatgaaccg	ggcggagAAC	ggagggcggc	240
	ctccccacca	cccctttgag	accaaagacg	tgtccgagta	cagctgccgc	gagctgcact	300
	tcacccgcta	cgtgaccgat	gggccgtgcc	gcagcgccaa	gccggtcacc	gagctggtgt	360
	gctccggcca	gtgcggcccc	gcgcgcctgc	tgcccaacgc	catcggccgc	ggcaagtgg	420
5	ggcgacctag	tgggccccgac	ttccgctgca	tccccgaccg	ctaccgcgcg	cagcgcgctgc	480
	agctgctgtg	tcccgggtgg	gaggcgccgc	gcgcgcgcaa	ggtgcgcctg	gtggcctcgt	540
	gcaagtgcaa	gcgcctcacc	cgcttccaca	accagtcgga	gctcaaggac	ttcgggaccg	600
	aggccgctcg	gccgcagaag	ggccggaagc	cgcggccccc	cgcccgagac	gccaaagcca	660
	accaggccga	gctggagAAC	gcctactaga	gcccgcgcgc	gcccctcccc	accggcgggc	720
10	gccccggccc	tgaaccgcgc	ccccacattt	ctgtcctctg	cgcgtgggtt	gattgtttat	780
	atttcattgt	aaatgcctgc	aaccagggc	agggggctga	gaccttccag	gccctgagga	840
	atcccgggcg	ccggcaaggc	ccccctcagc	ccgccagctg	aggggtccca	cggggcaggg	900
	gagggAattg	agagtcacag	acactgagcc	acgcagcccc	gcctctgggg	ccgcctacct	960
	ttgctgggtc	cacttcagag	gaggcagaaa	tggaagcatt	ttcaccgccc	tggggtttta	1020
15	agggagcgg	gtgggagtg	gaaagtccag	ggactgggtta	agaaagtTg	ataagattcc	1080
	cccttgcacc	tcgctgcccc	tcagaaagcc	tgaggcgctgc	ccagagcaca	agactggggg	1140
	caactgtaga	tgtggtttct	agtcctggct	ctgccactaa	cttgctgtgt	aaccttgaac	1200
	tacacaattc	tccttcggga	cctcaatttc	cactttgtaa	aatgaggggt	gaggtgggaa	1260
	taggatctcg	aggagactat	tggcatatga	ttccaaggac	tccagtgcct	tttgaatggg	1320
20	cagaggTgag	agagagagag	agaaagagag	agaatgaatg	cagttgcatt	gattcagtgc	1380
	caaggTcact	tccagaattc	agagttgtga	tgctctcttc	tgacagccaa	agatgaaaaa	1440
	caaacagaaa	aaaaaaagta	aagagtctat	ttatggctga	catattttacg	gctgacaaac	1500
	tcctggaaga	agctatgctg	cttcccagcc	tggcttcccc	ggatgtttgg	ctacctccac	1560
	ccctccatct	caaagaaata	acatcatcca	ttggggtaga	aaaggagagg	gtccgaggg	1620
25	ggtgggaggg	atagaaatca	catccgcccc	aacttcccaa	agagcagcat	ccctcccccg	1680
	acccatagcc	atgtttttaa	gtcaccttcc	gaagagaagt	gaaaggttca	aggacactgg	1740
	ccttgcaggc	ccgagggagc	agccatcaca	aactcacaga	ccagcacatc	ccttttgaga	1800
	caccgccttc	tgcccaccac	tcacggacac	atttctgcct	agaaaacagc	ttcttactgc	1860
	tcttacatgt	gatggcatat	cttacactaa	aagaatatta	ttgggggaaa	aactacaagt	1920
30	gctgtacata	tgctgagaaa	ctgcagagca	taatagctgc	cacccaaaaa	tctttttgaa	1980
	aatcattttcc	agacaacctc	ttactttctg	tgtagttttt	aattgttaaa	aaaaaaaagt	2040
	tttaaacaga	agcacatgac	atatgaaagc	ctgcaggact	ggtcggtttt	ttggcaattc	2100
	ttccacgtgg	gacttgtcca	caagaatgaa	agtagtggtt	tttaaagagt	taagttacat	2160
	atttattttc	tcacttaagt	tatttatgca	aaagtttttc	ttgtagagaa	tgacaatgtt	2220
35	aatattgctt	tatgaattaa	cagtctgttc	ttccagagtc	cagagacatt	gttaataaag	2280
	acaatgaatc	atgaccgaaa	g				2301

WO 00/32773

PCT/US99/27990

9

<210> 8

<211> 213

<212> PRT

5 <213> Homo sapien

<400> 8

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
 1 5 10 15
 10 Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
 20 25 30
 Ala Thr Glu Ile Ile Arg Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 15 50 55 60
 Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
 85 90 95
 20 Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
 100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
 115 120 125
 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 25 130 135 140
 Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 165 170 175
 30 Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 Leu Glu Asn Ala Tyr
 35 210

WO 00/32773

PCT/US99/27990

10

<210> 9

<211> 642

<212> DNA

<213> Cercopithecus pygerythrus

5

<400> 9

atgcagctcc cactggccct gtgtcttgct tgctgtctgg tacacgcagc cttccgtgta 60
 gtggagggcc aggggtggca ggccttcaag aatgatgcca cggaaatcat ccccgagctc 120
 ggagagtacc ccgagcctcc accggagctg gagaacaaca agaccatgaa ccgggaggag 180
 10 aatggagggc ggcctcccca ccaccccttt gagaccaaag acgtgtccga gtacagctgc 240
 cgagagctgc acttcacccg ctacgtgacc gatgggccgt gccgcagcgc caagccagtc 300
 accgagttgg tgtgctccgg ccagtgcggc ccggcacgcc tgctgcccga cgccatcggc 360
 cgcggaagt ggtggcgccc gagtgggccc gacttcgct gcatccccga ccgctaccgc 420
 gcgcagcgtg tgcagctgct gtgtcccggt ggtgccgcgc cgcgcgcgcg caaggtgcgc 480
 15 ctggtggcct cgtgcaagtg caagcgcctc acccgcttcc acaaccagtc ggagctcaag 540
 gacttcggtc ccgaggccgc tcggccgcag aagggccgga agccgcggcc ccgcgcccgg 600
 ggggccaag ccaatcaggc cgagctggag aacgcctact ag 642

<210> 10

20

<211> 213

<212> PRT

<213> Cercopithecus pygerythrus

<400> 10

25 Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Ala
 1 5 10 15
 Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
 20 25 30
 Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 30 35 40 45
 Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 50 55 60
 Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 35 Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
 85 90 95

WO 00/32773

PCT/US99/27990

11

Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
 100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
 115 120 125
 5 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 130 135 140
 Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 10 165 170 175
 Ser Glu Leu Lys Asp Phe Gly Pro Glu Ala Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 15 Leu Glu Asn Ala Tyr
 210

<210> 11

<211> 638

20 <212> DNA

<213> Mus musculus

<400> 11

atgcagccct cactagcccc gtgcctcattc tgcctacttg tgcacgctgc cttctgtgct 60
 25 gtggagggcc aggggtggca agccttcagg aatgatgcca cagagggtcat cccagggctt 120
 ggagagtacc ccgagcctcc tcctgagaac aaccagacca tgaaccgggc ggagaatgga 180
 ggcagacctc cccaccatcc ctatgacgcc aaaggtgtgt ccgagtacag ctgccgcgag 240
 ctgcactaca cccgcttcct gacagacggc ccatgccgca gcgccaagcc ggtcaccgag 300
 ttggtgtgct ccggccagtg cggccccgcg cggctgctgc ccaacgccat cgggcgcgctg 360
 30 aagtgggtggc gcccgaacgg accggatttc cgctgcatcc cggatcgcta ccgcgcgcag 420
 cgggtgcagc tgctgtgccc cgggggcgcg gcgcccgcgt cgcgcaaggt gcgtctggtg 480
 gcctcgtgca agtgcaagcg cctcaccgcg ttccacaacc agtcggagct caaggacttc 540
 gggccggaga ccgcgcggcc gcagaagggt cgcaagccgc ggcccggcgc ccggggagcc 600
 aaagccaacc aggcggagct ggagaacgcc tactagag 638

35

<210> 12

WO 00/32773

PCT/US99/27990

12

<211> 211

<212> PRT

<213> Mus musculus

5

<400> 12

Met Gln Pro Ser Leu Ala Pro Cys Leu Ile Cys Leu Leu Val His Ala
 1 5 10 15
 Ala Phe Cys Ala Val Glu Gly Gln Gly Trp Gln Ala Phe Arg Asn Asp
 20 25 30
 10 Ala Thr Glu Val Ile Pro Gly Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 Glu Asn Asn Gln Thr Met Asn Arg Ala Glu Asn Gly Gly Arg Pro Pro
 50 55 60
 His His Pro Tyr Asp Ala Lys Asp Val Ser Glu Tyr Ser Cys Arg Glu
 15 65 70 75 80
 Leu His Tyr Thr Arg Phe Leu Thr Asp Gly Pro Cys Arg Ser Ala Lys
 85 90 95
 Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala Arg Leu
 100 105 110
 20 Leu Pro Asn Ala Ile Gly Arg Val Lys Trp Trp Arg Pro Asn Gly Pro
 115 120 125
 Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val Gln Leu
 130 135 140
 Leu Cys Pro Gly Gly Ala Ala Pro Arg Ser Arg Lys Val Arg Leu Val
 25 145 150 155 160
 Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln Ser Glu
 165 170 175
 Leu Lys Asp Phe Gly Pro Glu Thr Ala Arg Pro Gln Lys Gly Arg Lys
 180 185 190
 30 Pro Arg Pro Gly Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu Leu Glu
 195 200 205
 Asn Ala Tyr
 210

35

<210> 13

<211> 674

WO 00/32773

PCT/US99/27990

13

<212> DNA

<213> Rattus norvegicus

<400> 13

5 gaggaccgag tgcccttcct ccttctggca ccatgcagct ctcactagcc ccttgcccttg 60
 cctgcctgct tgtacatgca gccttcgttg ctgtggagag ccaggggtgg caagccttca 120
 agaatgatgc cacagaaatc atcccgggac tcagagagta cccagagcct cctcaggaac 180
 tagagaacaa ccagaccatg aaccggggccg agaacggagg cagaccccc caccatcctt 240
 atgacaccaa agacgtgtcc gactacagct gccgcgagct gcactacacc cgcttcgtga 300
 10 ccgacggccc gtgccgcagt gccaaagccgg tcaccgagtt ggtgtgctcg ggccagtgcg 360
 gccccgcgcg gctgctgccc aacgccatcg ggcgcgtgaa gtggtggcgc ccgaacggac 420
 ccgacttccg ctgcatcccg gatcgctacc gcgcgcagcg ggtgcagctg ctgtgccccg 480
 gcggcgcggc gccgcgctcg cgcaaggtgc gtctggtggc ctcgtgcaag tgcaagcgcc 540
 tcaccgcgtt ccacaaccag tcggagctca aggacttcgg acctgagacc gcgcggccgc 600
 15 agaagggtcg caagccgcgg ccccgcgccc ggggagccaa agccaaccag gcggagctgg 660
 agaacgccta ctag 674

<210> 14

<211> 213

20 <212> PRT

<213> Rattus norvegicus

<400> 14

Met Gln Leu Ser Leu Ala Pro Cys Leu Ala Cys Leu Leu Val His Ala
 25 1 5 10 15
 Ala Phe Val Ala Val Glu Ser Gln Gly Trp Gln Ala Phe Lys Asn Asp
 20 25 30
 Ala Thr Glu Ile Ile Pro Gly Leu Arg Glu Tyr Pro Glu Pro Pro Gln
 35 40 45
 30 Glu Leu Glu Asn Asn Gln Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 50 55 60
 Pro Pro His His Pro Tyr Asp Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 Arg Glu Leu His Tyr Thr Arg Phe Val Thr Asp Gly Pro Cys Arg Ser
 35 85 90 95
 Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala

WO 00/32773

PCT/US99/27990

14

100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Val Lys Trp Trp Arg Pro Asn
 115 120 125
 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 5 130 135 140
 Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ser Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 165 170 175
 10 Ser Glu Leu Lys Asp Phe Gly Pro Glu Thr Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 Leu Glu Asn Ala Tyr
 15 210

<210> 15

<211> 532

<212> DNA

20 <213> Bos torus

<400> 15

agaatgatgc cacagaaatc atccccgagc tgggagagta ccccgagcct ctgccagagc 60
 tgaacaacaa gaccatgaac cgggagagga acggagggag acctccccac cacccttttg 120
 25 agaccaaaga cgcctccgag tacagctgcc gggagctgca cttcaccgcg tacgtgaccg 180
 atgggcccgtg ccgcagcgcc aagccgggtca ccgagctggt gtgctcgggc cagtgcggcc 240
 cggcgcgccct gctgcccac gccatcggcc gcggcaagtg gtggcgccca agcgggccc 300
 acttccgctg catccccgac cgctaccgcg cgcagcgggt gcagctgttg tgtcctggcg 360
 gcgcggcgcc gcgcgcgcgc aaggtgcgcc tgggtggcctc gtgcaagtgc aagcgccctca 420
 30 ctcgcttcca caaccagtcc gagctcaagg acttcggggc cgaggccgcg cggccgcaaa 480
 cgggcccggaa gctgcggccc cgcgcccggg gcaccaaagc cagccgggga ga 532

<210> 16

<211> 176

35 <212> PRT

<213> Bos torus

WO 00/32773

PCT/US99/27990

15

<400> 16

Asn Asp Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro
 1 5 10 15
 5 Leu Pro Glu Leu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly
 20 25 30
 Arg Pro Pro His His Pro Phe Glu Thr Lys Asp Ala Ser Glu Tyr Ser
 35 40 45
 Cys Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg
 10 50 55 60
 Ser Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro
 65 70 75 80
 Ala Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro
 85 90 95
 15 Ser Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg
 100 105 110
 Val Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ala Arg Lys Val
 115 120 125
 Arg Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn
 20 130 135 140
 Gln Ser Glu Leu Lys Asp Phe Gly Pro Glu Ala Ala Arg Pro Gln Thr
 145 150 155 160
 Gly Arg Lys Leu Arg Pro Arg Ala Arg Gly Thr Lys Ala Ser Arg Ala
 165 170 175

25

<210> 17

<211> 35828

<212> DNA

<213> Mus musculus

30

<220>

<221> misc_feature

<222> (1)...(35828)

<223> n = A,T,C or G

35

<400> 17

WO 00/32773

PCT/US99/27990

16

	cgcgtttttg	tgagcagcaa	tattgcgctt	cgatgagcct	tggcggtgag	attgatacct	60
	ctgctgcaca	aaaggcaatc	gaccgagctg	gaccagcgca	ttcgtgacac	cgtctccttc	120
	gaacttattc	gcaatggagt	gtcattcatic	aaggacngcc	tgatcgcaaa	tggtgctatc	180
	cacgcagcgg	caatcgaaaa	ccctcagccg	gtgaccaata	tctacaacat	cagccttggt	240
5	atcctgcgtg	atgagccagc	gcagaacaag	gtaaccgtca	gtgccgataa	gttcaaagtt	300
	aaacctgggtg	ttgataccaa	cattgaaacg	ttgatcgaaa	acgcgctgaa	aaacgctgct	360
	gaatgtgcgg	cgctggatgt	cacaaagcaa	atggcagcag	acaagaaagc	gatggatgaa	420
	ctggcttcct	atgtccgcac	ggccatcatg	atggaatgtt	tccccgggtg	tggtatctgg	480
	cagcagtgcc	gtcgatagta	tgcaattgat	aattattatc	atttgcgggt	cctttccggc	540
10	gatccgcctt	gttacggggc	ggcgacctcg	cgggttttcg	ctatttatga	aaattttccg	600
	gtttaaggcg	tttccgttct	tcttcgtcat	aacttaatgt	ttttatttaa	aataccctct	660
	gaaaagaaag	gaaacgacag	gtgctgaaag	cgagcttttt	ggcctctgtc	gtttcctttc	720
	tctgtttttg	tccgtggaat	gaacaatgga	agtcaacaaa	aagcagagct	tatcgatgat	780
	aagcgggtcaa	acatgagaat	tcgcggccgc	ataatacgac	tcactatagg	gatcgacgcc	840
15	tactccccgc	gcatgaagcg	gaggagctgg	actccgcatg	cccagagacg	ccccccaacc	900
	cccaaagtgc	ctgacctcag	cctctaccag	ctctggcttg	ggcttggggc	gggtcaaggc	960
	taccacgttc	tcttaacagg	tggttgggct	gtctcttggc	cgcgcgtcat	gtgacagctg	1020
	cctagtcttg	cagtgaggtc	accgtggaat	gtctgccttc	gttgccatgg	caacgggatg	1080
	acgttacaat	ctgggtgtgg	agcttttcct	gtccgtgtca	ggaaatccaa	ataccctaaa	1140
20	ataccctaga	agaggaagta	gctgagccaa	ggcttttcctg	gcttctccag	ataaagtttg	1200
	acttagatgg	aaaaaaacaa	aatgataaag	acccgagcca	tctgaaaatt	cctcctaatt	1260
	gcaccactag	gaaatgtgta	tattattgag	ctcgtatgtg	ttcttatttt	aaaaagaaaa	1320
	ctttagtcac	gttattaata	agaatttctc	agcagtggga	gagaaccaat	attaacacca	1380
	agataaaaagt	tggcatgac	cacattgcag	gaagatccac	gttgggtttt	catgaatgtg	1440
25	aagaccccat	ttattaaagt	cctaagctct	gtttttgcac	actaggaagc	gatggccggg	1500
	atggctgagg	ggctgtaagg	atctttcaat	gtcttacatg	tgtgtttcct	gtcctgcacc	1560
	taggacctgc	tgcttagcct	gcagcagagc	cagaggggtt	tcacatgatt	agtctcagac	1620
	acttgggggc	aggttgcacg	tactgcacg	cttatttcca	tacggagcac	ctactatgtg	1680
	tcaaacacca	tatggtgttc	actcttcaga	acggtggtgg	tcacatgggt	gcatttgctg	1740
30	acggttggtg	tggtggtaga	gagctgagat	atatggacgc	actcttcagc	attctgtcaa	1800
	cgtggctgtg	cattcttgct	cctgagcaag	tggctaaaca	gactcacagg	gtcagcctcc	1860
	agctcagtcg	ctgcatagtc	ttagggaacc	tctcccagtc	ctccctacct	caactatcca	1920
	agaagccagg	gggcttggcg	gtctcaggag	cctgcttgct	gggggacagg	ttgttgagtt	1980
	ttatctgcag	taggttgccct	aggcatagtg	tcaggactga	tggctgcctt	ggagaacaca	2040
35	tcctttgccc	tctatgcaaa	tctgaccttg	acatgggggc	gctgctcagc	tgggaggatc	2100
	aactgcatac	ctaaagccaa	gcctaaagct	tcttcgtcca	cctgaaactc	ctggaccaag	2160

WO 00/32773

PCT/US99/27990

17

	gggcttccgg	cacatcctct	caggccagt	agggagtctg	tgtgagctgc	actttccaat	2220
	ctcagggcgt	gagagggcaga	gggaggtggg	ggcagagcct	tgcagctctt	tcctcccac	2280
	tggacagcgc	tctggctcag	cagcccatat	gagcacaggc	acatccccac	cccaccccca	2340
	cctttcctgt	cctgcagaat	ttaggctctg	ttcacggggg	gggggggggg	ggggcagtc	2400
5	tatcctctct	taggtagaca	ggactctgca	ggagacactg	ctttgtaaga	tactgcagtt	2460
	taaatttgga	tgttgtagag	ggaaagcgaa	gggcctcttt	gaccattcag	tcaaggtacc	2520
	ttctaactcc	catcgtattg	gggggctact	ctagtgttag	acattgcaga	gagcctcaga	2580
	actgtagtta	ccagtgtggt	aggattgatc	cttcagggag	cctgacatgt	gacagttcca	2640
	ttcttcaccc	agtcaccgaa	catttattca	gtacctaccc	cgtaacaggc	accgtagcag	2700
10	gtactgaggg	acggaccact	caaagaactg	acagaccgaa	gccttggaat	ataaacacca	2760
	aagcatcagg	ctctgccaac	agaacactct	ttaacactca	ggccctttaa	cactcaggac	2820
	ccccacccc	acccaagca	gttggcactg	ctatccacat	tttacagaga	ggaaaaacta	2880
	ggcacaggac	gatataagt	gcttgcttaa	gcttgtctgc	atggtaaagt	gcagggctgg	2940
	attgagacc	agacattcca	actctagggt	ctatctttct	ttttctctgt	tgttcgaatc	3000
15	tgggtcttac	tgggtaaact	caggctagcc	tcacactcat	atccttctcc	catggcttac	3060
	gagtgttagg	attccaggtg	tgtgtacca	tgtctgactc	cctgtagctt	gtctatacca	3120
	tcctcacaac	ataggaattg	tgatagcagc	acacacaccg	gaaggagctg	gggaaatccc	3180
	acagagggct	ccgcaggatg	acaggcgaat	gcctacacag	aaggtgggga	agggaagcag	3240
	agggaacagc	atgggcgtgg	gaccacaagt	ctatctgggg	aagctgccgg	taaccgtata	3300
20	tggctgggg	gaggggagag	gtcatgagat	gaggcaggaa	gagccacagc	aggcagcggg	3360
	tacgggctcc	ttattgcaa	gaggctcgga	tcttcctcct	cttcctcctt	ccggggctgc	3420
	ctgttcattt	tccaccactg	cctcccaccc	aggtctgtgg	ctcaggacat	caccagctg	3480
	cagaaactgg	gcacaccca	cgtcctgaat	gctgccgagg	gcaggtcctt	catgcacgtc	3540
	aacaccagt	ctagcttcta	cgaggattct	ggcatcacct	acttgggcat	caaggccaat	3600
25	gatacgcagg	agttcaacct	cagtgtctac	tttgaaagg	ccacagattt	cattgaccag	3660
	gcgctggccc	ataaaaaatg	taaggaacgt	acattccggc	acccatggag	cgtaagccct	3720
	ctgggacctg	cttcctccaa	agaggccccc	acttgaaaaa	ggttccagaa	agatcccaaa	3780
	atatgccacc	aactagggat	taagtgtcct	acatgtgagc	cgatgggggc	cactgcatat	3840
	agtctgtgcc	atagacatga	caatggataa	taatatttca	gacagagagc	aggagttagg	3900
30	tagctgtgct	cctttccctt	taattgagt	tgcccathtt	tttattcatg	tatgtgtata	3960
	catgtgtgtg	cacacatgcc	ataggttgat	actgaacacc	gtcttcaatc	gttccccacc	4020
	ccaccttatt	ttttgaggca	gggtctcttc	cctgatcctg	gggctcattg	gtttatctag	4080
	gctgctggcc	agtgtgctct	ggagttctgc	ttttctctac	ctccctagcc	ctgggactgc	4140
	aggggcatgt	gctgggcccag	gcttttatgt	cgcgttgggg	atctgaactt	aggtccctag	4200
35	gcctgagcac	cgtaaagact	ctgccacatc	cccagcctgt	ttgagcaagt	gaaccattcc	4260
	ccagaattcc	cccagtgggg	ctttcctacc	cttttattgg	ctaggcattc	atgagtggtc	4320

WO 00/32773

PCT/US99/27990

18

	acctcgccag	aggaatgagt	ggccacgact	ggctcaggg	cagcagccta	gagatactgg	4380
	gttaagtctt	cctgccgctc	gctccctgca	gccgcagaca	gaaagtagga	ctgaatgaga	4440
	gctggctagt	ggtcagacag	gacagaaggc	tgagaggggtc	acagggcaga	tgtcagcaga	4500
	gcagacaggt	tctccctctg	tgggggaggg	gtggcccact	gcaggtgtaa	ttggccttct	4560
5	ttgtgctcca	tagaggcttc	ctgggtacac	agcagcttcc	ctgtcctgg	gattcccaaa	4620
	gagaactccc	taccactgga	cttacagaag	ttctattgac	tgggtgtaacg	gttcaacagc	4680
	tttggctctt	ggtggacgg	gcatactgct	gtatcagctc	aagagctcat	tcacgaatga	4740
	acacacacac	acacacacac	acacacacac	acacaagcta	atthttgat	gccttaacta	4800
	gctcagtga	tgggcatttc	tgaacatccc	tgaagttagc	acacatttcc	ctctgggtgtt	4860
10	cctggcttaa	caccttctaa	atctatat	tatctttgct	gccctgttac	cttctgagaa	4920
	gcccctaggg	ccacttccct	tcgcacctac	attgctggat	ggtttctctc	ctgcagctct	4980
	taaatctgat	ccctctgcct	ctgagccatg	ggaacagccc	aataactgag	ttagacataa	5040
	aaacgtctct	agccaaaact	tcagctaaat	ttagacaata	aatcttactg	gttgtggaat	5100
	ccttaagatt	cttcatgacc	tccttcacat	ggcacgagta	tgaagcttta	ttacaattgt	5160
15	ttattgatca	aactaactca	taaaaagcca	gttgtctttc	acctgctcaa	ggaaggaaca	5220
	aaattcatcc	ttaactgac	tgtgcacctt	gcacaatcca	tacgaatatc	ttaagagtac	5280
	taagatthtg	gttgtgagag	tcacatgtta	cagaatgtac	agctttgaca	aggtgcatcc	5340
	ttgggatgcc	gaagtgaact	gctgttccag	ccccctacct	tctgaggctg	ttttggaagc	5400
	aatgctctgg	aagcaacttt	aggaggtagg	atgctggaac	agcgggtcac	ttcagcatcc	5460
20	cgatgacgaa	tcccgtcaaa	gctgtacatt	ctgtaacaga	ctgggaaagc	tgcagacttt	5520
	aaggccaggg	ccctatgggtc	cctcttaatc	cctgtcacac	ccaacccgag	cccttctcct	5580
	ccagccgttc	tgtgcttctc	actctggata	gatggagaac	acggccttgc	tagttaaagg	5640
	agtgaggctt	cacccttctc	acatggcagt	ggttgggtcat	cctcattcag	ggaactctgg	5700
	ggcattctgc	ctttacttcc	tcttttttga	ctacagggaa	tatatgctga	cttgthtttga	5760
25	ccttgtgtat	ggggagactg	gatctttgg	ctggaatgtt	tcctgctagt	ttttcccat	5820
	cctttggcaa	accctatcta	tatcttacca	ctaggcatag	tggccctcgt	tctggagcct	5880
	gccttcaggc	tggttctcgg	ggacctatgc	cctggthttct	ccccagcata	tgggtgttcac	5940
	agtgttcact	gcgggtggtt	gctgaacaaa	gcggggattg	catcccagag	ctccgggtgcc	6000
	ttgtgggtac	actgctaaga	taaaatggat	actggcctct	ctctgaccac	ttgcagagct	6060
30	ctggtgcctt	gtgggtacac	tgctaagata	aaatggatac	tggcctctct	ctatccactt	6120
	gcaggactct	agggaaacagg	aatccattac	tgagaaaacc	aggggctagg	agcagggagg	6180
	tagctgggca	gctgaagtgc	ttggcgacta	accaatgaat	accagagtht	ggatctctag	6240
	aatactctta	aaatctgggt	gggcagagtg	gcctgcctgt	aatcccagaa	ctcgggaggc	6300
	ggagacaggg	aatcatcaga	gcaaactggc	taaccagaat	agcaaaacac	tgagctctgg	6360
35	gctctgtgag	agatcctgcc	ttaacatata	agagagagaa	taaaacattg	aagaagacag	6420
	tagatgccaa	ttttaagccc	ccacatgcac	atggacaagt	gtgcgtthtga	acacacatat	6480

WO 00/32773

PCT/US99/27990

19

	gcactcatgt gaaccaggca tgcacactcg ggcttatcac acacataatt tgaaagagag	6540
	agtgagagag gagagtgcac attagagttc acaggaaagt gtgagtgagc acacccatgc	6600
	acacagacat gtgtgccagg gagtaggaaa ggagcctggg tttgtgtata agagggagcc	6660
	atcatgtgtt tctaaggagg gcgtgtgaag gaggcgttgt gtgggctggg actggagcat	6720
5	ggttgtaact gagcatgctc cctgtgggaa acaggagggt ggccaccctg cagaggggtcc	6780
	cactgtccag cgggatcagt aaaagcccct gctgagaact ttaggtaata gccagagaga	6840
	gaaaggtagg aaagtggggg gactcccatc tctgatgtag gaggatctgg gcaagtagag	6900
	gtgcgtttga ggtagaaaga ggggtgcaga ggagatgctc ttaattctgg gtcagcagtt	6960
	tctttccaaa taatgcctgt gaggaggtgt aggtgggtggc cattcactca ctcagcagag	7020
10	ggatgatgat gcccgggtgga tgctggaaat ggccgagcat caaccctggc tctggaagaa	7080
	ctccatcttt cagaaggaga gtggatctgt gtatggccag cggggtcaca ggtgcttggg	7140
	gcccctgggg gactcctagc actgggtgat gtttatcgag tgctcttgtg tgccaggcac	7200
	tggcctgggg ctttgtttct gtctctgttt tgtttcgttt tttgagacag actcttgcta	7260
	tgtatccgtg tcaatcttgg aatctcactg catagcccag gctgcggaga gaggggaggg	7320
15	caataggcct tgtaagcaag ccacacttca gagactagac tccaccctgc gaatgatgac	7380
	aggtcagagc tgagttccgg aagatttttt ttccagctgc caggtggagt gtggagtggc	7440
	agctagcggc aagggtagag ggcgagctcc ctgtgcagga gaaatgcaag caagagatgg	7500
	caagccagtg agttaagcat tctgtgtggg gagcaggtgg atgaagagag aggctgggct	7560
	ttcgccctctg ggggggggggt gaggggtggg gatgaggtga gaggagggca gctccctgca	7620
20	gtgtgatgag atttttcctg acagtacact ttggcctctc cctccccac ttcccttctt	7680
	tcctttcttc ccaccattgc tttccttgtc cttgagaaat tctgagtttc cacttcactg	7740
	gtgatgcaga cggaaacaga agccgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt	7800
	gtgtgtgtgt ttgtgtgtat gtgtgtgtgt gtgtttgtgt gtatgtgtgt cagtgggaat	7860
	ggctcatagt ctgcaggaag gtgggcagga aggaataagc tgtaggctga ggcagtgtgg	7920
25	gatgcaggga gagaggagag gagggatacc agagaaggaa attaagggag ctacaagagg	7980
	gcattgttgg ggtgtgtgtg tgtgtgtgtt gtttatatatt gtattggaaa tacattcttt	8040
	taaaaaatac ttatccattt atttattttt atgtgcacgt gtgtgtgcct gcatgagttc	8100
	atgtgtgcca cgtgtgtgcg ggaacccttg gaggccacaa gggggcatct gatcccttg	8160
	aactggagtt ggaggaggtt gtgagtcctc tgacatgttt gctgggaact gaaccccgg	8220
30	cctatgcaag agcaggaagt gcagttatct gctgagccat ctctccagtc ctgaaatcca	8280
	ttctcttaaa atacacgtgg cagagacatg atgggattta cgtatggatt taatgtggcg	8340
	gtcattaagt tccggcacag gcaagcacct gtaaagccat caccacaacc gcaacagtga	8400
	atgtgacct ccccccatg ttcttcatgt cccctgtccc ctccatctc cattctcaag	8460
	cacctcttgc tctgcctctg tcgctggaga acagtgtgca tctgcacact cttatgtcag	8520
35	tgaagtcaca cagcctgcac cccttcctgg tctgagtatt tgggttctga ctctgctatc	8580
	acacactact gtactgcatt ctctcgtctt ctttttttaa acatattttt atttgtttgt	8640

WO 00/32773

PCT/US99/27990

20

	gtgtatgcac atgtgccaca tgtgtacaga tactatggag gccagaagag gccatggccg	8700
	tccctggagc tggagttaca ggcagcgtgt gagctgcctg gtgtgggtgc tgggaaccaa	8760
	acttgaatct aaagcaagca cttttaactg ctgaggcagc tctcagtacc cttcttcatt	8820
	tctccgctg ggttccattg tatggacaca tgtagctaga atatcttgct tatctaatta	8880
5	tgtacattgt tttgtgctaa gagagagtaa tgctctatag cctgagctgg cctcaacctt	8940
	gccatcctcc tgcctcagcc tctctctctt gagtgctagg atgacaggcg agtggttaact	9000
	tacatggttt catgttttgt tcaagactga aggataacat tcatacagag aaggctctggg	9060
	tcacaaagtg tgcagttcac tgaatggcac aaccctgat caagaaacaa aactcagggg	9120
	ctggagagat ggcactgact gctcttccag aggtccggag ttcaattccc agcaaccaca	9180
10	tggtggctca cagccatcta taacgagatc tgacgccctc ttctgggtgtg tctgaagaca	9240
	gctacagtgt actcacataa aataaataaa tctttaaaac acacacacac acacaattac	9300
	caccccagaa agcccactcc atgttccctc ccacgtctct gcctacagta ctcccagggt	9360
	accactgttc aggtcttctaa caacctgggt tacttggggc tcttttctgc tctgtggagc	9420
	cacacatttg tgtgcctcat acacgttctt tctagtaagt tgcataattac tctgcgtttt	9480
15	tacatgtatt tatttattgt agttgtgtgt gcgtgtgggc ccatgcatgg cacagtgtgt	9540
	ggggatgtca gagtattgtg aacaggggac agttcttttc ttcaatcatg tgggttccag	9600
	aggttgaact caggtcatca tgtgtggcag caaatgcctt taccactga gacatctcca	9660
	tattcttttt ttttccctg aggtgggggc ttgttccata gcccaaactg gctttgcact	9720
	tgcagttcaa agtgactccc tgtctccacc tcttagagta ttggaattac gatgtgtact	9780
20	accacacctg actggatcat taattctttg atggggggcg ggaagcgcac atgctgcagg	9840
	tgaagggatg actggactgg acatgagcgt ggaagccaga gaacagcttc agtctaagtc	9900
	tctcccaact gagctatttc ggtttgccag agaacaactt acagaaagtt ctcagtgcc	9960
	tgtggattcg gggttggagt tcaactcatc agcttgacat tggctcctct acccactgag	10020
	ccttctcact actctctacc tagatcatta attctttttt aaaaagactt attagggggc	10080
25	tggagagatg gctcagccgt taagagcacc gaatgccctt ccagagggtc tgagttcaat	10140
	tcccagcatg ccattgctgg gcagtagggg gcgcagggtg tcaacgtgag tagctgttgc	10200
	cagttttccg cgggtggagaa cctcttgaca ccctgctgtc cctgggtcatt ctgggtgggt	10260
	gcatgggtgat atgcttggtg tatggaagac tttgactgtt acagtgaagt tgggcttcca	10320
	cagttaccac gtctccctg tttcttgag gccgggtgct tgtccattgc cgcgagggt	10380
30	acagccgctc cccaacgcta gttatgcct acctcatgat gcggcagaag atggacgtca	10440
	agtctgctct gagtactgtg aggcagaatc gtgagatcgg cccaacgat ggcttcctgg	10500
	cccaactctg ccagctcaat gacagactag ccaaggaggg caagggtgaaa ctctagggtg	10560
	cccacagcct cttttgcaga ggtctgactg ggagggccct ggcagccatg tttaggaaac	10620
	acagtatacc cactccctgc accaccagac acgtgccac atctgtccca ctctggctct	10680
35	cggggggccac tccaccctta gggagcacat gaagaagctc cctaagaagt tctgctcctt	10740
	agccatcctt tctgtgaatt tatgtctctc cctgagggtg ggttcagggt tatgtccctg	10800

WO 00/32773

PCT/US99/27990

21

	tctgtggcat agatacatct cagtgaccca ggggtgggagg gctatcaggg tgcattggccc	10860
	gggacacggg cactcttcat gacccctccc ccacctgggt tcttcctgtg tggtecagaa	10920
	ccacgagcct ggtaaaggaa ctatgcaaac acaggccctg acctcccat gtctgttctt	10980
	ggtcctcaca gcccagacag ccctgctgag gcagacgaat gacattaagt tctgaagcag	11040
5	agtggagata gattagtgac tagatttcca aaaagaaggaa aaaaaaggc tgcattttta	11100
	aattatttcc ttagaattaa agatactaca tagggggcct tgggtaagca aatccatttt	11160
	tcccagagggc tatcttgatt ctttggaatg tttaaagtgt gccttgccag agagcttacg	11220
	atctatatct gctgcttcag agccttccct gaggatggct ctgttccttt gcttggttaga	11280
	agagcgatgc cttgggcagg gtttccccct tttcagaata cagggtgtaa agtccagcct	11340
10	attacaaaca aacaaacaaa caaacaaaca aaggacctcc atttgagagaa ttgcaaggat	11400
	tttatcctga attatagtgt tggtaggttc aagtcacac gccaaagtgt tgccatcctg	11460
	gttgctattc taagaataat taggaggagg aacctagcca attgcagctc atgtccgtgg	11520
	gtgtgtgcac ggggtgcatat gttggaagggt gtgcctgtcc ccttggggac agaaggaaaa	11580
	tgaaaggccc ctctgctcac cctggccatt tacgggaggc tctgctgggt ccacgggtgc	11640
15	tgtgcaggat cctgaaactg actcgctgga cagaaacgag acttggcggc accatgagaa	11700
	tggagagaga gagagcaaag aaagaaacag cctttaaaag aactttctaa ggggtggtttt	11760
	tgaacctcgc tggaccttgt atgtgtgcac atttgccaga gattgaacat aatcctcttg	11820
	ggacttcacg ttctcattat ttgtatgtct ccgggggtcac gcagagccgt cagccaccac	11880
	cccagcaccg ggcacatagg cgtctcataa aagcccatth tatgagaacc agagctgttt	11940
20	gagtaccccg tgtatagaga gagttgttgt cgtggggcac ccggatccca gcagcctgg	12000
	tgctgcctg taggatgtct tacaggagtt tgcagagaaa ccttccttgg agggaaagaa	12060
	atatcaggga tttttgttga atatttcaaa ttcagcttta agtgtaagac tcagcagtgt	12120
	tcattggttaa ggtaaggaaac atgccttttc cagagctgct gcaagaggca ggagaagcag	12180
	acctgtctta ggatgtcact cccagggtaa agacctctga tcacagcagg agcagagctg	12240
25	tgcagcctgg atggtcattg tcccctattc tgtgtgacca cagcaaccct ggtcacatag	12300
	ggctgggtcat cctttttttt tttttttttt tttttttttg gcccagaatg aagtgaccat	12360
	agccaagttg tgtacctcag tcttttagttt ccaagcggct ctcttgctca atacaatgtg	12420
	catttcaaaa taacactgta gagttgacag aactgggttca tgtgttatga gagaggaaaa	12480
	gagaggaaag aacaaaacaa aacaaaacac cacaaccaa aaacatctgg gctagccagg	12540
30	catgattgca atgtctacag gccagttca tgagaggcag agacaggaag accgccgaaa	12600
	ggtcaaggat agcatgggtct acgtatcgag actccagcca gggctacggg cccaagatcc	12660
	taggtttttg attttgggct ttggtttttg agacagggtt tctctgtgta gccctggctg	12720
	tcctggaact cgctctgtag accaggctgg cctcaaactt agagatctgc ctgactctgc	12780
	ctttgagggc tgggacgaat gccaccactg cccaactaag attccattaa aaaaaaaaaa	12840
35	agttcaagat aattaagagt tgccagctcg tttaaagctaa gtagaagcag tctcaggcct	12900
	gctgcttgag gctgttcttg gcttggacct gaaatctgcc cccaacagtg tccaagtgca	12960

WO 00/32773

PCT/US99/27990

22

	catgactttg agccatctcc agagaaggaa gtgaaaattg tggctcccca gtcgattggg	13020
	acacagtctc tctttgtcta ggtaacacat ggtgacacat agcattgaac tctccactct	13080
	gaggggtgggt ttccctcccc ctgcctcttc tgggttggtc accccatagg acagccacag	13140
	gacagtcact agcacctact ggaaacctct ttgtgggaac atgaagaaag agcctttggg	13200
5	agattcctgg ctttccatta gggctgaaag tacaacggtt cttgggtggc tttgcctcgt	13260
	gtttataaaa ctagctacta ttcttcaggt aaaataccga tggtgtggaa aagccaaccc	13320
	cgtggctgcc cgtgagtagg ggggtggggtt gggaatcctg gatagtgttc tatccatgga	13380
	aagtgggtgga ataggaatta aggggtgttcc ccccccccc aacctcttcc tcagacccag	13440
	ccactttcta tgacttataa acatccaggt aaaaattaca aacataaaaa tggtttctct	13500
10	tctcaatctt ctaaagtctg cctgcctttt ccaggggtag gtctgtttct ttgctgttct	13560
	attgtcttga gagcacagac taacacttac caaatgaggg aactcttggc ccatactaag	13620
	gctcttctgg gctccagcac tcttaagtta ttttaagaat tctcacttgg ccttttagcac	13680
	acccgccacc cccaagtggg tgtggataat gccatggcca gcagggggca ctggtgaggc	13740
	gggtgccttt ccaccttaag ttgcttatag tatttaagat gctaaatgtt ttaatcaaga	13800
15	gaagcactga tcttataata cgaggataag agattttctc acaggaaatt gtctttttca	13860
	taattctttt acaggctttg tcctgatcgt agcatagaga gaatagctgg atatttaact	13920
	tgtattccat tttcctctgc cagcgttagg ttaactccgt aaaaagtgat tcagtggacc	13980
	gaagaggctc agagggcagg ggatgggtggg gtgaggcaga gcactgtcac ctgccaggca	14040
	tgggaggtcc tgccatccgg gaggaaaagg aaagtttagc ctctagtcta ccaccagtgt	14100
20	taacgcactc taaagttgta accaaaataa atgtcttaca ttacaaagac gtctgttttg	14160
	tgtttccttt tgtgtgtttg ggctttttat gtgtgcttta taactgctgt ggtgggtgctg	14220
	ttgttagttt tgaggtagga tctcaggctg gccttgaact tctgatcgcc tgccccctgcc	14280
	cctgccccctg cccctgtccc tgccccaag tgctaggact aaaagcacat gccaccacac	14340
	cagtacagca tttttctaac atttaaaaat aatcacctag gggctggaga gagggttcca	14400
25	gctaagagtg cacactgctc ttgggtagga cctgagttta gttcccagaa cctatactgg	14460
	gtggctccag gtccagagga tccaggacct ctggcctcca tgggcatctg ctcttagcac	14520
	atacccacat acagatacac acataaaaat aaaatgaagc ctttaaaaac ctcctaaaac	14580
	ctagcccttg gaggtacgac tctggaaagc tggcatactg tgtaagtcca tctcatgggtg	14640
	ttctggctaa cgtaagactt acagagacag aaaagaactc aggggtgtgct ggggggttggg	14700
30	atggaggaag agggatgagt agggggagca cggggaactt gggcagtga aattctttgc	14760
	aggacactag aggaggataa ataccagtca ttgcaccac tactggacaa ctccaggga	14820
	ttatgctggg tgaaaagaga aggccccagg tattggctgc attggctgca tttgcgtaac	14880
	atttttttta attgaaaaga aaaagatgta aatcaagggt agatgagtgg ttgctgtgag	14940
	ctgagagctg ggggtgagtga gacatgtgga caactccatc aaaaagcgac agaaagaacg	15000
35	ggctgtggtg acagctacct ctaatctcca cctccgggag gtgatcaagg ttagccctca	15060
	gctagcctgt ggtgcatgag accctgtttc aaaaacttta ataaagaaat aatgaaaaaa	15120

WO 00/32773

PCT/US99/27990

23

	gacatcaggg cagatccttg gggccaaagg cggacaggcg agtctcgtgg taaggtcgtg	15180
	tagaagcggg tgcattgagca cgtgccgcag gcatcatgag agagccctag gtaagtaagg	15240
	atggatgtga gtgtgtcggc gtcggcgcac tgcacgtcct ggctgtggtg ctggactggc	15300
	atctttggtg agctgtggag gggaaatggg tagggagatc ataaaatccc tccgaattat	15360
5	ttcaagaact gtctattaca attatctcaa aatattaata aaaaagaaga attaaaaaac	15420
	aaaaaaccta tccaggtgtg gtggtgtgca cctatagcca cgggcacttg gaaagctgga	15480
	gcaagaggat ggcgagtttg aaggatctg gggctgtaca gcaagaccgt cgtcccaaaa	15540
	ccaaacaaa cagcaaacc attatgtcac acaagagtgt ttatagttag cggcctcgct	15600
	gagagcatgg ggtgggggtg ggggtggggg acagaaatat ctaaaactgca gtcaataggg	15660
10	atccactgag accctggggc ttgactgcag cttaaccttg ggaaatgata agggttttgt	15720
	gttgagtaaa agcatcgatt actgacttaa cctcaaata gaataaagaa aaaaagaaaa	15780
	caacaaaagc caaaccaagg ggctggtgag atggctcagt gggtaagagc acccgactgc	15840
	tcttccgaag gtccagagtt caaatcccag caaccacatg gtggctcaca accatctgta	15900
	acgagatatg atgccctctt ctggtgtgtc tgaagacagc tacagtgtac ttacatataa	15960
15	taaataaatc ttaaaaaaaa aaaaaaaaaa aaaagccaaa ccgagcaaac caggcccca	16020
	aacagaaggc aggcacgacg gcaggcacca cgagccatcc tgtgaaaagg cagggtacc	16080
	catgggccga ggagggtcca gagagatagg ctggtaagct cagtttctct gtataccctt	16140
	tttcttggtg acactacttc aattacagat aaaataacaa ataaacaaaa tctagagcct	16200
	ggccactctc tgctcgcttg atttttcctg ttacgtccag cagggtggcg aagtgttcca	16260
20	aggacagatc gcatcattaa ggtggccagc ataatctccc atcagcaggt ggtgctgtga	16320
	gaaccattat ggtgctcaca gaatcccggg cccaggagct gccctctccc aagtctggag	16380
	caataggaaa gctttctggc ccagacaggg ttaacagtcc acattccaga gcaggggaaa	16440
	aggagactgg aggtcacaga caaaagggcc agcttctaac aacttcacag ctctggtagg	16500
	agagatagat ccccccaac aatggccaca gctggttttg tctgccccga aggaaactga	16560
25	cttaggaagc aggtatcaga gtccccttcc tgaggggact tctgtctgcc ttgtaaagct	16620
	gtcagagcag ctgcattgat gtgtgggtga cagaagatga aaaggaggac ccaggcagat	16680
	cgccacagat ggaccggcca cttacaagtc gaggcaggtg gcagagcctt gcagaagctc	16740
	tgcaggtgga cgacactgat tcattacca gttagcatac cacagcgggc taggcggacc	16800
	acagcctcct tcccagtctt cctccagggc tggggagtcc tccaaccttc tgtctcagt	16860
30	cagcttccgc cagccctcc tctttttgca cctcaggtgt gaacctccc tctctcctt	16920
	ctccctgtgg catggccctc ctgctactgc aggtgagca ttggatttct ttgtgcttag	16980
	atagacctga gatggcttct tgatttatat atatatatcc atcccttggg tcttacatct	17040
	aggaccaga gctgtttgtg ataccataag aggtggggga gatgatatgg taagagtgt	17100
	tgctgtacaa gcatgaagac atgagttcga atccccagca accatgtgga aaaataacct	17160
35	tctaacctca gagttgaggg gaaaggcagg tggattctgg gggcttactg gccagctagc	17220
	cagcctaacc taaatgtctc agtcagagat cctgtctcag ggaataactt gggagaatga	17280

WO 00/32773

PCT/US99/27990

24

	ctgagaaaga cacctcctca ggtctcccat gcacccacac agacacacgg ggggggggta	17340
	atgtaataag ctaagaaata atgagggaaa tgattttttg ctaagaaatg aaattctgtg	17400
	ttggccgcaa gaagcctggc caggggaagga actgcctttg gcacaccagc ctataagtca	17460
	ccatgagttc cctggctaag aatcacatgt aatggagccc aggtccctct tgcctggtgg	17520
5	ttgcctctcc cactggtttt gaagagaaat tcaagagaga tctccttggg cagaattgta	17580
	ggtgctgagc aatgtggagc tgggggtcaat gggattcctt taaaggcatc cttcccaggg	17640
	ctgggtcata cttcaatagt aggggtgcttg cacagcaagc gtgagaccct aggttagagt	17700
	ccccagaatc tgcccccaac cccccaaaaa ggcattcctt tgcctctggg tgggtggggg	17760
	gagcaaacac ctttaactaa gaccattagc tggcaggggt aacaaatgac cttggctaga	17820
10	ggaatttggg caagctggat tccgccttct gtagaagccc cacttgtttc ctttggttaag	17880
	ctggcccaca gtttgttttg agaatgcctg agggggcccag ggagccagac aattaaaagc	17940
	caagctcatt ttgatatctg aaaaccacag cctgactgcc ctgcccgtgg gaggtactgg	18000
	gagagctggc tgtgtccctg cctcaccaac gccccccccc ccaacacaca ctctcgggt	18060
	cacctgggag gtgccagcag caatttggaa gtttactgag cttgagaagt cttgggaggg	18120
15	ctgacgctaa gcacaccctt tctccacccc cccccacccc acccccgtga ggaggaggg	18180
	gaggaaacat gggaccagcc ctgctccagc ccgtccttat tggctggcat gaggcagagg	18240
	gggctttaaa aaggcaaccg tatctaggct ggacactgga gcctgtgcta ccgagtgcc	18300
	tcctccacct ggcagcatgc agccctcact agccccgtgc ctcatctgcc tacttgtgca	18360
	cgctgccttc tgtgctgtgg agggccaggg gtggcaagcc ttcaggaatg atgccacaga	18420
20	ggtcatccca gggcttggag agtacccega gcctcctcct gagaacaacc agaccatgaa	18480
	ccgggcggag aatggaggca gacctccca ccatccctat gacgccaag gtacgggatg	18540
	aagaagcaca ttagtggggg ggggggtcct gggaggtgac tgggggtggt ttagcatctt	18600
	cttcagaggt ttgtgtgggt ggctagcctc tgctacatca gggcagggac acatttgcct	18660
	ggaagaatac tagcacagca ttagaacctg gagggcagca ttgggggggt ggtagagagc	18720
25	acccaaggca ggggtggaggc tgaggtcagc cgaagctggc attaacacgg gcatgggctt	18780
	gtatgatggg ccagagaatc tcctcctaag gatgaggaca caggtcagat ctagctgctg	18840
	accagtgggg aagtgatatg gtgaggctgg atgccagatg ccatccatgg ctgtactata	18900
	tcccacatga ccaccacatg aggtaaagaa ggccccagct tgaagatgga gaaaccgaga	18960
	ggctcctgag ataaagtcac ctgggagtaa gaagagctga gactggaagc tggtttgatc	19020
30	cagatgcaag gcaaccctag attgggtttg ggtgggaacc tgaagccagg aggaatccct	19080
	ttagttcccc cttgcccagg gtctgctcaa tgagcccaga gggttagcat taaaagaaca	19140
	gggtttgtag gtggcatgtg acatgagggg cagctgagtg aaatgtcccc tgtatgagca	19200
	caggtggcac cacttgccct gagcttgcac cctgacccca gctttgcctc attcctgagg	19260
	acagcagaaa ctgtggaggc agagccagca cagagagatg cctgggggtgg ggggtgggggt	19320
35	atcacgcacg gaactagcag caatgaatgg ggtgggggtg cagctggagg gacactccag	19380
	agaaatgacc ttgctgggtca ccatttgtgt gggaggagag ctcattttcc agcttgccac	19440

WO 00/32773

PCT/US99/27990

25

	cacatgctgt cctcctgtc tcctagccag taagggatgt ggaggaaagg gccaccccaa	19500
	aggagcatgc aatgcagtca cgttttttgca gaggaagtgc ttgacctaa ggcactattc	19560
	ttggaaagcc ccaaaactag tccttccctg ggcaaacagg cctccccccac ataccacctc	19620
	tgcaggggtg agtaaattaa gccagccaca gaaggggtggc aaggcctaca cctccccctt	19680
5	gttgtgcccc cccccccccc gtgaaggtgc atcctggcct ctgcccctct ggctttggta	19740
	ctgggatttt ttttttcctt ttatgtcata ttgatcctga caccatggaa cttttggagg	19800
	tagacaggac ccacacatgg attagttaaa agcctcccat ccatctaagc tcatggtagg	19860
	agatagagca tgtccaagag aggagggcag gcatcagacc tagaagatat ggctgggcat	19920
	ccaacccaat ctcttcccc ggagaacaga ctctaagtca gatccagcca cccttgagta	19980
10	accagctcaa ggtacacaga acaagagagt ctggtataca gcagggtgcta aacaaatgct	20040
	tgtggtagca aaagctatag gttttgggtc agaactccga cccaagtcgc gagtgaagag	20100
	cgaaaggccc tctactcgc accgccccgc cccacactgg ggtcctataa cagatcactt	20160
	tcacccttgc gggagccaga gagccctggc atcctaggta gcccccccg ccccccccc	20220
	gcaagcagcc cagccctgcc tttggggcaa gttcttttct cagcctggac ctgtgataat	20280
15	gaggggggtg gacgcgccgc ctttgggtgc tttcaagtct aatgaattct tatccctacc	20340
	acctgccctt ctaccccgct cctccacagc agctgtcctg atttattacc ttcaattaac	20400
	ctccactcct ttctccatct cctgggatac cgcccctgtc ccagtggctg gttaaaggagc	20460
	ttaggaagga ccagagccag gtgtggctag aggctaccag gcagggtctg ggatgaggag	20520
	ctaaactgga agagtgtttg gttagtaggc acaaagcctt ggggtgggatc cctagtaccg	20580
20	gagaagtgga gatgggcgct gagaagttca agaccatcca tccttaacta cacagccagt	20640
	ttgaggccag cctgggctac ataaaaaccc aatctcaaaa gctgccatt ctgattctgt	20700
	gccacgtagt gcccgatgta atagtggatg aagtcgttga atcctggggc aacctatttt	20760
	acagatgtgg ggaaaagcaa ctttaagtac cctgcccaca gatcacaag aaagtaagtg	20820
	acagagctcc agtgtttcat ccctgggttc caaggacagg gagagagaag ccagggtggg	20880
25	atctcactgc tccccggtgc ctcttctcta taatccatac agattcgaaa gcgcagggca	20940
	ggtttggaaa aagagagaag ggtggaagga gcagaccagt ctggcctagg ctgcagcccc	21000
	tcacgcatcc ctctctccgc agatgtgtcc gactacagct gccgcgagct gcactacacc	21060
	cgcttctga cagacggccc atgccgcagc gccaaagccg tcaccgagtt ggtgtgctcc	21120
	ggccagtgcg gcccgcgcgc gctgctgccc aacgccatcg ggccgctgaa gtggtggcgc	21180
30	ccgaacggac cggatttccg ctgcatcccg gatcgctacc gcgcgcagcg ggtgcagctg	21240
	ctgtgccccg ggggcgcgcg gccgcgctcg cgcaaggtgc gtctgggtggc ctctgcaag	21300
	tgcaagcgcc tcaccgctt ccacaaccag tcggagctca aggacttcgg gccggagacc	21360
	gcgcggccgc agaaggggtcg caagccgcgc cccggcgccc ggggagccaa agccaaccag	21420
	gcggagctgg agaacgccta ctagagcgag cccgcgccta tgcagcccc gcgcgatccg	21480
35	attcgttttc agtgtaaagc ctgcagccca ggccaggggt gccaaacttt ccagaccgtg	21540
	tggagttccc agcccagtag agaccgcagg tccttctgcc cgctgcgggg gatggggagg	21600

WO 00/32773

PCT/US99/27990

26

	gggtgggggtt cccgcggggcc aggagaggaa gcttgagtcc cagactctgc ctagccccgg	21660
	gtgggatggg ggtcttttcta ccctcgccgg acctatacag gacaaggcag tgtttccacc	21720
	ttaaagggaa gggagtgtgg aacgaaagac ctgggactgg ttatggacgt acagtaagat	21780
	ctactccttc caccctaatg taaagcctgc gtgggctaga tagggtttct gaccctgacc	21840
5	tggccactga gtgtgatgtt gggctacgtg gttctctttt ggtacgggtct tctttgtaaa	21900
	atagggaccg gaactctgct gagattccaa ggattggggg accccgtgta gactggtgag	21960
	agagaggaga acaggggagg ggttagggga gagattgtgg tgggcaaccg cctagaagaa	22020
	gctgtttgtt ggctcccagc ctccgcccct cagaggtttg gcttccccca ctcttctctc	22080
	tcaaactctgc cttcaaactc atatctggga tagggaaggc cagggtccga gagatggtgg	22140
10	aagggccaga aatcacactc ctggcccccc gaagagcagt gtcccgcccc caactgcctt	22200
	gtcatattgt aaagggattt tctacacaac agtttaaggt cgttggagga aactgggctt	22260
	gccagtcacc tcccatacct gtcccttgcc aggacaccac ctctgacctg ccaccacagg	22320
	acacatttct gtctagaaac agagcgtcgt cgtgctgtcc tctgagacag catatcttac	22380
	attaaaaaga ataatacggg gggggggggc ggagggcgca agtggtatac atatgctgag	22440
15	aagctgtcag gcgccacagc accaccaca atctttttgt aaatcatttc cagacacctc	22500
	ttactttctg tgtagatttt aattgttaaa aggggaggag agagagcgtt tgtaacagaa	22560
	gcacatggag gggggggtag ggggggtggg gctggtgagt ttggcgaact ttccatgtga	22620
	gactcatcca caaagactga aagccgcgtt ttttttttta agagtccagt gacatattta	22680
	ttttctcatt taagttattt atgccaacat ttttttcttg tagagaaagg cagtgttaat	22740
20	atcgctttgt gaagcacaag tgtgtgtggt tttttgtttt ttgttttttc cccgaccaga	22800
	ggcattgtta ataaagacaa tgaatctcga gcaggaggct gtgggtcttg tttgtcaacc	22860
	acacacaatg tctcgccact gtcattctac tcccttccct tggtcacaag acccaaacct	22920
	tgacaacacc tccgactgct ctctggtagc ccttggtggca atacgtgttt cctttgaaaa	22980
	gtcacattca tcctttcctt tgcaaacctg gctctcattc cccagctggg tcatcgtcac	23040
25	accctcacc cagcctccct ttagctgacc actctccaca ctgtcttcca aaagtgcacg	23100
	tttcaccgag ccagttccct ggtccaggtc atcccattgc tctccttgcc tccagaccct	23160
	tctcccacaa agatgttcat ctcccactcc atcaagcccc agtggccctg cggctatccc	23220
	tgtctcttca gttagctgaa tctacttgct gacaccacat gaattccttc cctgtctta	23280
	aggttcatgg aactcttgcc tgcccctgaa ccttccagga ctgtcccagc gtctgatgtg	23340
30	tcctctctct tgtaaagccc caccctacta tttgattccc aattctagat cttcccttgt	23400
	tcattccttc acgggatagt gtctcatctg gccaaagtcct gcttgatatt gggataaatg	23460
	caaagccaag tacaattgag gaccagttca tcattggggc aagctttttc aaaatgtgaa	23520
	ttttacacct atagaagtgt aaaagccttc caaagcagag gcaatgcctg gctcttcctt	23580
	caacatcagg gctcctgctt tatgggtctg gtggggtagt acattcataa acccaacact	23640
35	aggggtgtga aagcaagatg attgggagtt cgaggccaat cttggctatg aggccctgtc	23700
	tcaacctctc ctccctccct ccagggtttt gttttgtttt gtttttttga tttgaaactg	23760

WO 00/32773

PCT/US99/27990

27

	caacacttta	aatccagtca	agtgcattct	tgcgtgaggg	gaactctatc	cctaataataa	23820
	gcttccatct	tgattttgtgt	atgtgcacac	tgggggttga	acctgggcct	ttgtacctgc	23880
	cgggcaagct	ctctactgct	ctaaacccag	ccctcactgg	ctttctgttt	caactcccaa	23940
	tgaattcccc	taaatgaatt	atcaatatca	tgtctttgaa	aaataccatt	gagtgtctgct	24000
5	ggtgtccctg	tggttccaga	ttccaggaag	gacttttcag	ggaatccagg	catcctgaag	24060
	aatgtcttag	agcaggaggc	catggagacc	ttggccagcc	ccacaaggca	gtgtggtgca	24120
	gaggggtgagg	atggaggcag	gcttgcaatt	gaagctgaga	caggggtactc	aggattaaaa	24180
	agcttcccc	aaaacaattc	caagatcagt	tcctgggtact	tgcacctgtt	cagctatgca	24240
	gagcccagtg	ggcatagggtg	aagacaccgg	ttgtactgtc	atgtactaac	tgtgcttcag	24300
10	agccggcaga	gacaaataat	gttatgggtga	ccccagggga	cagtgattcc	agaaggaaca	24360
	cagaagagag	tgctgctaga	ggctgcctga	aggagaaggg	gtcccagact	ctctaagcaa	24420
	agactccact	cacataaaga	cacaggctga	gcagagctgg	ccgtggatgc	aggagacca	24480
	tccaccatcc	tttagcatgc	ccttgatttc	ccatcacatg	ccagggatga	ggggcatcag	24540
	agagtccaag	tgatgcccga	acccaaacac	acctaggact	tgctttctgg	gacagacaga	24600
15	tgcaggagag	actaggttgg	gctgtgatcc	cattaccaca	aagagggaaa	aaacaaaaaa	24660
	caaacaaca	aacaaaaaaa	aacaaaacaa	aacaaaaaaa	aaccaaggt	ccaaattgta	24720
	ggtcaggtta	gagtttattt	atggaaagtt	atattctacc	tccatgggggt	ctacaaggct	24780
	ggcgcccatc	agaaagaaca	aacaacaggc	tgatctggga	gggggtggtac	tctatggcag	24840
	ggagcacgtg	tgcttgggggt	acagccagac	acggggcttg	tattaatcac	agggcttgta	24900
20	ttaataggct	gagagtcaag	cagacagaga	gacagaagga	aacacacaca	cacacacaca	24960
	cacacacaca	cacacacaca	catgcacaca	ccactcactt	ctcactcgaa	gagcccctac	25020
	ttacattcta	agaacaaacc	attcctcctc	ataaaggaga	caaagttgca	gaaacccaaa	25080
	agagccacag	ggtccccact	ctctttgaaa	tgacttggac	ttgttgcagg	gaagacagag	25140
	gggtctgcag	aggcttcctg	ggtgaccag	agccacagac	actgaaatct	ggtgctgaga	25200
25	cctgtataaa	ccctcttcca	caggttccct	gaaaggagcc	cacattcccc	aacctgtct	25260
	cctgaccact	gaggatgaga	gcacttgggc	cttccccatt	cttggagtgc	acctgggttt	25320
	ccccatctga	gggcacatga	ggtctcaggt	cttgggaaag	ttccacaagt	attgaaagtg	25380
	ttcttgTTTT	gtttgtgatt	taatttaggt	gtatgagtgc	ttttgcttga	atatatgcct	25440
	gtgtagcatt	tacaagcctg	gtgcctgagg	agatcagaag	atggcatcag	ataccctgga	25500
30	actggacttg	cagacagtta	tgagccactg	tgtgggtgct	aggaacagaa	cctggatcct	25560
	ccggaagagc	agacagccag	cgctcttagc	cactaagcca	tcactgaggt	tctttctgtg	25620
	gctaaagaga	caggagacaa	aggagagttt	cttttagtca	ataggaccat	gaatgttcct	25680
	cgtaacgtga	gactagggca	gggtgatccc	ccagtgcac	cgatggccct	gtgtagttat	25740
	tagcagctct	agtcttattc	cttaataagt	cccagtttgg	ggcaggagat	atgtattccc	25800
35	tgctttgaag	tggtgaggt	ccagttatct	acttccaagt	acttgtttct	ctttctggag	25860
	ttggggaagc	tcctgcctg	cctgtaaagt	tgtccattct	tcaaccttag	acaagatcac	25920

WO 00/32773

PCT/US99/27990

28

	tttccctgag cagtcaggcc agtccaaagc ccttcaattt agctttcata aggaacaccc	25980
	cttttgttgg gtggaggtag cacttgccctt gaatcccagc attaagaagg cagagacagt	26040
	cggatctctg tgagttcaca gccagcctgg tctacggagt gagttccaag acagccaggc	26100
	ctacacagag aaaccctgtc tcgaaaaaaaa caaaaacaaa agaaataaag aaaaagaaaa	26160
5	caaaaacgaa caaacagaaa aacaagccag agtgtttgtc cccgtatttt attaatacata	26220
	tttttgtccc ttgcccattt tagactaaaa gactcgggaa agcaggtctc tctctgtttc	26280
	tcacccggac acaccagaa ccagatgtat ggaagatggc taatgtgctg cagttgcaca	26340
	tctggggctg ggtggattgg ttagatggca tgggctgggt gtggttacga tgactgcagg	26400
	agcaaggagt atgtggtgca tagcaaacga ggaagtttgc acagaacaac actgtgtgta	26460
10	ctgatgtgca ggtatgggca catgcaagca gaagccaagg gacagcctta gggtagtggt	26520
	tccacagacc cctccccctt tttaacatgg gcattctctca ttggcctgga gcttgccaac	26580
	tgggctgggc tggctagctt gtaggtccca gggatctgca tatctctgcc tccctagtgc	26640
	tgggattaca gtcatatatg agcacacctg gcttttttat gtgggttctg ggctttgaac	26700
	ccagatctga gtgcttgcaa ggcaatcggg tgaatgactg cttcatctcc ccagaccctg	26760
15	ggattctact ttctattaaa gtatttctat taaatcaatg agcccctgcc cctgcactca	26820
	gcagttctta ggcctgctga gagtcaagtg gggagtgaga gcaagcctcg agaccccatc	26880
	agcgaagcag aggacaaaga aatgaaaact tgggattcga ggctcgggat atggagatac	26940
	agaaagggtc agggaaggaa atgaaccaga tgaatagagg caggaagggt agggccctgc	27000
	atacatggaa cctgggtgtac atgttatctg catgggggtt gcattgcaat ggctcttcag	27060
20	caggttcacc aactgggaa acagaagcca aaaagaagag taggtggtgt tggagtcaga	27120
	tactgtcagt catgcctgaa gaaatggaag caattaacga tgcgccgcaa ttaggatatt	27180
	agctccctga agaaaggcaa gaagctgggc tgtgggcact gaaggagct ttgaatgatg	27240
	tcacattctc tgtatgccta gcagggcagt attggagact gagacttgac ttgtgtgtcc	27300
	atatgattcc tccctttcct acagtcattt ggggctcctg agcttcgtcc ttgtccaaga	27360
25	acctggagct ggcagtgggc agctgcagtg atagatgtct gcaagaaaga tctgaaaaga	27420
	gggaggaaga tgaaggaccc agaggaccac cgacctctgc tgcctgacaa agctgcagga	27480
	ccagtctctc ctacagatgg gagacagagg cgagagatga atggtcaggg gaggagtcag	27540
	agaaaggaga gggtgaggca gagaccaaag gagggaaaca cttgtgctct acagctactg	27600
	actgagtacc agctgcgtgg cagacagcca atgccaaggc tcggctgac atggcacctc	27660
30	gtgggactcc tagcccagtg ctggcagagg ggagtgtgta atgggtgcatg gtttggatat	27720
	gatctgaatg tgggtccagcc ctagtctcct tccagttgct gggataaagc acctgacca	27780
	aagctacttt ttgttttgtt tgtttttggtt tggttttgtt tggtttttcg aggcagggtt	27840
	tctctgtatc acctagctg tccctggaact cactctgtag accaggctgg cctcgaactc	27900
	agaaatcccc ctgcctctgc ctccctaagtg ctggaattaa aggcctgcgc caccactgcc	27960
35	ggcccaaagc tactttaaga gagagagagg aatgtataag tattataatt ccagggtata	28020
	gttcattgct gtagaattgg agtcttcata ttccaggtaa tctcccacag acatgccaca	28080

WO 00/32773

PCT/US99/27990

29

	aaacaacctg ttctacgaaa tctctcatgg actcccttcc ccagtaattc taaactgtgt	28140
	caaatctaca agaaatagtg acagtcacag tctctaactg tttgggcatg agtctgaagt	28200
	ctcattgcta agtactggga agatgaaaac tttacctagt gtcagcattt ggagcagagc	28260
	ctttgggatt tgagatggtc ttttgcagag ctctaatgg ctacatggag agagggggcc	28320
5	tgggagagac ccatacacct tttgctgcct tatgtcacct gacctgctcc ttgggaagct	28380
	ctagcaagaa ggccttccct ggatcaccca ccaccttgca cctccagaac tcagagccaa	28440
	attaaacttt cttgttactg tcgtcaaagc acagtcggtc tgggttgtat cactgtcaat	28500
	gggaaacaga cttgcctgga tggataactt gtacattgca taatgtctag aaatgaaaag	28560
	tcctatagag aaaaagaaaa ttagctggca cacagataga ggccctggag gaggctggct	28620
10	ttgtcctccc cgaggaggtg gcgagtaagg tgtaaattgt catggatgta aatgggcccc	28680
	tatatgaggg tctggggtaa caagaaggcc tgtgaatata aagcactgaa ggtatgtcta	28740
	gtctggagaa ggtcactaca gagagtctc caactcagt cccatacaca cacacacaca	28800
	cacacacaca cacacacaca cacacacaca ccacaaagaa aaaaaggaag aaaaatctga	28860
	gagcaagtac agtacttaaa attgtgtgat tgtgtgtgtg actctgatgt cacatgctca	28920
15	tcttgcccta tgagttgaaa accaaatggc ccctgagagg cataacaacc acactgttgg	28980
	ctgtgtgctc acgtttttct taaagcgtct gtctggtttg ctgctagcat caggcagact	29040
	tgcagcagac tacatatgct cagccctgaa gtccttctag ggtgcatgtc tcttcagaat	29100
	ttcagaaagt catctgtggc tccaggaccg cctgcactct ccctctgccg cgaggctgca	29160
	gactctaggg tgggggtggaa gcaacgctta cctctgggac aagtataaca tgttggcttt	29220
20	tctttccctc tgtggctcca acctggacat aaaatagatg caagctgtgt aataaatatt	29280
	tcctcccgtc cacttagttc tcaacaataa ctactctgag agcacttatt aataggtggc	29340
	ttagacataa gctttggctc attccccac tagctcttac ttctttaact ctttcaaacc	29400
	attctgtgtc ttccacatgg ttagttacct ctcttccat cctgggtcgc ttcttccttc	29460
	gagtcgccct cagtgtctct aggtgatgct tgtaagatat tctttctaca aagctgagag	29520
25	tgggtggcact ctgggagttc aaagccagcc tgatctacac agcaagctcc aggatatcca	29580
	gggcaatgtt gggaaaacct ttctcaaaca aaaagagggg ttcagttgtc aggaggagac	29640
	ccatgggtta agaagtctag acgagccatg gtgatgcata cttttcatcc aagcacttag	29700
	gaggcaaaga aaggtgaaac tctttgactt tgaggccagc taggttacat agtgataccc	29760
	tgcttagtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtaatt taaaagtcta	29820
30	aaaatgcatt cttttaaaaa tatgtataag tatttgcttg cacatatgta tgtatgtatg	29880
	tataccatgt gtgtgtctgg tgctgaagga ctaggcatag actccctaga actagagtca	29940
	tagacagttg tgacactccc caacccccca ccatgtgggt gcttgaagct aaactcctgt	30000
	cctttgtaaa gcagcaggtg tctatgaacc ctgaaccatc tctccagtct ccagatgtgc	30060
	attctcaaag aggagtcctt catatttccc taaactgaac atccttatca gtgagcatcc	30120
35	tcgagtcacc aaagctactg caaacctct tagggaacat tcactattca cttctacttg	30180
	gctcatgaaa cttaagtaca cacacacaaa cacacacaca cacacagagt catgcactca	30240

WO 00/32773

PCT/US99/27990

30

	caaaagcatg catgtacacc attcttatta gactatgctt tgctaaaaga ctttcctaga	30300
	tacttttaaaa catcacttct gccttttggt gggcagggtc caagattggt actggcgtag	30360
	tggaaactga acaaggtaga gatctagaaa tcacagcagg tcagaagggc cagcctgtac	30420
	aagagagagt tccacacctt ccaggaacac tgagcagggg gctgggacct tgcctctcag	30480
5	cccaagaaac tagtgcggtt cctgtatgca tgcttctcag agattccata agatctgcct	30540
	tctgccataa gatctcctgc atccagacaa gcctagggga agttgagagg ctgcctgagt	30600
	ctctcccaca ggccccttct tgctggcag tattttttta tctggaggag aggaatcagg	30660
	gtgggaatga tcaaatacaa ttatcaagga aaaagtaaaa aacatatata tatatatatt	30720
	aactgatcta gggagctggc tcagcagtta agagttctgg ctgcccttgc ttcagatctt	30780
10	gctttgatct ccagcaccca catgatggct ttcaactgta tctctgcttc caggggatcc	30840
	aacagcctct tctgacctcc atagacaaga cctagtcctc tgcaagagca ccaaagtctc	30900
	ttatctgttg atccatctct ctagcctcat gccagatcat ttaaaactac tggacactgt	30960
	cccattttac gaagatgtca ctgcccagtc atttgccatg agtggatatt tcgattcttt	31020
	ctatgttctc acccttgcaa ttataagaa agatatctgc atttgtctcc tgagagaaca	31080
15	aagggtggag ggctactgag atggctctag gggtaaaggt gcttgccaca aaatctgaca	31140
	acttaagttt ggtcttgga tccacatggg ggagagagag aagagattcc cgtaagttgt	31200
	cctcaaactt cccacacatg tgctgtggct tatgtgtaac cccaataagt aaagatagtt	31260
	ttaaactact cataaggtag ggtttcttca tgaccccaag gaatgatgcc cctgatagag	31320
	cttatgctga aaccccatct ccattgtgcc atctggaaag agacaattgc atcccggaaa	31380
20	cagaatcttc atgaatggat taatgagcta ttaagaaagt ggcttggtta ttgcacatgc	31440
	tggcggcgta atgacctcca ccatgatgtt atccagcatg aaggctcctca ccagaagtca	31500
	tacaaatctt cttaggcttc cagagtcgtg agcaaaaaaa gcacacctct aaataaatta	31560
	actagcctca ggtagttaac caccgaaaat gaaccaaggc agttctaata caaaaccact	31620
	tcccttcctt gttcaaacca cagtgcctta ttatctaaaa gataaacttc aagccaagct	31680
25	tttaggttgc cagtatttat gtaacaacaa ggcccgttga cacacatctg taactcctag	31740
	tactgggcct caggggcaga gacaggtgga gccctggagt ttgaattcca ggttctgtga	31800
	gaaactctgt ctgaaaagac aatatggtga gtgacccggg aggatatctg atattgactt	31860
	ctggccaaca cacagccatc tctgcacatc tgtagttgca agccttttgc actaagtttg	31920
	gccagagtca gagtttgcaa gtgtttgtgg actgaatgca cgtgttgctg gtgatctaca	31980
30	aagtcaccct ccttctcaag ctagcagcac tggttcggc cagctgctca ttcaagcctc	32040
	tttgagagt catcacgggg atgggggagc agggccctc cctagaacac caagcctgtg	32100
	gttgtttatt caggacatta ttgagggcca agatgacaga taactctatc acttggccaa	32160
	cagtcgggtg ttgcggtgtt aggttatctc tgtgtctgca gaaaacagtg caacctggac	32220
	aaaagaaata aatgatata tttttcattc aggcaactag attccgtggt acaaaaggct	32280
35	ccctggggaa cgaggccggg acagcgcggc tcctgagtcg ctatttccgt ctgtcaactt	32340
	ctctaacttc ttgatttctt cctctgtctt gtttccttcc tcttgctggg gccagtgga	32400

WO 00/32773

PCT/US99/27990

31

	gtctgtgtac tcacagggag gaggggtggca aagccctggg cctctacggg ctggggggaag	32460
	gggggaagct gtcggcccag tgactttttc ccctttctct ttttcttaga aaccagtctc	32520
	aatttaagat aatgagtctc ctcatcacg tgtgctcact attcataggg acttatccac	32580
	ccccgccctg tcaatctggc taagtaagac aagtcaaatt taaaaggga cgtttttcta	32640
5	aaaatgtggc tggaccgtgt gccggcacga aaccagggat ggcgggtctaa gttacatgct	32700
	ctctgccagc cccgggtgcct tttcctttcg gaaaggagac ccggaggtaa aacgaagttg	32760
	ccaacttttg atgatgggtgt gcgccgggtg actcttttaa atgtcatcca tacctgggat	32820
	aggggaaggct cttcagggag tcatctagcc ctcccttcag gaaaagattc cacttccggt	32880
	ttagttagct tccacctggg cccttatccg ctgtctctgc ccactagtcc tcatccatcc	32940
10	ggtttccgcc ctcatccacc ttgccctttt agttcctaga aagcagcacc gtagtcttgg	33000
	caggtgggcc attggtcact ccgctaccac tgttaccatg gccaccaagg tgtcatttaa	33060
	atatgagctc actgagtcct gcgggatggc ttgggttggt atagtcttgc tgcaaaatcg	33120
	tgagaactgg agttcaattc ccagcacatg gatgtatttc cagcacctgg aaggcaggga	33180
	gcagagatct taaagctcct ggccagacag cccagcctaa ttagtaatca gtgagagacc	33240
15	ctgtctcaag aaacaagatg gaacatcaaa ggtcaacctc ttgtctccac acacacaaat	33300
	acacacatgc acatacatcc acacacaggc aaacacatgc acacacctga acaccctcca	33360
	caaatacata cataaaaaaa taaatacata cacacataca tacatacacc aacattccct	33420
	ctccttagtc tccctggctac gctcttgta cccccactaa ggcttcaact tcttctatct	33480
	cttcatcttg actcctctgt actttgcatg ccttttccag caaaggcttt tctttaaatc	33540
20	tccgtcattc ataaactccc tctaaatttc tccccctgcc cttttctttc tctctaggga	33600
	gataaagaca cactactaaa agtcaccgtg ggaccagttt attcaccac ccaccctgc	33660
	ttctgttcat ccggccagct aagtagtcca acctctctgg tgetgtacct tggaccctgg	33720
	cttcaccaca gtcctccat gctaccacgc cctgcaaacc ttcagcctag cctctgggtc	33780
	tccaaccagc acaggcccag tctggcttct atgtcctaga aatctccttc attctctcca	33840
25	tttccctcct gaatctacca ctttctttct cccttctcct gacctcta atgtcttggtca	33900
	aacgattaca aggaagccaa tgaaattagc agtttggggg acctcagagt cagcagggga	33960
	gctgggatga attcacattt ccaggccttt gctttgctcc ccggattctg acaggcagtt	34020
	ccgaagctga gtccaggaag ctgaatttaa aatcacactc cagctgggtt ctgaggcagc	34080
	cctaccacat cagctggccc tgactgagct gtgtctgggt ggcagtggtg ctggtgggtg	34140
30	tggtgggtgct ggtgggtggg gtgggtgggt tggtgggtgg ggtgggtggg tgtgtgtgtg	34200
	ttttctgctt ttacaaaact tttctaattc ttatacaaag gacaaatctg cctcatatag	34260
	gcagaaagat gacttatgcc tatataagat ataaagatga ctttatgcca cttattagca	34320
	atagttactg tcaaaagtaa ttctatttat acacccttat acatgggtatt gcttttggtg	34380
	gagactctaa aatccagatt atgtatttaa aaaaaattc cccagtcctt aaaagggtgaa	34440
35	gaatggaccc agatagaagg tcacggcaca agtatggagt cggagtgtgg agtcctgcca	34500
	atgggtctgga cagaagcatc cagagagggt ccaagacaaa tgccctgcct cctaaggaa	34560

WO 00/32773

PCT/US99/27990

32

actggcagcc ctgatgaggt accagagatt gctaagtgga ggaatacagg atcagaccca 34620
 tggaggggct taaagcgtga ctgtagcagc cctccgctga ggggctccag gtgggagccc 34680
 aaggtgctgc agtgggagcc acatgagagg tgatgtcttg gagtcacctc gggtagcatt 34740
 gtttagggag gtggggattt gtggtgtgga gacaggcagc ctcaaggatg cttttcaaca 34800
 5 atggttgatg agttggaact aaaacagggg ccatcacact ggctcccata gctctgggct 34860
 tgccagcttc cacatctgcc cccaccccc tgtctggcac cagctcaagc tctgtgattc 34920
 tacacatcca aaagaggaag agtagcctac tgggcatgcc acctcttctg gaccatcagg 34980
 tgagagtgtg gcaagcccta ggctcctgtc caggatgcag ggctgccaga taggatgtc 35040
 agctatctcc tgagctggaa ctattttagg aataaggatt atgcccggcc ggggttggcc 35100
 10 agcaccacag cagcctgtgc ttgcgtaaaa gcaagtgtg ttgatttatt taaaaacaga 35160
 gcggtggacc caccacacag acaagtatgt atgcatctgt ttcattgtatc tgaaaagcga 35220
 cacaaccatt tttcacatca tggcatcttc ctaaccccc ttcttttttg ttttgttttt 35280
 ttgagacagg gtttctctgt gtagtcctgg ctgtcctgga actcactttg tagaccaggc 35340
 tggcctcgaa ctcaaaaatc ctgggattaa aggtgtgtgc caccacggcc ggccctaacc 35400
 15 cccattctta atggtgatcc agtgggtgaa atttcggggc acacacatgt ccattagggg 35460
 ttagctgctg tcttctgagc tacctggtag aatctttatc ccctggggcc tgggctcctg 35520
 atccctgact cgggcccgat caagtccagt tcctggggcc gatcaagtcc agttcctggg 35580
 cccgaacaag tccagtcctt agctcgatta gctcactctg gctccctggc ctgttcttac 35640
 ttacactctt ccccttgctc tggacttggt gctttcttta ctcaagttgt ctgccacagt 35700
 20 ccctaagcca cctctgtaag acaactaaga taatacttcc ctcaagcacg gaaagtcctg 35760
 agtcaccaca ccctctggag gtgtgtggac acatgttcat gcgtgtgggt gcgcttacgt 35820
 acgtgtgc 35828

<210> 18

25

<211> 9301

<212> DNA

<213> Homo sapien

<400> 18

30 tagaggagaa gtctttgggg agggtttgct ctgagcacac ccctttccct ccctccgggg 60
 ctgagggaaa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120
 agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180
 ggtggcgtgc cctcctctgg ctggtaccat gcagctccca ctggccctgt gtctcgtctg 240
 cctgctggta cacacagcct tccgtgtagt ggagggccag ggggtggcagg cgttcaagaa 300
 35 tgatgccacg gaaatcatcc ccgagctcgg agagtacccc gagcctccac cggagctgga 360
 gaacaacaag accatgaacc gggcggagaa cggagggcgg cctccccacc acccctttga 420

WO 00/32773

PCT/US99/27990

33

	gaccaaaggt atgggggtgga ggagagaatt cttagtaaaa gatcctgggg aggtttttaga	480
	aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg	540
	ccagcactgg tcgaggaaca gtcttgccctg gaggtggggg aagaatggct cgctgggtgca	600
	gccttcaa at tcaggtgcag aggcattgagg caacagacgc tggtagagagc ccagggcagg	660
5	gaggacgctg ggggtggtag ggtatggcat cagggcatca gaacaggctc aggggctcag	720
	aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgctc cagctgctgg	780
	taccactggg aagggaaaca ggtaagggag cctcccatcc acagaacagc acctgtgggg	840
	caccggacac tctatgctgg tgggtggctgt cccaccaca cagaccaca tcatggaatc	900
	cccaggaggt gaacccccag ctccaagggg aagaaacagg ttccaggcac tcagtaactt	960
10	ggtagtgaga agagctgagg tgtgaacctg gtttgatcca actgcaagat agccctgggtg	1020
	tgtggggggg tgtgggggac agatctccac aaagcagtgg ggaggaaggc cagagaggca	1080
	ccctgcagt gtgcattgcc catggcctgc ccaggagct ggcacttgaa ggaatgggag	1140
	ttttcggcac agtttttagcc cctgacatgg gtgcagctga gtccaggccc tggaggggag	1200
	agcagcatcc tctgtgcagg agtagggaca tctgtcctca gcagccacc cagtcccaac	1260
15	cttgccctcat tccaggggag ggagaaggaa gaggaaccct gggttcctgg tcaggcctgc	1320
	acagagaagc ccaggtgaca gtgtgcatct ggctctataa ttggcaggaa tcctgaggcc	1380
	atgggggctg ctgaaatgac acttcagact aagagcttcc ctgtcctctg gccattatcc	1440
	aggtggcaga gaagtccact gccaggctc ctggaccca gccctccccg cctcacaacc	1500
	tgttgggact atgggggtgct aaaaagggca actgcatggg aggccagcca ggaccctccg	1560
20	tcttcaaaat ggaggacaag ggcgcctccc cccacagctc cccttctagg caaggctcagc	1620
	tgggctccag cgactgcctg aagggtgta aggaacccaa acacaaaatg tccaccttgc	1680
	tggactccca cgagaggcca cagcccctga ggaagccaca tgctcaaaac aaagtcatga	1740
	tctgcagagg aagtgcctgg cctaggggag ctattctcga aaagccgcaa aatgccccct	1800
	tccctgggca aatgcccccc tgaccacaca cacattccag ccctgcagag gtgaggatgc	1860
25	aaaccagccc acagaccaga aagcagcccc agacgatggc agtggccaca tctcccctgc	1920
	tgtgcttgct cttcagagtg ggggtggggg gtggccttct ctgtcccctc tctggtttgg	1980
	tcttaagact atttttcatt ctttcttgct acattggaac tatccccatg aaacctttgg	2040
	gggtggactg gtactcacac gacgaccagc tatttaaaaa gctcccacc atctaagtc	2100
	accataggag acatgggtcaa ggtgtgtgca ggggatcagg ccaggcctcg gagcccaatc	2160
30	tctgcctgcc cagggagtat caccatgagg cgcctattca gataacacag aacaagaaat	2220
	gtgcccagca gagagccagg tcaatgtttg tggcagctga acctgtaggt tttgggtcag	2280
	agctcagggc ccctatggta ggaaagtaac gacagtaaaa agcagccctc agctccatcc	2340
	cccagcccag cctcccatgg atgctcgaac gcagagcctc cactcttgcc ggagccaaaa	2400
	ggtgctggga ccccagggaa gtggagtccg gagatgcagc ccagcctttt gggcaagttc	2460
35	ttttctctgg ctgggcctca gtattctcat tgataatgag ggggttggac aactgcctt	2520
	tgattccttt caagtetaat gaattcctgt cctgatcacc tccccttcag tccctcgcct	2580

WO 00/32773

PCT/US99/27990

34

	ccacagcagc	tgccctgatt	tattaccttc	aattaacctc	tactcctttc	tccatcccct	2640
	gtccaccccct	cccaagtggc	tggaaaagga	at ttgggaga	agccagagcc	aggcagaagg	2700
	tgtgctgagt	acttaccctg	cccaggccag	ggaccctgcg	gcacaagtgt	ggcttaaatac	2760
	ataagaagac	cccagaagag	aatgataat	aataatacat	aacagccgac	gctttcagct	2820
5	atatgtgcca	aatgggtat	tctgcattgc	gtgtgtaatg	gattaactcg	caatgcttgg	2880
	ggcggcccat	tttgcagaca	ggaagaagag	agagggttaag	gaacttgccc	aagatgacac	2940
	ctgcagtgag	cgatggagcc	ctggtgtttg	aaccccagca	gtcatttggc	tccgagggga	3000
	caggggtgcg	aggagagctt	tccaccagct	ctagagcatc	tgggaccttc	ctgcaataga	3060
	tgttcagggg	caaaagcctc	tggagacagg	cttggcaaaa	gcagggctgg	ggtggagaga	3120
10	gacggggccg	tccagggcag	gggtggccag	gcggggccgc	accctcacgc	gcgcctctct	3180
	ccacagacgt	gtccgagtac	agctgccgcg	agctgcactt	cacccgctac	gtgaccgatg	3240
	ggccgtgccg	cagcgccaag	ccggtcacccg	agctgggtgtg	ctccggccag	tgcggcccgg	3300
	cgcgcctgct	gcccacgccc	atcgggccg	gcaagtgggtg	gcgacctagt	gggcccgact	3360
	tccgctgcat	ccccgaccgc	taccgcgcgc	agcgcgtgca	gctgctgtgt	cccgggtggtg	3420
15	aggcgccg	cgcgcgcaag	gtgcgcctgg	tggcctcggtg	caagtgcaag	cgcctcaccc	3480
	gcttccacaa	ccagtcggag	ctcaaggact	tccgggaccga	ggccgctcgg	ccgcagaagg	3540
	gccggaagcc	gcggccccgc	gcccggagcg	ccaaagccaa	ccaggccgag	ctggagaacg	3600
	cctactagag	cccggcccgc	cccctcccca	ccggcgggcg	ccccggccct	gaacccgcgc	3660
	cccacatttc	tgtcctctgc	gcgtgggtttg	attgtttata	tttcattgta	aatgcctgca	3720
20	accaggggca	gggggctgag	accttccagg	ccctgaggaa	tcccggggcg	cggcaaggcc	3780
	cccctcagcc	cgccagctga	gggggtccac	ggggcagggg	agggaattga	gagtcacaga	3840
	cactgagcca	cgcagccccg	cctctggggc	cgcctacctt	tgctgggtccc	acttcagagg	3900
	aggcagaaat	ggaagcattt	tcaccgccc	ggggttttta	gggagcggtg	tgggagtggg	3960
	aaagtccagg	gactgggtta	gaaagttgga	taagattccc	ccttgcacct	cgtgcccac	4020
25	cagaaagcct	gaggcgtgcc	cagagcacia	gactgggggc	aactgtagat	gtgggtttcta	4080
	gtcctgggtc	tgccactaac	ttgctgtgta	accttgaact	acacaattct	ccttcggggac	4140
	ctcaattttc	actttgtaaa	atgaggggtg	agggtgggaat	aggatctcga	ggagactatt	4200
	ggcatatgat	tccaaggact	ccagtgcctt	ttgaatgggc	agaggtgaga	gagagagaga	4260
	gaaagagaga	gaatgaatgc	agttgcattg	attcagtgcc	aaggtcactt	ccagaattca	4320
30	gagttgtgat	gctctcttct	gacagccaaa	gatgaaaaac	aaacagaaaa	aaaaaagtaa	4380
	agagtctatt	tatggctgac	atattttacg	ctgacaaact	cctggaagaa	gctatgctgc	4440
	ttcccagcct	ggcttccccg	gatgttttgg	tacctccacc	cctccatctc	aaagaaataa	4500
	catcatccat	tggggtagaa	aaggagaggg	tccgaggggtg	gtgggagggga	tagaaatcac	4560
	atccgcccc	acttcccaaa	gagcagcatc	cctcccccca	cccatagcca	tgttttaaa	4620
35	tcaccttccg	aagagaagtg	aaagggttcaa	ggacactggc	cttgcaggcc	cgagggagca	4680
	gccatcacia	actcacagac	cagcacatcc	cttttgagac	accgccttct	gcccaccact	4740

WO 00/32773

PCT/US99/27990

35

	cacggacaca	tttctgccta	gaaaacagct	tcttactgct	cttacatgtg	atggcatatc	4800
	ttacactaaa	agaatattat	tgggggaaaa	actacaagtg	ctgtacatat	gctgagaaac	4860
	tgcagagcat	aatagctgcc	acccaaaaat	ctttttgaaa	atcattttcca	gacaacctct	4920
	tactttctgt	gtagttttta	attgttaaaa	aaaaaaagtt	ttaaacagaa	gcacatgaca	4980
5	tatgaaagcc	tgcaggactg	gtcgtttttt	tggcaattct	tccacgtggg	acttgtccac	5040
	aagaatgaaa	gtagtggttt	ttaaagagtt	aagttacata	tttattttct	cacttaagtt	5100
	atztatgcaa	aagttttttct	tgtagagaat	gacaatgtta	atattgcttt	atgaattaac	5160
	agtctgttct	tccagagtcc	agagacattg	ttaataaaga	caatgaatca	tgaccgaaag	5220
	gatgtggctct	cattttgtca	accacacatg	acgtcatttc	tgtcaaagtt	gacacccttc	5280
10	tcttggtcac	tagagctcca	accttggaca	cacctttgac	tgctctctgg	tggcccttgt	5340
	ggcaattatg	tcttcctttg	aaaagtcattg	tttatccctt	cctttccaaa	cccagaccgc	5400
	atctcttcac	ccagggcatg	gtaataacct	cagccttgta	tccttttagc	agcctcccct	5460
	ccatgctggc	ttccaaaatg	ctgttctcat	tgtatcactc	ccctgctcaa	aagccttcca	5520
	tagctcccc	ttgcccagga	tcaagtgcag	tttccctatc	tgacatggga	ggccttctct	5580
15	gcttgactcc	cacctcccac	tccaccaagc	ttcctactga	ctccaaatgg	tcatgcagat	5640
	ccctgcttcc	ttagtgtgcc	atccacactt	agcaccocca	ataactaatc	ctctttcttt	5700
	aggattcaca	ttacttgtca	tctcttcccc	taaccttcca	gagatgttcc	aatctcccat	5760
	gatecctctc	tcctctgagg	ttccagcccc	ttttgtctac	accactactt	tggttcctaa	5820
	ttctgttttc	catttgacag	tcattcatgg	aggaccagcc	tggccaagtc	ctgcttagta	5880
20	ctggcataga	caacacaaag	ccaagtacaa	ttcaggacca	gctcacagga	aacttcatct	5940
	tcttcgaagt	gtggatttga	tgcctcctgg	gtagaaatgt	aggatcttca	aaagtgggcc	6000
	agcctcctgc	acttctctca	aagtctcgcc	tccccaaggt	gtcttaatag	tgctggatgc	6060
	tagctgagtt	agcatcttca	gatgaagagt	aaccctaaag	ttactcttca	gttgccctaa	6120
	ggtgggatgg	tcaactggaa	agcttttaat	taagtccagc	ctaccttggg	ggaaccacc	6180
25	cccacaaaga	aagctgaggt	ccctcctgat	gacttgtcag	tttaactacc	aataaccac	6240
	ttgaattaat	catcatcatc	aagtctttga	taggtgtgag	tgggtatcag	tggccggtcc	6300
	cttcctgggg	ctccagcccc	cgaggaggcc	tcagtgagcc	cctgcagaaa	atccatgcat	6360
	catgagtgtc	tcagggccca	gaatatgaga	gcaggtagga	aacagagaca	tcttccatcc	6420
	ctgagaggca	gtgcgggtcca	gtgggtgggg	acacgggctc	tgggtcaggt	ttgtgttggt	6480
30	tgtttgtttg	ttttgagaca	gagtctcgct	ctattgcccc	ggctggagtg	cagtgtcaca	6540
	atctcggtct	actgcaactt	ctgccttccc	ggattcaagt	gattctcctg	cctcagcctc	6600
	cagagtagct	gggattacag	gtgcgtgcca	ccacgcctgg	ctaatttttg	tatttttgat	6660
	agagacgggg	tttcaccatg	ttggccaggc	tagtctcgaa	ctcttgacct	caagtgatct	6720
	gcctgcctcg	gcctcccaaa	gtgctgggat	tacaggcgtg	agccaccaca	cccagcccca	6780
35	ggttggtggt	tgaatctgag	gagactgaag	caccaagggg	ttaaatgttt	tgcccacagc	6840
	catacttggg	ctcagttcct	tgccctaccc	ctcacttgag	ctgcttagaa	cctggtgggc	6900

WO 00/32773

PCT/US99/27990

36

	acatgggcaa taaccagggtc acactgtttt gtaccaagtg ttatgggaat ccaagatagg	6960
	agtaatttgc tctgtggagg ggatgaggga tagtggttag ggaaagcttc acaaagtggg	7020
	tgttgcttag agattttcca ggtggagaag ggggcttcta ggcagaaggc atagcccaag	7080
	caaagactgc aagtgcattg ctgctcatgg gtagaagaga atccaccatt cctcaacatg	7140
5	taccgagtcc ttgccatgtg caaggcaaca tgggggtacc aggaattcca agcaatgtcc	7200
	aaacctaggg tctgctttct gggacctgaa gatacaggat ggatcagccc aggctgcaat	7260
	cccattacca cgagggggaa aaaaacctga aggctaaatt gtaggtcggg ttagaggtta	7320
	tttatggaaa gttatattct acctacatgg ggtctataag cctggcgcca atcagaaaag	7380
	gaacaaacaa cagacctagc tgggaggggc agcattttgt tgtagggggc ggggcacatg	7440
10	ttctgggggt acagccagac tcagggttg tattaatagt ctgagagtaa gacagacaga	7500
	gggatagaag gaaatagggt cctttctctc tctctctctc tctctctctc actctctctc	7560
	tctctcacac acacacacag acacacacac acgctctgta ggggtctact tatgctccaa	7620
	gtacaaatca ggccacattt acacaaggag gtaaaggaaa agaacgttgg aggagccaca	7680
	ggaccccaaa attccctgtt ttccttgaat caggcaggac ttacgcagct gggaggggtg	7740
15	agagcctgca gaagccacct gcgagtaagc caagttcaga gtcacagaca ccaaaagctg	7800
	gtgccatgtc ccacaccgc ccacctcca cctgctcctt gacacagccc tgtgctccac	7860
	aaccgggtc ccagatcatt gattatagct ctggggcctg caccgtcctt cctgccacat	7920
	ccccaccca ttcttgaac ctgccctctg tcttctcctt tgtccaaggg caggcaaggg	7980
	ctcagctatt gggcagcttt gaccaacagc tgaggctcct tttgtggctg gagatgcagg	8040
20	aggcagggga atattcctct tagtcaatgc gaccatgtgc ctggtttgcc cagggtggtc	8100
	tcgtttacac ctgtaggcca agcgttaatta ttaacagctc ccacttctac tctaaaaaat	8160
	gacccaatct gggcagtaaa ttatatggtg cccatgctat taagagctgc aacttgctgg	8220
	gcgtggtggc tcacacctgt aatcccagta ctttgggacg tcaaggcggg tggatcacct	8280
	gaggtcacga gttagagact ggcctggcca gcatggcaaa accccatctt tactaaaaat	8340
25	acaaaaatta gcaaggcatg gtggcatgca cctgtaatcc cagggtactg ggaggctgag	8400
	acaggagaat ggcttgaacc caggaggcag aggttgcagt gagccaagat tgtgccactg	8460
	ccctccagcc ctggcaacag agcaagactt catctcaaaa gaaaaaggat actgtcaatc	8520
	actgcaggaa gaaccaggt aatgaatgag gagaagagag gggctgagtc accatagtgg	8580
	cagcaccgac tcctgcagga aaggcgagac actgggtcat ggggtactgaa ggggtgccctg	8640
30	aatgacgttc tgcttttagag accgaacctg agccctgaaa gtgcatgcct gttcatgggt	8700
	gagagactaa attcatcatt ccttggcagg tactgaatcc tttcttacgg ctgccctcca	8760
	atgcccaatt tccctacaat tgtctgggggt gcctaagctt ctgcccacca agagggccag	8820
	agctggcagc gagcagctgc aggtaggaga gatagggtacc cataaggag gtgggaaaga	8880
	gagatggaag gagaggggtg cagagcacac acctcccctg cctgacaact tcctgagggc	8940
35	tggtcatgcc agcagattta aggcggaggc aggggagatg gggcgggaga ggaagtgaaa	9000
	aaggagaggg tggggatgga gaggaagaga ggggtgatcat tcattcattc cattgctact	9060

WO 00/32773

PCT/US99/27990

37

gactggatgc cagctgtgag ccaggcacca ccctagctct gggcatgtgg ttgtaatctt 9120
 ggagcctcat ggagctcaca gggagtgtg gcaaggagat ggataatgga cggataacaa 9180
 ataaacattt agtacaatgt ccgggaatgg aaagttctcg aaagaaaaat aaagctggtg 9240
 agcatataga cagccctgaa ggcggccagg ccaggcattt ctgaggagggt ggcatttgag 9300
 5 c 9301

<210> 19

<211> 21

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Primer for PCR

15 <400> 19

ccggagctgg agaacaacaa g

21

<210> 20

<211> 19

20 <212> DNA

<213> Artificial Sequence

<220>

<223> PRimer for PCR

25

<400> 20

gcactggccg gagcacacc

19

<210> 21

30 <211> 23

<212> DNA

<213> Artificial Sequence

<220>

35 <223> Primer for PCR

WO 00/32773

PCT/US99/27990

38

<400> 21

aggccaaccg cgagaagatg acc

23

<210> 22

5

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

10

<223> Primer for PCR

<400> 22

gaagtccagg gcgacgtagc a

21

15

<210> 23

<211> 25

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Primer for PCR

<400> 23

aagcttggtgta ccatgcagct cccac

25

25

<210> 24

<211> 50

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Primer for PCR

<400> 24

35

aagcttctac ttgtcatcgt cgtccttgta gtcgtaggcg ttctccagct

50

WO 00/32773

PCT/US99/27990

39

<210> 25

<211> 19

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Primer for PCR

<400> 25

10 gcactggccg gagcacacc

19

<210> 26

<211> 39

<212> DNA

15

<213> Artificial Sequence

<220>

<223> Primer for PCR

20

<400> 26

gtcgtcggat ccatgggggtg gcaggcgttc aagaatgat

39

<210> 27

<211> 57

25

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

30

<400> 27

gtcgtcaagc ttctacttgt catcgtcctt gtagtcgtag gcgttctcca gctcggc

57

<210> 28

35

<211> 29

<212> DNA

WO 00/32773

PCT/US99/27990

40

<213> Artificial Sequence

<220>

<223> Primer for PCR

5

<400> 28

gacttggatc ccaggggtgg caggcggtc

29

<210> 29

10

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Primer for PCR

<400> 29

agcataagct tctagtaggc gttctccag

29

20

<210> 30

<211> 29

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Primer for PCR

<400> 30

gacttggatc cgaagggaaa aagaaaggg

29

30

<210> 31

<211> 29

<212> DNA

<213> Artificial Sequence

35

<220>

WO 00/32773

PCT/US99/27990

41

<223> Primer for PCR

<400> 31

agcataagct tttaatccaa atcgatgga

29

5

<210> 32

<211> 33

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Primer for PCR

<400> 32

15 actacgagct cggccccacc acccatcaac aag

33

<210> 33

<211> 34

<212> DNA

20

<213> Artificial Sequence

<220>

<223> Primer for PCR

25

<400> 33

acttagaagc tttagtcct cagccccctc ttcc

34

<210> 34

<211> 66

30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

35

<400> 34

WO 00/32773

PCT/US99/27990

42

aatctggatc cataacttcg tatagcatac attatacgaa gttatctgca ggattcgagg 60
 gcccct 66

5

<210> 35

<211> 82

<212> DNA

<213> Artificial Sequence

<220>

10

<223> Primer for PCR

<400> 35

aatctgaatt ccaccggtgt taattaaata acttcgtata atgtatgcta tacgaagtta 60
 tagatctaga gtcagcttct ga 82

15

<210> 36

<211> 62

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Primer for PCR

<400> 36

atttaggtga cactatagaa ctcgagcagc tgaagcttaa ccacatggtg gctcacaacc 60
 at 62

30

<210> 37

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

35

<400> 37

WO 00/32773

PCT/US99/27990

43

aacgacggcc agtgaatccg taatcatggt catgctgcca ggtggaggag ggca

54

<210> 38

<211> 31 <212> DNA

5

<213> Artificial Sequence

<220>

<223> Primer for PCR

10

<400> 38

attaccaccg gtgacacccg cttcctgaca g

31

<210> 39

<211> 61

15

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

20

<400> 39

attacttaat taaacatggc gcgccatatg gccggcccct aattgcggcg catcgттаат
t

60

61

25

<210> 40

<211> 34

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Primer for PCR

<400> 40

attacggccg gccgcaaagg aattcaagat ctga

34

35

<210> 41

WO 00/32773

PCT/US99/27990

44

<211> 34

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Primer for PCR

<400> 41

attacggcgc gccctcaca ggccgcaccc agct

34

CLAIMS:

1. An isolated nucleic acid molecule selected from the group consisting of:
 - (a) an isolated nucleic acid molecule comprising any one of SEQ ID Nos., 1, 5, 9, 11, 13, or 15 or the complement thereof;
 - (b) an isolated nucleic acid molecule that specifically hybridizes to any one of SEQ ID Nos., 1, 5, 9, 11, 13, or 15 or the complement thereof under conditions of high stringency comprising 5XSSPE, 5XDenhardt's solution and 0.5% SDS at 55-60°C, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content;
 - (c) an isolated nucleic acid molecule comprising a sequence at least 85% identical to any one of SEQ ID NOs: 1, 5, 9, 11, 13, or, 15, or the complement thereof, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content;
 - (d) an isolated nucleic acid molecule comprising a sequence at least 85% identical to nucleotides 48-689 of SEQ ID NO: 1 or the complement thereof, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content;
 - (e) an isolated nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 2, 6, 10, 12, 14 and 16, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content;
 - (f) an isolated nucleic acid molecule comprising nucleotides 119-686 of SEQ ID NO: 1 or the complement thereof;
 - (g) an isolated nucleic acid molecule comprising a sequence at least 85% identical to nucleotides 119-686 of SEQ ID NO: 1 or the complement thereof and encodes a protein that retains the ability of BEER protein to decrease bone mineral content;

(h) an isolated nucleic acid molecule comprising a sequence that encodes amino acids 25-213 of SEQ ID NO: 2; and

(i) an isolated nucleic acid molecule comprising a sequence that encodes a polypeptide at least 85% identical to amino acids 25-213 of SEQ ID NO: 2 that retains the ability of BEER protein to decrease bone mineral content.

2. The isolated nucleic acid molecule according to claim 1 that encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO: 2 that retains the ability of BEER protein to decrease bone mineral content.

3. The isolated nucleic acid molecule according to claim 1, that encodes a polypeptide comprising amino acids 25-213 of SEQ ID NO: 2.

4. The isolated nucleic acid molecule according to claim 1, comprising any one of SEQ ID NOs., 1, 5, 9, 11, 13, or 15 or the complement thereof.

5. The isolated nucleic acid molecule according to claim 1, comprising an isolated nucleic acid molecule that specifically hybridizes to any one of SEQ ID Nos., 1, 5, 9, 11, 13, or 15 or the complement thereof under conditions of high stringency comprising 5XSSPE, 5XDenhardt's solution and 0.5% SDS at 55-60°C, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content.

6. The isolated nucleic acid molecule according to claim 1, comprising an isolated nucleic acid molecule comprising a sequence at least 85% identical to any one of SEQ ID Nos, 1, 5, 9, 11, 13, or, 15, or the complement thereof, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content.

7. The isolated nucleic acid molecule according to claim 1, comprising an isolated nucleic acid molecule comprising a sequence at least 85% identical to nucleotides 48-689 of SEQ ID NO: 1 or the complement thereof, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content.

8. The isolated nucleic acid molecule according to claim 1, comprising an isolated nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 2, 6, 10, 12, 14 and 16, wherein the isolated nucleic acid molecule encodes a polypeptide that retains the ability of BEER protein to decrease bone mineral content.

9. The isolated nucleic acid molecule according to claim 1, comprising an isolated nucleic acid molecule comprising nucleotides 119-686 of SEQ ID NO: 1 or the complement thereof.

10. The isolated nucleic acid molecule according to claim 1, comprising an isolated nucleic acid molecule comprising a sequence at least 85% identical to nucleotides 119-686 of SEQ ID NO: 1 or the complement thereof and encodes a protein that retains the ability of BEER protein to decrease bone mineral content.

11. The isolated nucleic acid molecule according to claim 1, comprising an isolated nucleic acid molecule comprising a sequence that encodes a polypeptide at least 85% identical to amino acids 25-213 of SEQ ID NO: 2 that retains the ability of BEER protein to decrease bone mineral content.

12. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 2.

13. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 6.

14. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 10.

15. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 12.

16. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 14.

17. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid molecule encodes a protein comprising the amino acid sequence of SEQ ID NO: 16.

18. An expression vector, comprising a regulatory sequence that controls transcriptional expression operably linked to a nucleic acid molecule according to any one of claims 1-7.

19. The expression vector according to claim 18 wherein said promoter is selected from the group consisting of cytomegalovirus (CMV) major immediate early (I-E) promoter, simian virus 40 (SV40) early promoter and murine leukemia virus (MuLV) long terminal repeat (LTR).

20. The expression vector according to claim 18 wherein said promoter is a tissue-specific promoter.

21. A method of producing a protein that decreases bone mineral content comprising, culturing a cell which contains a vector according to any one of claims 8 to 20 under conditions and for a time sufficient to produce said protein and optionally purifying or isolating said protein.

22. A viral vector comprising the nucleic acid molecule according to any one of claims 1-17.

23. The viral vector according to claim 22 wherein said vector is selected from the group consisting of a herpes simplex viral vector, an adenoviral vector, an adenovirus-associated viral vector and a retroviral vector.

24. A host cell carrying a vector according to any one of claims 18-20, 22 and 23.

25. A host cell comprising a nucleic acid molecule operably linked to a heterologous regulatory sequence that controls transcriptional expression, wherein said nucleic acid molecule encodes a polypeptide comprising amino acids 25-213 of SEQ ID NO: 2.

26. The host cell according to claim 24 or 25, wherein said cell is selected from the group consisting of a human cell, dog cell, monkey cell, rat cell and mouse cell.

27. A method of making a polypeptide that decreases bone mineral content comprising (a) culturing the host cell according to claim 25 under conditions and for a time sufficient to produce said polypeptide, and optionally (b) isolating said polypeptide.

28. An isolated protein that retains the ability of BEER protein to decrease bone mineral content, comprising an amino acid sequence encoded by a nucleic acid molecule according to any one of claims 1-17.

29. An isolated protein comprising SEQ ID NO: 2.

30. An isolated protein comprising amino acids 25-213 of SEQ ID NO: 2.

31. An isolated protein that retains the ability of BEER protein to decrease bone mineral content, comprising an amino acid sequence at least 85% identical to SEQ ID NO: 2.

32. An isolated protein that retains the ability of BEER protein to decrease bone mineral content, comprising an amino acid sequence at least 85% identical to amino acids 25-213 of SEQ ID NO: 2.

33. An isolated protein that retains the ability of BEER protein to decrease bone mineral content, comprising an amino acid sequence encoded by a nucleic acid of claim 5.

34. An isolated protein that retains the ability of BEER protein to decrease bone mineral content, comprising an amino acid sequence encoded by a nucleic acid of claim 6.

35. An isolated protein that retains the ability of BEER protein to decrease bone mineral content, comprising an amino acid sequence encoded by a nucleic acid of claim 10.

36. An isolated polypeptide comprising a fragment of a protein of SEQ ID NO: 2 that is at least 50 amino acids in length.

37. An isolated polypeptide comprising a fragment of a protein of SEQ ID NO: 2 that is at least 100 amino acids in length.

38. The polypeptide or protein of any one of claims 29-37 which comprises a detectable label.

39. An antibody that binds to a protein encoded by the nucleic acid molecule according to any one of claims 1-38.

40. An antibody or fragment thereof which binds to a protein encoded by any one of SEQ ID NO: 1, 5, 7, 9, 11, 13 or 15, with a K_a of greater than or equal to $10^6 M^{-1}$.

41. An antibody which binds to the secreted protein of SEQ ID NO: 2 with a K_a of greater than or equal to $10^6 M^{-1}$.

42. An antibody or fragment thereof that binds to a protein encoded by SEQ ID NO: 1 with a K_a of greater than or equal to $10^6 M^{-1}$.

43. The antibody or fragment according to claim 40, wherein the encoded protein is selected from the group consisting of SEQ ID NOs: 2, 6, 8, 10, 12, 14 and 16.

44. The antibody or fragment according to claim 40, wherein the antibody or fragment binds the protein obtainable by expressing any one of SEQ ID NO: 1, 5, 7, 9, 11, 13 or 15 in insect cells, with a K_a of greater than or equal to $10^6 M^{-1}$.

45. The antibody or fragment according to claim 44, wherein the antibody or fragment binds the protein obtainable by expressing any one of SEQ ID NO: 1, 5, 7, 9, 11, 13 or 15 using a baculovirus system in *Sf9* cells, with a K_a of greater than or equal to $10^6 M^{-1}$.

46. The antibody or fragment according to claim 42, wherein the antibody or fragment binds the protein obtainable by expressing any one of SEQ ID NO: 1, 5, 7, 9, 11, 13 or 15 in human embryonic kidney cells, with a K_a of greater than or equal to $10^6 M^{-1}$.

47. The antibody or fragment of any one of claims 40-46, which binds to said protein with a K_a of greater than or equal to $10^7 M^{-1}$.

48. The antibody according to any one of claims 39-47, wherein said antibody is a monoclonal antibody.

49. The antibody according to claim 42 wherein said monoclonal antibody is selected from the group consisting of a murine antibody and a human antibody.

50. The antibody of claim 41 that is an IgG antibody.

51. The antibody of claim 49, wherein the IgG antibody is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.

52. The antibody according to any one of claims 39-47, wherein said antibody is an antibody fragment.

53. The antibody according to any one of claims 39-47 which is a polyclonal antibody.

54. The antibody according to any one of claims 39-47, wherein said antibody is an antibody fragment.

55. An isolated antibody that binds the protein obtainable by expressing SEQ ID NO: 1 in human embryonic kidney cells, with a K_a of greater than or equal to $10^6 M^{-1}$.

56. The antibody or fragment according to claim 55, wherein the antibody or fragment is conjugated to a polymer.

57. The antibody or fragment according to claim 56, wherein the antibody or fragment is conjugated to polyethylene glycol.

58. The antibody or fragment of any one of claims 39-57, wherein the antibody or fragment is isolated.

59. The antibody of any one of claims 39-57 which increases bone density or bone mineral content.

60. A polypeptide comprising the antibody of any one of claims 39-59 and a reporter or effector molecule.

61. The polypeptide of claim 60 wherein the effector or reporter molecule is selected from the group consisting of antineoplastic agents, toxins, biologically active proteins and fragments thereof, enzymes and fragments thereof, nucleic acids and fragments thereof, naturally occurring and synthetic polymers and derivatives thereof, radionuclides, chelated metals, fluorescent compounds and compounds which may be detected by NMR or ESR spectroscopy.

62. A polypeptide comprising the antibody of any one of claims 39-59, wherein the polypeptide binds a polypeptide of SEQ ID NO: 2 with a K_a of greater than or equal to $10^6 M^{-1}$.

63. Use of an antibody according to any one of claims 39-47 or a polypeptide according to claim 56 for the manufacture of a medicament for increasing bone mineral content in a warm-blooded animal.

64. The use according to claim 63, wherein the medicament is for treatment of osteopenia.

65. The use according to 64, wherein the osteopenia is caused by an anemic state, steroids, heparin, a bone marrow disorder, scurvy, malnutrition, calcium deficiency, idiopathic osteoporosis, congenital osteopenia or osteoporosis, alcoholism, chronic liver disease, senility, post menstrual state, oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, transient regional osteoporosis or osteomalacia.

66. The use according to claim 63, wherein the medicament is for treatment of osteoporosis.

67. The use according to claim 63, wherein the animal has achondroplasia, cleidocranial dysostosis, echondromatosis, fibrous dysplasia, Gaucher's hypophosphatemic rickets, Marfan's, multiple hereditary exostoses, neurofibromatosis, osteogenesis imperfecta,

osteopetrosis, osteopoikilosis sclerotic lesions, fractures, periodontal disease, pseudoarthrosis or pyogenic osteomyelitis.

68. The use according to claim 63, wherein the medicament is for treatment of bone fracture.

69. The use of claim 63 wherein the medicament is for treatment of dysplasias associated with abnormal growth or development of bone.

70. The use of the antibody according to any one of claims 39-59 or the polypeptide according to claim 58 for preparation of a medicament for co-administration with an inhibitor of bone resorption.

71. The use of claim 70 wherein the inhibitor of bone resorption is selected from the group consisting of calcitonin, estrogen, bisphosphonates, growth factors having anti-resorptive activity, and tamoxifen.

72. A pharmaceutical composition, comprising the antibody according to any one of claims 39-59 or the polypeptide according to claim 62 and a pharmaceutically acceptable carrier or diluent.

73. The pharmaceutical composition of claim 72 further comprising an inhibitor of bone resorption.

74. A nucleic acid molecule encoding the antibody or fragment according to any one of claims 39-42.

75. A hybridoma which produces the antibody according to any one of claims 39-59.

76. A fusion protein, comprising a polypeptide encoded by the nucleic acid molecule according to any one of claims 1 to 17 and a heterologous protein.

77. An isolated oligonucleotide which hybridizes to a nucleic acid molecule according to claim 4, under conditions of high stringency comprising 5XSSPE, 5XDenhardt's solution and 0.5% SDS at 55-60°C.

78. An isolated oligonucleotide which hybridizes to RNA that is fully complementary to at least 100 nucleotides of nucleic acid molecule according to claim 4, under conditions of high stringency comprising 5XSSPE, 5XDenhardt's solution and 0.5% SDS at 55-60°C.

79. An isolated oligonucleotide according to claim 77 or 78, wherein said oligonucleotide is at least 20 nucleotides in length.

80. An isolated oligonucleotide according to claim 77 or 78, wherein said oligonucleotide is at least 30 nucleotides in length.

81. An isolated oligonucleotide according to claim 77 or 78, wherein said oligonucleotide is at least 50 nucleotides in length.

82. An isolated oligonucleotide according to claim 77 or 78, wherein said oligonucleotide is at least 50 to 100 nucleotides in length.

83. A pair of primers which specifically amplifies all or a portion of a nucleic acid molecule according to any one of claims 1 to 17, wherein the primers are selected from the group consisting of

- (i) the primers of SEQ ID NOs: 19 and 20;
- (ii) the primers of SEQ ID NOs: 23 and 24
- (iii) the primers of SEQ ID NOs: 26 and 27; and
- (iv) the primers of SEQ ID NOs: 28 and 29.

84. A ribozyme comprising an antisense sequence that specifically recognizes RNA fully complementary to the nucleic acid molecule of any of SEQ ID NOs: 1, 5, 7, 8, 11, 13 or 15.

85. The ribozyme according to claim 84, wherein said ribozyme is composed of ribonucleic acids.

86. The ribozyme according to claim 85, wherein one or more of said ribonucleic acids are 2'-O-methyl ribonucleic acids.

87. The ribozyme according to claim 85 wherein said ribozyme is composed of a mixture of deoxyribonucleic acids and ribonucleic acids.

88. The ribozyme according to claim 84 wherein said ribozyme is composed of nucleic acids having phosphothioate linkages.

89. A nucleic acid molecule comprising a nucleic acid sequence which encodes a ribozyme according to claim 83 or an oligonucleotide according to claim 77 or 78.

90. The nucleic acid molecule of claim 89, wherein the nucleic acid is DNA or cDNA.

91. The nucleic acid molecule of claim 89, under the control of a promoter to transcribe the nucleic acid.

92. A use for nucleic acid molecule of claim 89 for the manufacture of a medicament for increasing bone mineral content in a warm-blooded animal.

93. The use according to claim 92 wherein the medicament is for treatment of osteopenia.

94. The use according to 93, wherein the osteopenia is caused by an anaemic state, steroids, heparin, a bone marrow disorder, scurvy, malnutrition, calcium deficiency, idiopathic osteoporosis, congenital osteopenia or osteoporosis, alcoholism, chronic liver disease, senility, post menstrual state, oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, transient regional osteoporosis or osteomalacia.

95. The use according to claim 92, wherein the medicament is for treatment of osteoporosis.

96. The use according to claim 92, wherein the animal has achondroplasia, cleidocranial dysostosis, chondromatosis, fibrous dysplasia, Gaucher's hypophosphatemic rickets, Marfan's, multiple hereditary exostoses, neurofibromatosis, osteogenesis imperfecta,

osteopetrosis, osteopoikilosis sclerotic lesions, fractures, periodontal disease, pseudoarthrosis or pyrogenic osteomyelitis.

97. The use according to claim 92, wherein the medicament is for treatment of bone fracture.

98. The use of claim 92, wherein the medicament is for treatment of dysplasias associated with abnormal growth or development of bone.

99. The use of a nucleic acid molecule of claim 89, for preparation of a medicament for co-administration with an inhibitor of bone resorption.

100. The use of claim 99, wherein the inhibitor of bone resorption is selected from the group consisting of calcitonin, estrogen, bisphosphonates, growth factors having anti-resorptive activity, and tamoxifen.

101. A pharmaceutical composition, comprising the nucleic acid molecule of claim 84 and a pharmaceutically acceptable carrier or diluent.

102. The pharmaceutical composition of claim 101, further comprising an inhibitor of bone resorption.

103. A host cell comprising the ribozyme of claim 84.

104. A vector, comprising the nucleic acid molecule of any one of claims 89-91.

105. The vector of claim 104, wherein the vector is a plasmid, a virus, retrotransposon or a cosmid.

106. The vector of claim 105, wherein said virus is selected from the group consisting of a retrovirus, an adenovirus, and an adeno-associated virus.

107. A host cell containing the vector according to any one of claims 104 or 105.

108. The host cell according to claim 107, wherein said host cell is stably transformed with said vector.

109. The host cell according to claim 107, wherein the host cell is a human cell.

110. A method for producing a ribozyme, comprising providing DNA encoding the ribozyme according to claim 84 under the transcriptional control of a promoter, transcribing the DNA to produce the ribozyme and purifying the ribozyme.

111. The method of claim 110, wherein the ribozyme is produced *in vitro*.

112. A pharmaceutical composition, comprising the ribozyme according to any one of claims 84-88, and a pharmaceutically-acceptable carrier or diluent.

113. A method for detecting a nucleic acid molecule which encodes a polypeptide that decreases bone mineral content comprising hybridizing an isolated oligonucleotide according to claim 77 under conditions of high stringency comprising 5XSSPE, 5XDenhardt's solution and 0.5% SDS at 55-60°C, and detecting hybridization of said nucleic acid molecule and said isolated oligonucleotide.

114. The method according to claim 113 wherein said oligonucleotide is labeled.

115. The method according to claim 113 or 114 wherein said oligonucleotide is bound to a solid support.

116. A method for detecting a polypeptide encoded by SEQ ID NO: 1, comprising incubating an antibody according to any one of claims 39-59 under conditions and for a time sufficient to permit said antibody to bind to said polypeptide, and detecting said binding.

117. A method of detecting binding of a polypeptide encoded by SEQ ID NO: 1 to an antibody, comprising the step of incubating an antibody according to any one of claims 39-59 with said polypeptide under conditions and for a time sufficient to permit said antibody to bind to said polypeptide, and detecting said binding.

118. A method of detecting binding of a fusion protein according to claim 76 to an antibody, comprising the step of incubating an antibody according to any one of claims 39-59 with said fusion protein under conditions and for a time sufficient to permit said antibody to bind to said fusion protein, and detecting said binding.

119. A method of detecting binding of SEQ ID NO: 2 minus the secretion signal sequence to an antibody, comprising the step of incubating an antibody according to any one of claims 39-59 with said polypeptide under conditions and for a time sufficient to permit said antibody to bind to said polypeptide, and detecting said binding.

120. The method according to any one of claims 116-119 wherein said antibody is bound to a solid support.

121. The method according to any one of claims 116-120 wherein said antibody is labeled.

122. The method according to claim 121, wherein said antibody is labeled with a marker selected from the group consisting of an enzyme, a fluorescent protein, and a radioisotope.

123. A method for determining whether a candidate molecule is capable of increasing bone mineral content, comprising: determining whether a candidate molecule inhibits the binding of a protein according to claim 28 to bone, or an analogue thereof.

124. The method according to claim 123, wherein said analogue of bone is hydroxyapatite.

125. A kit for detection of BEER gene expression, comprising a container that comprises a nucleic acid molecule and a pharmaceutically acceptable carrier or excipient, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1,5,7,9,11,13, or 15; (b) a nucleic acid molecule comprising the complement of the nucleotide sequence of (a); and (c) a nucleic acid molecule that is a fragment of (a) or (b) of at least 20 nucleotides in length.

126. A kit for detection of a mature protein of SEQ ID NO: 2 without the signal sequence, comprising a container that comprises an antibody according to any one of claims 39-59.

127. An antisense oligonucleotide, comprising a nucleic acid molecule which hybridizes to a nucleic acid molecule according to SEQ ID NOs: 1, 5, 7, 9, 11, 13, or 15, or the

complement thereto, and wherein said oligonucleotide inhibits the expression of a protein according to claim 28.

128. The oligonucleotide according to claim 127, wherein said oligonucleotide is 15 nucleotides in length.

129. The oligonucleotide according to claim 127, wherein said oligonucleotide is 20 nucleotides in length.

130. The oligonucleotide according to claim 127, wherein said oligonucleotide is 50 nucleotides in length.

131. The oligonucleotide according to claim 127, wherein said oligonucleotide is comprised of one or more nucleic acid analogs.

132. The oligonucleotide according to claim 127, wherein said oligonucleotide is comprised of one or more ribonucleic acids.

133. The oligonucleotide according to claim 127, wherein said oligonucleotide is comprised of one or more deoxyribonucleic acids.

134. The oligonucleotide according to claim 127, wherein said oligonucleotide sequence comprises one or more modified covalent linkages.

135. The oligonucleotide according to claim 134, wherein said modified covalent linkage is selected from the group consisting of a phosphorothioate linkage, a phosphotriester linkage, a methyl phosphonate linkage, a methylene (methylimino) linkage, a morpholino linkage, an amide linkage, a polyamide linkage, a short chain alkyl intersugar linkage, a cycloalkyl intersugar linkage, a short chain heteroatomic intersugar linkage and a heterocyclic intersugar linkage.


Common Cysteine Backbone

1					50
human_gremlin.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
human_cerberus.pro	MHLLLFQLLV	LLPLGKTTRH	QDGRQNQSSL	SPVLLPRNQ	ELPTGNHEEA
human_dan.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
human_beer.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	51				100
human_gremlin.pro	~~~~~	~~~~~M	SRTAYTVGAL	LLLLGTLLPA	AEGKKKGSQG
human_cerberus.pro	EEKPDLFVAV	PHLVAT.SPA	GEGQRQREKM	LSRFGFRFWK	PEREMHPSRD
human_dan.pro	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
human_beer.pro	~~~~~	~~~~~	~~~~~	~~~~~MQLPLA	LCLVCLLVHT
	101				150
human_gremlin.pro	AI.PPPDKAQ	HNDSEQTQSP	QQPGSRNRGR	GQGRGTAMPG	EEVLESSQEA
human_cerberus.pro	SDSEPFPPGT	QSLIQPID.G	MKMEKSPLRE	EAKKFWHHFM	FRKTPASQGV
human_dan.pro	~~~~~	~~~~~	~~~~~	MLRVLVCAVL	PAMLLAAPP
human_beer.pro	AFRVVEGQGW	QAFKNDATET	IPELGEYPEP	PPELENNKTM	NRAENGGRPP
	151	↓	↓	↓	200
human_gremlin.pro	LHVTERKYLK	RDWCKTQPLK	QTIHEEGCNS	RTIINRF.CY	GQCNSFYIPR
human_cerberus.pro	ILPIKSHEVH	WETCRTVPFS	QTITHEGCEK	VVVQNNL.CF	GKCGSVHFP.
human_dan.pro	INKLALFPDK	SAWCEAKNIT	QIVGHSGCEA	KSIQNRA.CL	GQCFSYSVPN
human_beer.pro	HHPFETKDVS	EYSCRELHFT	RYVTDGPCRS	AKPVTELVCS	GQCGPARLLP
	201	↓	↓		250
human_gremlin.pro	HIRKEEGSFQ	SCSF...CKP	KKFTTMMVTL	NCPQLQPPTK	K.KRVTRVKQ
human_cerberus.pro	..GAAQHSHT	SCSH...CLP	AKFTTMHLPL	NCTELSSVIK	V...VMLVEE
human_dan.pro	TFPQSTESLV	HCDS...CMP	AQSMWEIVTL	ECPGHVEEVR	VDKLVEKILH
human_beer.pro	NAIGRGKWWR	PSGPDFRCIP	DRYRAQRVQL	LCPGGEAPRA	RKVRLVAS..
	↓↓				300
human_gremlin.pro	CRC.ISIDLD	~~~~~	~~~~~	~~~~~	~~~~~
human_cerberus.pro	CQCKVKTEHE	DGHILHAGSQ	DSFIPGVSA~	~~~~~	~~~~~
human_dan.pro	CSCQACGKEP	SHEGLSVYVQ	GEDGPGSQPG	THPHPHPHPH	PGGQTPEPED
human_beer.pro	CKCKRLTRFH	NQSELKDFGT	EAARPQKGRK	PRPRARSAKA	NQAELENAY~
	301	314			
human_gremlin.pro	~~~~~	~~~~~			
human_cerberus.pro	~~~~~	~~~~~			
human_dan.pro	PPGAPHTEEE	GAED			
human_beer.pro	~~~~~	~~~~~			

Figure 1

2/6

Human Beer Gene Expression by RT-PCR

*Fig. 2*

3/6

Fig. 3B




Fig. 3D



Fig. 3A





Fig. 3C



WO 00/32773

4/6

PCT/US99/27990

Antibody Selectivity





Fig. 4

Evaluation of Beer binding to BMP family members
Anti-FLAG Immunoprecipitation



*Anti-BMP-6 western blot




*Anti-BMP-4 western blot

Fig. 5

BMP-5/Beer Dissociation Constant Characterization


.75 1.5 7.5 15 30 60 120 nM BMP-5



*Anti-FLAG immunoprecipitation *Anti-BMP-5 western blot

Ionic Disruption of BMP-5/ Beer Binding

NaCl(mM)	500	150	150
Beer	+	+	-
BMP-5	+	+	+
			BMP-5 western control



* Anti FLAG immunoprecipitation *Anti BMP-5 western

Fig. 6